WO2023138522A1 - 特异性识别FasL的抗体及其应用 - Google Patents

特异性识别FasL的抗体及其应用 Download PDF

Info

Publication number
WO2023138522A1
WO2023138522A1 PCT/CN2023/072295 CN2023072295W WO2023138522A1 WO 2023138522 A1 WO2023138522 A1 WO 2023138522A1 CN 2023072295 W CN2023072295 W CN 2023072295W WO 2023138522 A1 WO2023138522 A1 WO 2023138522A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
acid sequence
cdr1
cdr2
Prior art date
Application number
PCT/CN2023/072295
Other languages
English (en)
French (fr)
Inventor
王广菲
任晓叶
李忠
Original Assignee
北京三诺佳邑生物技术有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京三诺佳邑生物技术有限责任公司 filed Critical 北京三诺佳邑生物技术有限责任公司
Priority to CN202380009454.2A priority Critical patent/CN116829594A/zh
Publication of WO2023138522A1 publication Critical patent/WO2023138522A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Definitions

  • the present application relates to an antibody or antigen-binding fragment that specifically recognizes FasL, its preparation method and use.
  • FasL (CD95L) is a transmembrane protein and a pro-apoptotic member of the tumor necrosis factor (TNF) superfamily.
  • the extracellular domain of FasL contains a ligand dimer and receptor binding domain (TNF homology domain, THD), while the intracellular domain of FasL participates in various signaling pathways, especially as a T cell receptor co-stimulatory molecule in the process of T cell activation (TNF)
  • THD tumor necrosis factor homology domain
  • FasL contains an extended polyproline domain capable of interacting with proteins with proline-binding motifs, such as Src homology 3 (SH3) and WW domains (Wenzel, J et al. FEBS letters vol. 509, 2(2001): 255-62.; Blott, E J et al. Journal of cell science vol. 114, Pt 13 (2001):2405-16.).
  • proline-binding motifs such as Src homology 3 (SH3) and WW domains
  • FasL protein has two forms of membrane-bound protein and soluble protein.
  • the soluble form is produced by alternative splicing or proteolysis of the membrane-bound form.
  • FasL is tightly controlled and restricted in cells of the innate and adaptive immune system as well as in immune privileged sites such as the eye, placenta or testis (Stenqvist, Ann-Christin et al. Journal of immunology (Baltimore, Md.: 1950) vol. 191, 11(2013): 5515-23.).
  • FasL is expressed on the surface of two major immune effector cells, activated T cells and natural killer (NK) cells, but also on macrophages, neutrophils, and dendritic cells (Kiener, P A et al.
  • FasL can be induced by TCR (T cell receptor) activation, and its expression can also be regulated by transcription after cytokine stimulation, especially interferon (INF) stimulation (Tsutsui, H et al. Journal of immunology (Baltimore, Md.: 1950) vol. 157, 9 (1996): 3967-73.).
  • IFN interferon
  • Fas receptor CD95/APO-1 is a member of the TNF receptor superfamily. There are two forms of Fas protein, membrane-bound protein and soluble protein, and Fas mainly exists in membrane-bound form. However, soluble Fas protein cannot interact with FasL to induce apoptosis due to the lack of a transmembrane domain, so it plays a regulatory role in apoptosis, such as inhibiting apoptosis induced by membrane-bound Fas (mFas) (Jee, Youngheun et al. Journal of veterinary science vol.11,2(2010):115-9.).
  • mFas membrane-bound Fas
  • the ectodomain contains three cysteine-rich domains (CRDs), which is a structural feature of the TNF receptor family (Zhang, Gongyi. Current opinion in structural biology vol. 14, 2(2004): 154-60.).
  • CCDs cysteine-rich domains
  • the C-terminus of the intracellular domain of the Fas protein contains a death domain (DD), which is required for apoptosis induction and is characteristic of this subset of death receptors (Chan, F K et al. Science (New York, NY) vol. 288, 5475 (2000): 2351-4.).
  • Fas is expressed in multiple organ tissues, especially in peripheral blood T and B lymphocytes, NK cells, monocytes, fibroblasts, endothelial cells, epithelial cells, etc. (Wang, Mei, and Ping Su. Systems biology in reproductive medicine vol.64,2(2018):93-102.).
  • Fas-mediated apoptotic pathway the binding of FasL drives Fas aggregation and the binding of Fas to Fas-binding protein (FADD).
  • FADD recruits caspase-8 and caspase-10 to form the death-inducing signaling complex (DISC) (Wilson, Nicholas S et al. Nature immunology vol. 10,4(2009):348-55.).
  • DISC is activated by specific post-translational modifications of the death receptor (DR), such as palmitoylation and O-linked glycosylation (Muppidi, Jagan R, and Richard M Siegel. Nature immunology vol.5,2(2004):182-9.; Wagner, Klaus W et al. Nature medicine vol.13,9(2007):1070-9. 7).
  • DR death receptor
  • DISC mediates the autocatalytic processing and activation of caspase-8 and caspase-10, which amplify the death signal through the proteolysis of effector caspases such as caspase-3, caspase-6 and caspase-7.
  • type I cells such as thymocytes
  • the action of caspases is sufficient to induce apoptosis.
  • type II cells such as B cells
  • apoptosis requires caspase-8-mediated cleavage of the BH3-interacting domain death agonist (Bid), a BH3-only protein that increases the permeability of the outer mitochondrial membrane and the release of cytochrome c.
  • cytochrome c can serve as a cofactor in the assembly of cytosolic caspase-activating complexes called apoptosomes, which amplify caspase cascade activation (Wagner, Klaus W et al. Nature medicine vol. 13, 9(2007): 1070-7.).
  • Fas can also induce NF- ⁇ B signaling.
  • NF- ⁇ B caspase-8-like inhibitory protein
  • cFLIP caspase-8-like inhibitory protein
  • TRAF2 TRAF2 in the Fas signaling pathway
  • T cell proliferation through NF- ⁇ B activation
  • the cFLIP N-terminal cleavage products p43FLIP and p22FLIP induce NF- ⁇ B activation by binding to the IKK complex (Golks, Alexander et al.
  • Fas signaling regulates peripheral T cell homeostasis by regulating the balance between proliferation and cell death, for example, in naive and memory T cell subsets (Jaleco, Sara et al. Journal of immunology (Baltimore, Md.: 1950) vol. 171, 1(2003): 61-8.). Therefore, the homeostasis of peripheral T cells may be maintained by the dual effects of FasL/Fas signaling.
  • the Fas-FasL signaling pathway is related to the occurrence and development of various diseases, including autoimmune diseases, transplant rejection, spinal cord injury, sepsis and so on. Therefore, it is crucial to develop inhibitors against FasL targets.
  • FasL inhibitors for example, Chinese patent CN1283662C discloses antagonistic anti-hFAS ligand antibody and its application; is a control antibody) and its application; Chinese patent CN104662039B discloses the Fas-Fc fusion protein APG101 (as a control in the example part of this application) and its application. Anti-FasL antibodies with high affinity and high biological activity are still needed in the existing therapeutic fields.
  • an isolated anti-FasL antibody comprising: (i) V h , which comprises V as shown in the amino acid sequence SEQ ID NO:99 h HC-CDR1, HC-CDR2, and HC-CDR3 contained; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO:127 L LC-CDR1, LC-CDR2 and LC-CDR3 contained; (ii) V h , which comprises V shown in the amino acid sequence SEQ ID NO:100 h HC-CDR1, HC-CDR2, and HC-CDR3 contained; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 128 L LC-CDR1, LC-CDR2 and LC-CDR3 contained; (iii) V h , which comprises V shown in the amino acid sequence SEQ ID NO:101 h HC-CDR1, HC-CDR2, and HC-CDR3 contained; and V L , which
  • an isolated anti-FasL antibody comprising: (i) a VH comprising: HC- CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 18, and HC-CDR3, ⁇ SEQ ID NO:32; ⁇ V L , ⁇ V L ⁇ :LC-CDR1, ⁇ SEQ ID NO:51,LC-CDR2, ⁇ SEQ ID NO:67, ⁇ LC-CDR3, ⁇ SEQ ID NO:77;(ii)V H , ⁇ V H ⁇ :HC-CDR1, ⁇ SEQ ID NO:2,HC-CDR2, ⁇ SEQ ID NO:19, ⁇ HC-CDR3, ⁇ SEQ ID NO:32; ⁇ V L , ⁇ V L ⁇ :LC-CDR1, ⁇ SEQ ID NO:51,LC-CDR2, ⁇ SEQ ID NO:68, ⁇ LC-CDR3, ⁇ SEQ ID NO:78;(iii)V H , ⁇ V H ⁇ :HC-
  • any of the isolated anti-FasL antibodies described above comprising: V h , which comprises the amino acid sequence shown in SEQ ID NO:99 or a variant thereof having at least about 80% sequence identity to the amino acid sequence shown in SEQ ID NO:99; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 127 or a variant thereof having at least about 80% sequence identity to the amino acid sequence shown in SEQ ID NO: 127; (ii) V h , which comprises the amino acid sequence shown in SEQ ID NO: 100 or a variant thereof having at least about 80% sequence identity to the amino acid sequence shown in SEQ ID NO: 100; and V L , It comprises the amino acid sequence shown in SEQ ID NO: 128 or a variant thereof having at least about 80% sequence identity to the amino acid sequence shown in SEQ ID NO: 128; (iii) V h , which comprises the amino acid sequence shown in SEQ ID NO: 101 or a variant thereof having at least about 80% sequence identity to the amino acid
  • an isolated anti-FasL antibody that competes with any of the isolated anti-FasL antibodies described above for specific binding to FasL is provided. In some embodiments, an isolated anti-FasL antibody is provided that specifically binds to the same epitope as any of the isolated anti-FasL antibodies described above.
  • the isolated anti-FasL antibody is a full length IgG antibody.
  • the isolated anti-FasL antibody is a full length IgGl or IgG4 antibody.
  • the isolated anti-FasL antibody is a chimeric, fully human or humanized antibody.
  • the isolated anti-FasL antibody is an antigen binding fragment selected from the group consisting of Fab, Fab', F(ab)' 2 , Fab'-SH, single chain Fv (scFv), Fv fragment, dAb, Fd, nanobody, diabody, and linear antibody.
  • an isolated nucleic acid molecule encoding any of the anti-FasL antibodies described above is provided.
  • a vector comprising any one of the nucleic acid molecules described above.
  • a host cell comprising any of the above-mentioned anti-FasL antibodies, any of the above-mentioned nucleic acid molecules, or any of the above-mentioned vectors.
  • a method for preparing an anti-FasL antibody comprising: a) culturing any one of the above-mentioned host cells under conditions capable of effectively expressing the anti-FasL antibody; and b) obtaining the expressed anti-FasL antibody from the host cell.
  • a method of treating a disease or condition in an individual in need thereof comprising administering to said individual an effective amount of any one of the anti-FasL antibodies described above.
  • use of any one of the anti-FasL antibodies described above for the manufacture of a pharmaceutical composition for treating a disease or condition in an individual in need thereof.
  • use of any anti-FasL antibody or a pharmaceutical composition comprising an anti-FasL antibody as described above in the preparation of a medicament for treating a disease or disorder is provided.
  • the disease or disorder is associated with the FasL-Fas signaling pathway, including an inflammatory disease, cancer, or an autoimmune disease or disorder.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune Chronic hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • the cancer is a FasL positive cancer.
  • compositions, kits, and manufactured goods comprising any of the above-mentioned anti-FasL antibodies.
  • the application provides anti-FasL antibody molecules.
  • anti-FasL antibody molecules Through natural scFv phage library screening, a combination of appropriately designed biochemical and biological experiments, and antibody humanization, highly effective antibody molecules capable of binding human FasL and inhibiting the interaction of human FasL with its receptor have been identified. The results presented herein indicate that the antibodies of the present application have better biological activity compared to known anti-FasL antibodies.
  • Anti-FasL antibodies provided by the present application include, for example, full-length anti-FasL antibodies, anti-FasL single-chain antibodies (scFvs), anti-FasL Fc fusion proteins, multispecific (such as bispecific) anti-FasL antibodies, anti-FasL immunoconjugates, and the like.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO:99; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO:127.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 100; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 128.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 101; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 129.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 102; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 130.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 103; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 131.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 104; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 132.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 105; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 133.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 106; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 134.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 107; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 135.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 108; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 136.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 109; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 137.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 110; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 138.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 111; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 139.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 112; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 140.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 113; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 141.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 114; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 142.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 115; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 143.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 116; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 144.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 117; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 145.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 118; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 146.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 119; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 147.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO:120; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO:148.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 121; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 149.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 122; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 150.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO:123; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO:151.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 124; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 152.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 125; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 153.
  • the present application provides an anti-FasL antibody comprising: VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO:126; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO:154.
  • nucleic acids encoding anti-FasL antibodies are also provided.
  • compositions comprising anti-FasL antibodies are also provided.
  • treatment is an approach to obtain a beneficial or desired outcome, including a clinical outcome.
  • beneficial or desired clinical outcome includes, but is not limited to, one or more of the following: alleviation of one or more symptoms caused by a disease, reduction of the extent of the disease, stabilization of the disease (e.g., prevention or delay of disease progression), prevention or delay of spread of the disease (e.g., metastasis), prevention or delay of disease recurrence, delay or slowing of disease progression, improvement of disease state, remission of disease (partial or total) , reduce the dose of one or more other drugs needed to treat the disease, delay disease progression, improve or increase quality of life, increase body weight, and/or prolong survival.
  • treatment also includes the reduction of disease pathological results (for example, for cancer, tumor volume). The methods of the present application consider any one or more aspects of these treatments.
  • antibody includes full-length antibodies and antigen-binding fragments thereof.
  • Full-length antibodies include two heavy chains and two light chains.
  • the variable regions of the light and heavy chains are responsible for antigen binding.
  • the variable regions in both chains usually include three hypervariable loops, called complementarity determining regions (CDRs) (light chain (LC) CDRs include LC-CDR1, LC-CDR2, and LC-CDR3, and heavy chain (HC) CDRs include HC-CDR1, HC-CDR2, and HC-CDR3).
  • CDRs complementarity determining regions
  • the CDR boundaries of the antibodies or antigen-binding fragments disclosed herein can be defined or identified by the Kabat, Chothia or Al-Lazikani conventions (Al-Lazikani 1997; Chothia 1985; Chothia 1987; Chothia 1989; Kabat 1987; Kabat 1991).
  • the three CDR regions of the heavy or light chain are inserted between flanking segments called framework regions (FRs), which are more conserved than the CDR regions and form a scaffold to support the hypervariable loops.
  • FRs flanking segments
  • the constant regions of the heavy and light chains are not involved in antigen binding, but exhibit various effector functions.
  • Antibodies are classified based on the amino acid sequence of the constant region of their heavy chains.
  • the five major classes or isotypes of antibodies are IgA, IgD, IgE, IgG and IgM, characterized by heavy chains of the alpha, delta, epsilon, gamma and mu types, respectively.
  • major antibody classes are divided into subclasses, such as IgG1 ( ⁇ 1 heavy chain), IgG2 ( ⁇ 2 heavy chain), IgG3 ( ⁇ 3 heavy chain), IgG4 ( ⁇ 4 heavy chain), IgA1 ( ⁇ 1 heavy chain), or IgA2 ( ⁇ 2 heavy chain).
  • an antigen-binding fragment is capable of binding the same antigen as a parent antibody or a fragment of a parent antibody (eg, a parent scFv).
  • Antigen-binding fragments also include fusion proteins comprising the antibody fragments described above.
  • an antigen-binding fragment may comprise one or more CDRs from a particular human antibody grafted into framework regions from one or more different human antibodies.
  • epitope refers to a specific atom or group of amino acids on an antigen to which an antibody or antibody portion binds. If two antibodies or antibody portions appear to compete for binding to an antigen, they likely bind the same epitope on the antigen.
  • a first antibody "competes" with a second antibody for binding to the FasL target, and vice versa, when the first antibody inhibits the binding of the second antibody to the FasL target by at least 50% (e.g., at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%) at an equimolar concentration.
  • PCT publication WO 03/48731 describes a cross-competition based high throughput antibody "epitope mapping" approach.
  • the term “specifically binds,” “specifically recognizes,” or “specific for” refers to a measurable and reproducible interaction, such as the binding of an antibody to a target that can determine the presence of that target in a heterogeneous population of molecules, including biomolecules.
  • the ability of an antibody to specifically recognize a certain target means that the antibody binds to the target with higher affinity, avidity, easier and/or longer duration than other targets.
  • an antibody that specifically recognizes an antigen reacts with one or more epitopes of the antigen with a binding affinity at least 10 times greater than its binding affinity for other targets.
  • an "isolated" anti-FasL antibody refers to an anti-FasL antibody that is (1) not related to a naturally occurring protein, (2) free of other proteins of the same origin, (3) expressed by a cell of a different species, or (4) not found in nature.
  • isolated nucleic acid refers to nucleic acid of genomic, cDNA or synthetic origin or combinations thereof. Depending on its source, an “isolated nucleic acid” means (1) not related to all or part of a polynucleotide found in nature in an “isolated nucleic acid", (2) operably linked to a polynucleotide to which it is not associated in nature, or (3) not present in nature as part of a longer sequence.
  • CDR complementarity determining region
  • chimeric antibody refers to an antibody in which a part of the heavy chain and/or light chain is identical or homologous to the corresponding sequence in an antibody from a specific species or belonging to a specific antibody class or subclass, and the remaining part of this (some) chain is consistent with or has homology to the corresponding sequence in an antibody from another genus or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they have biological activity in this application (see U.S. Patent No. 4,816,567; and Morri Son et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).
  • Fv is the smallest antibody fragment that contains the complete antigen recognition and binding site. This fragment is a dimer formed by tight non-covalent linkage of one heavy chain variable domain and one light chain variable domain. Six hypervariable loops (3 loops each in the light and heavy chains) are derived from the folding of these two domains, which provide the antibody with amino acid residues for antigen-binding and confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv fragment, which contains only the 3 CDRs specific for an antigen) has the ability to recognize and bind antigen, albeit with a lower affinity than the full binding site.
  • Single-chain Fv also abbreviated “sFv” or “scFv”
  • sFv is an antibody fragment comprising the VH and VL antibody domains linked into a single polypeptide chain.
  • the scFv polypeptide further includes a linking polypeptide between the VH and VL domains , which allows the scFv to form a desired structure for antigen binding.
  • diabody is a small antibody fragment prepared by constructing a scFv fragment (see above) using a short linker (for example, 5-10 residues) between the VH and VL domains, so that the variable domains are paired between the chains rather than within the chain, resulting in a bivalent fragment, that is, a fragment with two antigen-binding sites.
  • Bispecific diabodies are heterodimers of two "crossover" scFv fragments in which the VH and VL domains of the two antibodies are located on different polypeptide chains.
  • Diabodies are fully described in EP 404,097; WO 93/11161; Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).
  • Humanized forms of non-human (eg, rodent) antibodies are chimeric antibodies, which include minimal sequence derived from the non-human antibody.
  • a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from the hypervariable region (HVR) of the recipient antibody are replaced by residues from the hypervariable region (HVR) from a non-human species such as mouse, rat, rabbit or non-human mammal having the desired antibody specificity, affinity and performance (donor antibody).
  • residues in the framework regions of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies can include residues that are found neither in the recipient antibody nor in the donor antibody. These modifications can further improve antibody performance.
  • a humanized antibody will comprise substantially all, at least one, and usually two variable domains in which all or substantially all hypervariable loops correspond to those of a non-human immunoglobulin and in which all or substantially all framework regions are human immunoglobulin sequences.
  • the human antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • Percent amino acid sequence identity (%) or “homology” of the polypeptide and antibody sequences identified herein is defined as the percentage of amino acid residues in the candidate sequence that are identical to the polypeptide sequence being compared when the sequences are compared where conservative substitutions are considered to be part of the sequence identity. Percent amino acid sequence identity can be determined by various alignment methods that are within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, Megalign (DNASTAR), or MUSCLE software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • percent amino acid sequence identity values were generated using the sequence alignment computer program MUSCLE (Edgar, R.C., Nucleic Acids Research 32(5):1792-1797, 2004; Edgar, R.C., BMC Bioinformatics 5(1):113, 2004).
  • Fc receptor or "FcR” is used to describe a receptor that binds the Fc region of an antibody.
  • the FcR described herein is an FcR that binds an IgG antibody, a gamma receptor, including receptors of the FcyRI, FcyRII, and FcyRIII subclasses, including allelic variants and alternatively spliced forms of these receptors.
  • FcyRII receptors include FcyRIIA ("activating receptor") and FcyRIIB ("inhibiting receptor”), which have similar amino acid sequences and differ primarily in the cytoplasmic domain.
  • the cytoplasmic domain of the activating receptor Fc ⁇ RIIA contains an immunoreceptor tyrosine activation motif (ITAM).
  • the cytoplasmic domain of the inhibitory receptor Fc ⁇ RIIB contains an immunoreceptor tyrosine inhibition motif (ITIM) (see M.in Annu. Rev. Immunol. 15:203-234 (1997)).
  • ITAM immunoreceptor tyrosine activation motif
  • ITIM immunoreceptor tyrosine inhibition motif
  • the term also includes allotypes, eg FcyRIIIA allotypes: FcyRIIIA-Phe158, FcyRIIIA-Val158, FcyRIIA-R131 and/or FcyRIIA-H131.
  • FcRs are described in Ravetch and Kinet, Annu. Rev.
  • FcR in this application encompasses other types of FcRs, including FcRs identified in the future.
  • FcR also includes the neonatal receptor FcRn, which is responsible for the transfer of maternal IgGs to the neonate (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)).
  • FcRn refers to the neonatal Fc receptor (FcRn).
  • FcRn is structurally similar to the major histocompatibility complex (MHC) and consists of an alpha chain non-covalently bound to beta2 microglobulin.
  • MHC major histocompatibility complex
  • FcRn plays an important role in the passive transport of immunoglobulin IgGs from mother to neonate and in the regulation of serum IgG levels.
  • FcRn acts as a salvage receptor that binds and transports endocytosed IgG in intact form within and between cells and saves them from undergoing the default degradation pathway.
  • the "CH1 domain" of the human IgG heavy chain constant region typically extends from amino acid 118 to amino acid 215 (EU numbering system).
  • a "hinge region” is generally defined as extending from Glu 216 to Pro 230 of human IgGl (Burton, Molec. Immunol. 22:161-206 (1985)). Hinge regions of other IgG isotypes can be aligned with the IgGl sequence by placing the first and last cysteine residues that form inter-heavy chain disulfide bonds in the same position as IgGl.
  • the "CH2 domain" of the human IgG Fc region generally extends from amino acid 231 to amino acid 340.
  • the CH2 domain is unique in that it is not tightly paired with another region, but is inserted between the two CH2 domains of the intact native IgG molecule Two branched sugar chains connected at the N-terminus. It has been hypothesized that sugars may act as a surrogate for domain-to-domain pairing to help keep the CH2 domain stable.
  • a "CH3" domain includes a stretch within the Fc region from the C-terminal residue to the CH2 domain (from amino acid 341 to the C-terminus of the antibody sequence, usually amino acid residue 446 or 447 of IgG).
  • a “functional Fc fragment” has the "effector function” that a native Fc region sequence has.
  • exemplary “effector functions” include Clq binding; complement-dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; Such effector functions typically require binding of the Fc region to a binding domain (eg, antibody variable region) and can be assessed using a variety of assays well known in the art.
  • Antibodies of IgG Fc variants having "altered" FcR binding affinity or ADCC activity have increased or decreased FcR binding activity and/or ADCC activity compared to a parent polypeptide or a polypeptide comprising a native Fc sequence.
  • An Fc variant exhibiting "enhanced binding" to an FcR has a higher binding affinity for at least one FcR (eg, a lower apparent Kd or IC50 value) than a parental polypeptide or a polypeptide comprising a native IgG Fc sequence.
  • the binding ability is increased by 3 times, such as 5, 10, 25, 50, 60, 100, 150, 200, even up to 500 times or the binding ability is increased by 25% to 1000% compared with the parental polypeptide.
  • An Fc variant that exhibits "reduced binding" to an FcR has a lower affinity for at least one FcR (eg, a higher apparent Kd or IC50 value) than a parental polypeptide.
  • the binding ability is reduced by 40% or more compared to the parental polypeptide.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • FcRs Fc receptors
  • cytotoxic cells such as natural killer cells (NK), neutrophils, and macrophages
  • NK natural killer cells
  • neutrophils neutrophils
  • macrophages enabling these cytotoxic effector cells to specifically bind antigen-bearing target cells and subsequently kill the target cells using cytotoxicity.
  • Antibodies "arm" the cytotoxic cells and are required for this killing.
  • NK cells only express Fc ⁇ RIII, while monocytes express Fc ⁇ RI, Fc ⁇ RII, and Fc ⁇ RIII.
  • FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991).
  • an in vitro ADCC assay can be performed, as described in US Patent No. 5,500,362 or 5,821,337. Suitable effector cells for such experiments include peripheral blood mononuclear cells (PBMC) and natural killer cells (NK).
  • PBMC peripheral blood mononuclear cells
  • NK natural killer cells
  • the ADCC activity of a molecule of interest can also be assessed in vivo, for example as described in animal models as disclosed in Clynes et al. PNAS (USA) 95:652-656 (1998).
  • the polypeptide comprising the Fc region variant Compared with the polypeptide comprising the wild-type IgG Fc polypeptide or the parent polypeptide, the polypeptide comprising the Fc region variant exhibits "enhanced ADCC activity" or can more effectively mediate the ADCC effect in the presence of human effector cells, and when the polypeptide comprising the Fc region variant is substantially the same in number as the wild-type IgG Fc polypeptide (or parent polypeptide) in the experiment, it can mediate ADCC more effectively in vitro or in vivo.
  • Such variants are typically identified using any in vitro ADCC assay known in the art, eg, assays or methods for identifying ADCC activity, eg, in animal models and the like. In some embodiments, such variants mediate ADCC 5 to 100 fold more efficiently, eg 25 to 50 fold, compared to wild type Fc (or parental polypeptide).
  • “Complement-dependent cytotoxicity” or “CDC” refers to the lysis of target cells in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (Clq) to antibodies (subclasses of appropriate structure) that bind cognate antigens.
  • a CDC assay can be performed, such as Gazzano-Santoro et al., J. Immunol. Methods 202:163 as described in (1996).
  • Polypeptide variants with altered Fc region amino acid sequences and increased or decreased C1q binding ability are described in US Patent No. 6,194,551B1 and WO99/51642. The contents of these patent publications are expressly incorporated herein by reference. See also Idusogie et al. J. Immunol. 164:4178-4184 (2000).
  • nucleotide sequence encoding an amino acid sequence includes all nucleotide sequences that are mutually degenerate forms and encode the same amino acid sequence.
  • a nucleotide sequence encoding a protein or RNA may also include introns, eg, a nucleotide sequence encoding a protein may, in some forms, include introns.
  • operably linked refers to a functional linkage between a regulatory sequence and a heterologous nucleotide sequence such that the latter is expressed.
  • a first nucleotide sequence is operably linked to a second nucleotide sequence when the first nucleotide sequence is in a functional relationship with the second nucleotide sequence.
  • a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence.
  • operably linked DNA sequences are contiguous and, when necessary, join two protein coding regions in the same reading frame.
  • “Homologous” refers to sequence similarity or sequence identity between two polypeptides or between two nucleic acid molecules. If the same position in the two compared sequences is the same base or amino acid monomer subunit, for example, the same position in the two DNA molecules is adenine, then the two DNA molecules are homologous at this position.
  • the percent homology between two sequences is a function of the ratio of the number of matching or homologous positions shared by the two sequences to the total number of positions multiplied by 100. For example, if 6 out of 10 positions in two sequences are matched or homologous, then the homology of the two sequences is 60%. For example, the DNA sequences ATTGCC and TATGGC share 50% homology. Generally speaking, when comparing two sequences, the comparison is performed with the aim of obtaining the maximum homology.
  • an “effective amount” of an anti-FasL antibody or composition disclosed herein refers to an amount sufficient to achieve a specific purpose.
  • An “effective amount” can be determined empirically and by methods known in relation to the purpose.
  • therapeutically effective amount refers to the amount of the anti-FasL antibody or its composition disclosed herein that can effectively treat the individual's disease or symptoms, that is, an amount sufficient to reduce or improve the severity and/or duration of the disease or one or more symptoms thereof; prevent the development of the disease, cause the regression of the disease, prevent the recurrence, development, onset or progression of one or more symptoms associated with the disease, detect the disease, or enhance/improve the preventive or therapeutic effect of another therapy (such as a preventive agent or a therapeutic agent).
  • another therapy such as a preventive agent or a therapeutic agent
  • a therapeutically effective amount of an anti-FasL antibody or a composition thereof is capable of reducing the number of cancer cells; reducing the size or weight of a tumor; inhibiting (i.e., slowing down or preferably stopping) the infiltration of tumor cells into surrounding organs; inhibiting (that is, slowing down or preferably stopping) tumor metastasis; inhibiting tumor growth to a certain extent, and/or alleviating one or more symptoms associated with cancer to a certain extent.
  • Anti-FasL antibodies or compositions thereof disclosed herein are capable of preventing or inhibiting the binding of FasL to its receptor Fas to the extent that, in addition to apoptotic signaling pathways, Fas-mediated non-apoptotic signals (such as NF-kB, MAPK, or PI3K) promote inflammation, contribute to carcinogenesis, and modulate immunological parameters (e.g., tumor infiltrating T cell populations). All of these activities may be inhibited by the antibodies described herein.
  • Fas-mediated non-apoptotic signals such as NF-kB, MAPK, or PI3K
  • pharmaceutically acceptable refers to a material that has no biological activity or other undesired properties, for example, the material can be incorporated into a pharmaceutical composition administered to a patient without causing significant adverse biological reactions, or, does not interact in a deleterious manner with any other components contained in the composition.
  • Pharmaceutically acceptable carriers or excipients preferably meet the required criteria for toxicology or manufacturing testing and/or are included in the inactive ingredient guidelines prepared by the US Food and Drug Administration.
  • Embodiments of the application described herein are to be understood to include “consisting of” and/or “consisting essentially of” embodiments.
  • reference to "not" a value or parameter generally means and describes "other than” a value or parameter.
  • the method cannot be used to treat type X cancer, meaning that the method is usually used to treat other types of cancer than type X cancer.
  • the application provides an anti-FasL antibody that specifically binds human FasL.
  • the anti-FasL antibodies include, but are not limited to, humanized antibodies, chimeric antibodies, mouse antibodies, human antibodies, and antibody molecules comprising heavy and/or light chain CDRs described herein.
  • the application provides an isolated antibody that binds FasL.
  • Contemplated anti-FasL antibodies include, for example, full-length anti-FasL antibodies (e.g., full-length IgG1 or IgG4), anti-FasL single-chain antibodies, anti-FasL Fc fusion proteins, multispecific (e.g., bispecific) anti-FasL antibodies, anti-FasL immunoconjugates, and the like.
  • the anti-FasL antibody is a full-length antibody (eg, full-length IgGl or IgG4) or an antigen-binding fragment thereof that specifically binds FasL.
  • the anti-FasL antibody is Fab, Fab', F(ab)' 2 , Fab'-SH, single chain Fv (scFv), Fv fragment, dAb, Fd, nanobody, diabody, or linear antibody.
  • an antibody that specifically binds to FasL refers to an antibody that binds to FasL with an affinity at least 10 times (including, for example, 10, 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , or 10 7 times the binding affinity to a non-target).
  • non-target refers to an antigen other than FasL.
  • Binding affinity can be determined by methods known in the art, such as ELISA, fluorescence activated cell sorting (FACS) analysis or radioimmunoprecipitation analysis (RIA).
  • Kd values can be determined by methods known in the art, such as surface plasmon resonance (SPR) techniques or biolayer interferometry (BLI).
  • non-human anti-FasL antibodies comprising human sequences (eg, human heavy and light chain variable domains comprising human CDR sequences) are broadly discussed herein, non-human anti-FasL antibodies are also contemplated.
  • a non-human anti-FasL antibody comprises the human CDR sequences and non-human framework region sequences of an anti-FasL antibody described herein, in some embodiments, the non-human framework region sequences comprise any sequence useful for generating heavy and/or light chain variable domains using one or more human CDR sequences as described herein, including, for example, mammals such as mice, rats, rabbits, pigs, bovine (e.g., cow, bull, buffalo), deer, sheep, goat, chicken, cat, dog, ferret, primate ( For example, lesser apes, macaques) etc.
  • non-human anti-FasL antibodies include anti-FasL antibodies produced by grafting one or more human CDR sequences described herein into non-human framework
  • the complete amino acid sequence of an exemplary human FasL comprises or consists of the amino acid sequence set forth in SEQ ID NO:159.
  • An exemplary human FasL extracellular domain amino acid sequence comprises or consists of the amino acid sequence shown in SEQ ID NO:160.
  • an anti-FasL antibody described herein specifically recognizes an epitope in human FasL.
  • the anti-FasL antibody cross-reacts with FasL of a species other than human.
  • the anti-FasL antibody is fully specific for human FasL and does not cross-react with other non-human species.
  • the anti-FasL antibody cross-reacts with at least one allelic variant of the FasL protein (or fragment thereof).
  • the allelic variant has up to 30 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30) amino acid substitutions (e.g., conservative substitutions) compared to a naturally occurring FasL protein (or fragment thereof).
  • the anti-FasL antibody does not cross-react with any allelic variant of the FasL protein (or fragment thereof).
  • the anti-FasL antibody cross-reacts with at least one interspecies variant of the FasL protein.
  • the FasL protein (or fragment thereof) is human FasL
  • the interspecies variant of the FasL protein (or fragment thereof) is a variant in cynomolgus monkeys.
  • the anti-FasL antibody does not cross-react with any interspecies variants of the FasL protein.
  • any anti-FasL antibody described herein comprising an antibody heavy chain constant region and an antibody light chain constant region.
  • the anti-FasL antibody comprises an IgG1 heavy chain constant region.
  • the anti-FasL antibody comprises an IgG2 heavy chain constant region.
  • the anti-FasL antibody comprises an IgG3 type heavy chain constant region.
  • the anti-FasL antibody comprises an IgG4 type heavy chain constant region.
  • the heavy chain constant region comprises (including consists of or consists essentially of) the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises (including consists of or consists essentially of) the amino acid sequence of SEQ ID NO: 156.
  • the anti-FasL antibody comprises a kappa light chain constant region.
  • the light chain constant region comprises (including consists of or consists essentially of) the amino acid sequence of SEQ ID NO: 157.
  • the anti-FasL antibody comprises a lambda light chain constant region.
  • the light chain constant region comprises (including consists of or consists essentially of) the amino acid sequence of SEQ ID NO: 158.
  • the anti-FasL antibody comprises an antibody heavy chain variable domain and an antibody light chain variable domain.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO: 1, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO: 18, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 32, or the V h A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:51, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:67, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:77, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:18, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:32; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:51, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:67, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:77.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO:99; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO:127.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO:99, and a VL comprising the amino acid sequence of SEQ ID NO:127.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO:2, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO:19, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO:32, or the V h Variants comprising up to about 5 amino acid substitutions in their HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:51, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:68, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:78, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:19, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:32; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:51, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:68, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:78.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 100; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 128.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 100, and a VL comprising the amino acid sequence of SEQ ID NO: 128.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO:1, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO:18, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO:32, or the V h Variants comprising up to about 5 amino acid substitutions in their HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:51, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:67, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:79, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 18, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:32; and V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:51, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:67 , and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:79.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 101; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 129.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 101, and a VL comprising the amino acid sequence of SEQ ID NO: 129.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO:3, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO:20, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO:33, or the V h Variants comprising up to about 5 amino acid substitutions in their HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:52, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:68, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:80, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:33; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:52, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:68, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:80.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 102; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 130.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 102, and a VL comprising the amino acid sequence of SEQ ID NO: 130.
  • the anti-FasL antibody comprises a VH comprising: HC- CDR1 comprising the amino acid sequence of SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:20, HC-CDR3 comprising the amino acid sequence of SEQ ID NO:34, or a variant of said VH comprising up to about 5 amino acid substitutions in the HC-CDRs; and a VL comprising: LC- CDR1 comprising amino acid Sequence SEQ ID NO:52, LC-CDR2, comprising the amino acid sequence SEQ ID NO: 68, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 81, or a variant of said VL , comprising up to about 5 amino acid substitutions in its LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:34; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:52, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:68, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:81.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 103; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 131.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 103, and a VL comprising the amino acid sequence of SEQ ID NO: 131.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO:4, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO:20, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO:35, or the V h A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:53, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:69, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:82, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:4, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:35; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:53, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:69, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:82.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 104; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 132.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 104, and a VL comprising the amino acid sequence of SEQ ID NO: 132.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO:5, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO:21, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO:36, or the V h Variants comprising up to about 5 amino acid substitutions in their HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:54, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:70, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:83, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:5, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:21, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:36; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:54, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:70, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:83.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 105; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 133.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 105, and a VL comprising the amino acid sequence of SEQ ID NO: 133.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO:6, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO:22, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO:37, or the V h A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:84, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:6, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:22, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:37; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:55, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:84.
  • the anti-FasL antibody comprises VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 106; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 134.
  • the anti-FasL antibody comprises: a VH comprising the amino acid sequence of SEQ ID NO: 106 or a variant thereof having at least about 80% ( e.g. , at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity; and a VL comprising the amino acid sequence of SEQ ID NO: 134 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 134.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 106, and a VL comprising the amino acid sequence of SEQ ID NO: 134.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO:7, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO:23, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO:38, or the V h A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:23, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:38; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:55, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 107; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 135.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 107, and a VL comprising the amino acid sequence of SEQ ID NO: 135.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:24, HC-CDR3 comprising the amino acid sequence of SEQ ID NO:37, or the V h Variants comprising up to about 5 amino acid substitutions in their HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:24, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:37; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:55, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 108; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 136.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 108, and a VL comprising the amino acid sequence of SEQ ID NO: 136.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO:8, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO:25, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO:38, or the V h Variants comprising up to about 5 amino acid substitutions in their HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:8, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:25, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:38; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:55, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 109; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 137.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 109, and a VL comprising the amino acid sequence of SEQ ID NO: 137.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO:7, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO:24, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO:38, or the V h A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:72, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:24, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:38; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:55, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:72, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 110; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 138.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 110, and a VL comprising the amino acid sequence of SEQ ID NO: 138.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO:7, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO:24, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO:38, or the V h Variants comprising up to about 5 amino acid substitutions in their HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:24, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:38; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:55, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 111; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 139.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 111, and a VL comprising the amino acid sequence of SEQ ID NO: 139.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:8, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:25, HC-CDR3 comprising the amino acid sequence SEQ ID NO:38, or a variant of said VH comprising a substitution of up to about 5 amino acids in its HC-CDRs; and a VL comprising: LC- CDR1 comprising the amino acid sequence of SEQ ID NO:56, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:71, LC-CDR3 comprising the amino acid sequence of SEQ ID NO:85, or a variant of said VL comprising at most about 5 amino acids in its LC-CDRs amino acid substitutions.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:8, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:25, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:38; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:56, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85.
  • the anti-FasL antibody comprises VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in VH as shown in amino acid sequence SEQ ID NO: 112; and VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in VL as shown in amino acid sequence SEQ ID NO: 140.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 112, and a VL comprising the amino acid sequence of SEQ ID NO: 140.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO:7, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO:24, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO:38, or the V h A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:86, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:24, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:38; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:55, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:86.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 113; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 141.
  • the anti-FasL antibody comprises: a VH comprising the amino acid sequence of SEQ ID NO: 113 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 113; and a VL comprising the amino acid sequence of SEQ ID NO: 141 or a variant thereof, The variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 113, and a VL comprising the amino acid sequence of SEQ ID NO: 141.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO:9, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO:26, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO:39, or the V h A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:57, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:73, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:87, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:9, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:26, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:39; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:57, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:73, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:87.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 114; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 142.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 114, and a VL comprising the amino acid sequence of SEQ ID NO: 142.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO:2, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO:27, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO:40, or the V h A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:58, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:73, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:88, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:27, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:40; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:73, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:88.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 115; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 143.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 115, and a VL comprising the amino acid sequence of SEQ ID NO: 143.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO: 10, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO: 20, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 41, or the V h A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:59, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:68, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:89, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises VH comprising: HC- CDR1 comprising the amino acid sequence of SEQ ID NO: 10, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 41; and VL comprising: LC- CDR1 comprising the amino acid sequence of SEQ ID NO: 59, LC-
  • CDR2 comprising the amino acid sequence of SEQ ID NO:68
  • LC-CDR3 comprising the amino acid sequence of SEQ ID NO:89.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 116; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 144.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 116, and a VL comprising the amino acid sequence of SEQ ID NO: 144.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO:6, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO:22, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO:37, or the V h A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:90, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:6, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:22, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:37; and V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:55, LC -CDR2 comprising the amino acid sequence of SEQ ID NO:71, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:90.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 117; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 145.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 117, and a VL comprising the amino acid sequence of SEQ ID NO: 145.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO: 11, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO: 28, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 42, or the V h A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:60, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:74, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:91, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC- CDR1 comprising the amino acid sequence of SEQ ID NO: 11, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 42; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 60, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:74, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:91.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 118; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 146.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 118, and a VL comprising the amino acid sequence of SEQ ID NO: 146.
  • the anti-FasL antibody comprises a VH comprising: HC- CDR1 comprising the amino acid sequence of SEQ ID NO: 12, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 29, HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43, or a variant of the VH comprising up to about 5 amino acid substitutions in the HC-CDRs; and a VL comprising: LC- CDR1 comprising Amino acid sequence SEQ ID NO:61, LC-CDR2 comprising the amino acid sequence SEQ ID NO: 75, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 92, or a variant of said VL , comprising up to about 5 amino acid substitutions in its LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC- CDR1 comprising the amino acid sequence of SEQ ID NO:12, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:29, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:43; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:61, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:75, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:92.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 119; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 147.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 119, and a VL comprising the amino acid sequence of SEQ ID NO: 147.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO: 12, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO: 29, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 44, or the V h A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:62, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:75, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:93, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC- CDR1 comprising the amino acid sequence of SEQ ID NO: 12, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 29, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 44; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 62, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:75, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:93.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 120; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 148.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 120, and a VL comprising the amino acid sequence of SEQ ID NO: 148.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO: 13, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO: 30, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 45, or the V h Variants comprising up to about 5 amino acid substitutions in their HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:63, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:73, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:94, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC- CDR1 comprising the amino acid sequence of SEQ ID NO:13, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:30, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:45; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:63, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:73, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:94.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 121; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 149.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 121, and a VL comprising the amino acid sequence of SEQ ID NO: 149.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO: 14, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO: 20, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 46, or the V h A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:51, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:68, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:95, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC- CDR1 comprising the amino acid sequence of SEQ ID NO:14, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:46; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:51, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:68, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:95.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 122; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 150.
  • the anti-FasL antibody comprises: a VH comprising the amino acid sequence of SEQ ID NO: 122 or a variant thereof having at least about 80% ( e.g. , at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity; and a VL comprising the amino acid sequence of SEQ ID NO: 150 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 150.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 122, and a VL comprising the amino acid sequence of SEQ ID NO: 150.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO: 15, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO: 20, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 47, or the V h Variants comprising up to about 5 amino acid substitutions in their HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:64, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:68, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:96, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 15, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 47; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 64, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:68, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:96.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 123; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 151.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 123, and a VL comprising the amino acid sequence of SEQ ID NO: 151.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO: 16, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO: 31, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 48, or the V h Variants comprising up to about 5 amino acid substitutions in their HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:65, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:76, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:97, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises VH comprising: HC- CDR1 comprising the amino acid sequence of SEQ ID NO:16, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:31, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:48; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:65, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:76, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:97.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 124; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 152.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 124, and a VL comprising the amino acid sequence of SEQ ID NO: 152.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO: 17, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO: 28, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 49, or the V h A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:66, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:74, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:98, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises VH comprising: HC- CDR1 comprising the amino acid sequence of SEQ ID NO:17, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:28, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:49; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:66, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:74, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:98.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 125; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 153.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 125, and a VL comprising the amino acid sequence of SEQ ID NO: 153.
  • the anti-FasL antibody comprises V h , the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO: 17, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO: 28, HC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 50, or the V h A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:60, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:74, LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:91, or the V L variants comprising up to about 5 amino acid substitutions in the LC-CDRs.
  • the anti-FasL antibody comprises a VH comprising: HC- CDR1 comprising the amino acid sequence of SEQ ID NO: 17, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 50; and VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 60, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:74, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:91.
  • the anti-FasL antibody comprises a VH comprising HC-CDR1, HC-CDR2 and HC-CDR3 contained in a VH as shown in the amino acid sequence of SEQ ID NO: 126; and a VL comprising LC-CDR1, LC-CDR2 and LC-CDR3 contained in a VL as shown in the amino acid sequence of SEQ ID NO: 154.
  • the anti-FasL antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 126, and a VL comprising the amino acid sequence of SEQ ID NO: 154.
  • amino acid substitutions described above are limited to the "exemplary substitutions” shown in Table 4 herein. In some embodiments, amino acid substitutions are limited to the "preferred substitutions” shown in Table 4 herein.
  • functional epitopes can be resolved by combined alanine scanning methods.
  • combinatorial alanine scanning techniques can be used to identify amino acids in the FasL protein that are essential for interaction with anti-FasL antibodies.
  • the epitope is conformational, and the crystal structure of an anti-FasL antibody bound to a FasL protein can be used to identify the epitope.
  • the application provides antibodies that compete for binding to FasL with any of the anti-FasL antibodies described herein.
  • antibodies are provided that compete for binding to an epitope on FasL with any of the anti-FasL antibodies described herein.
  • an anti-FasL antibody is provided that binds to the same epitope as an anti-FasL antibody molecule comprising a VH and a VL , wherein the VH comprises the amino acid sequence set forth in any of SEQ ID NOs: 99-126, and the VL comprises the amino acid sequence set forth in any of SEQ ID NOs: 127-154.
  • an anti-FasL antibody that competes for binding to FasL with an anti-FasL antibody comprising a VH and a VL , wherein the VH comprises the amino acid sequence set forth in any of SEQ ID NOs: 99-126, and the VL comprises the amino acid sequence set forth in any of SEQ ID NOs: 127-154.
  • competition assays can be used to identify monoclonal antibodies that compete for binding to FasL with the anti-FasL antibodies described herein. Competition experiments can determine whether two antibodies bind to the same epitope by recognizing the same or sterically overlapping epitopes or by one antibody competitively inhibiting binding of the other antibody to the antigen. In certain embodiments, such competing antibodies bind to the same epitope as the antibodies described herein.
  • Some exemplary competition assays include, but are not limited to, conventional assays as mentioned in Harlow and Lane (1988) Antibodies: A Laboratory Manual ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
  • each antibody is said to bind the same epitope if it blocks 50% or more of the binding of the other antibody.
  • antibodies that compete with the anti-FasL antibodies described herein are chimeric, humanized, or fully human antibodies.
  • Exemplary anti-FasL antibody sequences are shown in Table 2 and Table 3, wherein the CDRs are numbered according to the Chothia definition. Those skilled in the art will recognize that there are a number of known algorithms (Chothia's definition) to predict the location of CDRs and define antibody light and heavy chain variable regions. Also within the scope of this application are antibodies comprising the CDRs, VH and/or VL sequences of antibodies as described herein, but based on prediction algorithms other than those exemplified in the table below.
  • the anti-FasL antibody is a full length anti-FasL antibody.
  • the full length anti-FasL antibody is IgA, IgD, IgE, IgG or IgM.
  • the full-length anti-FasL antibody comprises an IgG constant region, such as the constant region of IgGl, IgG2, IgG3, IgG4, or variants thereof.
  • the full-length anti-FasL antibody comprises Contains the lambda light chain constant region.
  • the full length anti-FasL antibody comprises a kappa light chain constant region.
  • the full length anti-FasL antibody is a full length human anti-FasL antibody. In some embodiments, the full length anti-FasL antibody comprises a mouse immunoglobulin Fc sequence. In some embodiments, the full-length anti-FasL antibody comprises an altered or otherwise altered Fc sequence such that it has enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effector functions.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • CDC complement-dependent cytotoxicity
  • a full length anti-FasL antibody comprising an IgG1 constant region that specifically binds FasL.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG2 constant region that specifically binds FasL is provided.
  • the IgG2 is human IgG2.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG3 constant region that specifically binds FasL is provided.
  • the IgG3 is human IgG3.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region that specifically binds FasL.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence shown in any of SEQ ID NOs: 1-17, HC-CDR2 comprising the amino acid sequence shown in any of SEQ ID NOs: 18-31, and HC-CDR3 comprising SEQ ID NOs: 32-5 Any of the amino acid sequences shown in O, or variants of the heavy chain variable domain, comprising up to about 5 (eg, 1, 2, 3, 4 or 5) amino acid substitutions in its HC-CDR sequence; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence shown in any of SEQ ID NOs: 51-66, LC-CDR2 comprising the amino acid sequence shown in any of SEQ ID NOs: 67-76, and LC- CDR3 comprising SEQ ID NOs: The amino acids shown in O, or variants of the heavy chain variable domain, compris
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region wherein the anti-FasL antibody comprises a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence shown in any of SEQ ID NOs: 1-17, HC-CDR2 comprising the amino acid sequence shown in any of SEQ ID NOs: 18-31, and HC-CDR3 comprising SEQ ID NOs: 32 -An amino acid sequence shown in any of -50, or a variant of the heavy chain variable domain, comprising at most about 5 (such as 1, 2, 3, 4 or 5) amino acid substitutions in its HC-CDR sequence; and b) a light chain variable domain, the light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence shown in any of SEQ ID NOs:51-66, LC-CDR2 comprising the amino acid sequence shown in any of SEQ ID NOs:67-76, and LC-CDR3 comprising the amino
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence shown in any of SEQ ID NOs: 1-17, HC-CDR2 comprising the amino acid sequence shown in any of SEQ ID NOs: 18-31, and HC-CDR3 comprising SEQ ID NOs: 32-5 The amino acid sequence shown in any of O; and b) the light chain variable domain, the light chain variable domain comprising: LC-CDR1, it comprises the amino acid sequence shown in any of SEQ ID NOs:51-66, LC-CDR2, it comprises the amino acid sequence shown in any of SEQ ID NOs:67-76, and LC-CDR3, it comprises the amino acid sequence shown in any of SEQ ID NOs:77-98.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence shown in any of SEQ ID NOs: 1-17, HC-CDR2 comprising the amino acid sequence shown in any of SEQ ID NOs: 18-31, and HC-CDR3 comprising SEQ ID NOs: 3 The amino acid sequence shown in any of 2-50; and b) the light chain variable domain, the light chain variable domain comprising: LC-CDR1, which comprises the amino acid sequence shown in any of SEQ ID NOs:51-66, LC-CDR2, which comprises the amino acid sequence shown in any of SEQ ID NOs:67-76, and LC-CDR3, which comprises the amino acid sequence shown in any of SEQ ID NOs:77-98.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 18, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 32; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:51, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:67, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:77.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:19, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:32; and b) a light chain variable domain comprising : LC-CDR1 comprising the amino acid sequence of SEQ ID NO:51, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:68, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:78.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 18, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 32; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:51, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:67, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:79.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:33; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:52, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:68, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:80.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:34; and b) a light chain variable domain comprising : LC-CDR1 comprising the amino acid sequence of SEQ ID NO:52, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:68, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:81.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:4, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:35; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:53, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:69, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:82.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:5, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:21, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:36; and b) a light chain variable domain comprising the light chain variable
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:54, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:70, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:83.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:6, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:22, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:37; and b) a light chain variable domain comprising : LC-CDR1 comprising the amino acid sequence of SEQ ID NO:55, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:71, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:84.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 23, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 38; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 24, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:8, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:25, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:38; and b) a light chain variable domain comprising : LC-CDR1 comprising the amino acid sequence of SEQ ID NO:55, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:71, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:85.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 24, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 38; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:72, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 24, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 38; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:8, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:25, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:38; and b) a light chain variable domain comprising : LC-CDR1 comprising the amino acid sequence of SEQ ID NO:56, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:71, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:85.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 24, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 38; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:86.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:9, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:26, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:39; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:57, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:73, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:87.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:27, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:40; and b) a light chain variable domain comprising : LC-CDR1 comprising the amino acid sequence of SEQ ID NO:58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:73, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:88.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 10, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 41; and b) a light chain variable domain comprising the light chain
  • the variable domain comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:59, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:68, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:89.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 22, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:90.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 11, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 42; and b) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 42; Comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:60, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:74, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:91.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 12, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 29, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43; and b) a light chain variable domain comprising the light chain
  • the variable domain comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:61, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:75, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:92.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 12, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 29, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 44; and b) a light chain variable domain comprising the light chain
  • the variable domain comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:62, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:75, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:93.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 13, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 30, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 45; and b) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 45; and b) a light chain variable domain comprising Comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:63, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:73, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:94.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 14, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 46; and b) a light chain variable domain comprising the light chain
  • the variable domain comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:51, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:68, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:95.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 15, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 47; and b) a light chain variable domain comprising the light chain
  • the variable domain comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:64, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:68, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:96.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 16, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 31, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 48; and b) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 48; and b) a light chain variable domain comprising Comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:65, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:76, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:97.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 17, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 49; and b) a light chain variable domain comprising the light chain
  • the variable domain comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:66, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:74, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:98.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 17, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 50; and b) a light chain variable domain comprising the light chain
  • the variable domain comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:60, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:74, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:91.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 18, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 32; and b) a light chain variable domain comprising : LC-CDR1 comprising the amino acid sequence of SEQ ID NO:51, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:67, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:77.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:19, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:32; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:51, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:68, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:78.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 18, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 32; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:51, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:67, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:79.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:33; and b) a light chain variable domain comprising : LC-CDR1 comprising the amino acid sequence of SEQ ID NO:52, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:68, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:80.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:34; and b) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:34; and b) a light chain variable domain comprising
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:52, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:68, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:81.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:4, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:35; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:53, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:69, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:82.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:5, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:21, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:36; and b) a light chain variable domain comprising : LC-CDR1 comprising the amino acid sequence of SEQ ID NO:54, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:70, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:83.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:6, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:22, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:37; and b) a light chain variable domain comprising
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:84.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 23, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 38; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:24, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:37; and b) a light chain variable domain comprising : LC-CDR1 comprising the amino acid sequence of SEQ ID NO:55, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:71, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:85.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:8, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:25, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:38; and b) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:38; and b) a light chain variable domain comprising The structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 24, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 38; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:72, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:24, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:38; and b) a light chain variable domain comprising : LC-CDR1 comprising the amino acid sequence of SEQ ID NO:55, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:71, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:85.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:8, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:25, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:38; and b) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:38; and b) a light chain variable domain comprising The structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:56, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:85.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 24, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 38; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:55, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:71, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:86.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:9, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:26, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:39; and b) a light chain variable domain comprising : LC-CDR1 comprising the amino acid sequence of SEQ ID NO:57, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:73, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:87.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:27, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:40; and b) a light chain variable domain comprising:
  • the structural domain comprises: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:58, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:73, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:88.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 10, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 41; and b) a light chain variable domain comprising the light chain
  • the variable domain comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:59, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:68, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:89.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:6, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:22, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:37; and b) a light chain variable domain comprising : LC-CDR1 comprising the amino acid sequence of SEQ ID NO:55, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:71, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:90.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 11, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 42; and b) a light chain variable domain comprising the light chain
  • the variable domain comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:60, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:74, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:91.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 12, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 29, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43; and b) a light chain variable domain comprising the light chain
  • the variable domain comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:61, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:75, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:92.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 12, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 29, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 44; and b) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 44; and b) a light chain variable domain comprising Comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:62, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:75, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:93.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 13, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 30, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 45; and b) a light chain variable domain comprising the light chain
  • the variable domain comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:63, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:73, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:94.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 14, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 46; and b) a light chain variable domain comprising the light chain
  • the variable domain comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:51, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:68, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:95.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 15, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 47; and b) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 47; and b) a light chain variable domain comprising Comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:64, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:68, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:96.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 16, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 31, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 48; and b) a light chain variable domain comprising the light chain
  • the variable domain comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:65, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:76, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:97.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 17, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 49; and b) a light chain variable domain comprising the light chain
  • the variable domain comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:66, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:74, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:98.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 17, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 50; and b) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 50; and b) a light chain variable domain comprising Comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:60, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:74, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:91.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the IgG2 is human IgG2.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the IgG3 is human IgG3.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region
  • the anti-FasL antibody comprises: a heavy chain variable domain (V H ), said (V H ) comprising the amino acid sequence shown in any one of SEQ ID NOs:99-126, and a light chain variable domain (V L ), said (V L ) comprising an amino acid sequence shown in any one of SEQ ID NOs:127-154.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region
  • the anti-FasL antibody comprises: a heavy chain variable domain (V H ), said V H comprising the amino acid sequence shown in any of SEQ ID NOs:99-126, and a light chain variable domain (V L ), said V L comprising an amino acid sequence shown in any of SEQ ID NOs:127-154.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO:99 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:99; and VL comprising the amino acid sequence of SEQ ID NO:127 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:127 .
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region
  • the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 100 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 100; and VL comprising the amino acid sequence of SEQ ID NO: 128 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 128 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 101 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 101; and VL comprising the amino acid sequence of SEQ ID NO: 129 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 129 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 102 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 102; and VL comprising the amino acid sequence of SEQ ID NO: 130 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 130 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 103 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 103; and VL comprising the amino acid sequence of SEQ ID NO: 131 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 131 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light The chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 104 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 104; and VL comprising the amino acid sequence of SEQ ID NO: 132 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 132 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 105 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 105; and VL comprising the amino acid sequence of SEQ ID NO: 133 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 133 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 106 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 106; and VL comprising the amino acid sequence of SEQ ID NO: 134 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 134 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 107 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 107; and VL comprising the amino acid sequence of SEQ ID NO: 135 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 135 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises Contains or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 108 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 108; and VL comprising the amino acid sequence of SEQ ID NO: 136 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 136 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 109 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 109; and VL comprising the amino acid sequence of SEQ ID NO: 137 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 137 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 110 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 110; and VL comprising the amino acid sequence of SEQ ID NO: 138 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 138 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 111 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 111; and VL comprising the amino acid sequence of SEQ ID NO: 139 or a variant thereof comprising the amino acid sequence of SEQ ID NO: 139 has at least about 80% sequence identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 112 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 112; and VL comprising the amino acid sequence of SEQ ID NO: 140 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 140 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 113 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 113; and VL comprising the amino acid sequence of SEQ ID NO: 141 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 141 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising an IgG1 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 114 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 114; and VL comprising the amino acid sequence of SEQ ID NO: 142 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 142 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 115 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 115; and VL comprising the amino acid sequence of SEQ ID NO: 143 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 143 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 116 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 116; and VL comprising the amino acid sequence of SEQ ID NO: 144 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 144 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 117 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 117; and VL comprising the amino acid sequence of SEQ ID NO: 145 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 145 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 118 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 118; and VL comprising the amino acid sequence of SEQ ID NO: 146 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 146 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light The chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 119 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119; and VL comprising the amino acid sequence of SEQ ID NO: 147 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 147 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 120 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 120; and VL comprising the amino acid sequence of SEQ ID NO: 148 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 148 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 121 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 121; and VL comprising the amino acid sequence of SEQ ID NO: 149 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 149 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 122 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 122; and VL comprising the amino acid sequence of SEQ ID NO: 150 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 150 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises Contains or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 123 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 123; and VL comprising the amino acid sequence of SEQ ID NO: 151 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 151 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 124 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 124; and VL comprising the amino acid sequence of SEQ ID NO: 152 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 152 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 125 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 125; and VL comprising the amino acid sequence of SEQ ID NO: 153 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 153 identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG1 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 126 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 126; and VL comprising the amino acid sequence of SEQ ID NO: 154 or a variant thereof comprising the amino acid sequence of SEQ ID NO: 154 has at least about 80% sequence identity.
  • the IgG1 is human IgG1.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO:99 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:99; and VL comprising the amino acid sequence of SEQ ID NO:127 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:127 .
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 100 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 100; and VL comprising the amino acid sequence of SEQ ID NO: 128 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 128 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 101 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 101; and VL comprising the amino acid sequence of SEQ ID NO: 129 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 129 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 102 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 102; and VL comprising the amino acid sequence of SEQ ID NO: 130 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 130 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 103 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 103; and VL comprising the amino acid sequence of SEQ ID NO: 131 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 131 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 104 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 104; and VL comprising the amino acid sequence of SEQ ID NO: 132 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 132 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 105 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 105; and VL comprising the amino acid sequence of SEQ ID NO: 133 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 133 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light The chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 106 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 106; and VL comprising the amino acid sequence of SEQ ID NO: 134 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 134 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 107 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 107; and VL comprising the amino acid sequence of SEQ ID NO: 135 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 135 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 108 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 108; and VL comprising the amino acid sequence of SEQ ID NO: 136 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 136 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 109 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 109; and VL comprising the amino acid sequence of SEQ ID NO: 137 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 137 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises Contains or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 110 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 110; and VL comprising the amino acid sequence of SEQ ID NO: 138 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 138 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 111 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 111 ; and VL comprising the amino acid sequence of SEQ ID NO: 139 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 139 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 112 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 112; and VL comprising the amino acid sequence of SEQ ID NO: 140 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 140 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 113 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 113; and VL comprising the amino acid sequence of SEQ ID NO: 141 or a variant thereof comprising the amino acid sequence of SEQ ID NO: 141 has at least about 80% sequence identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 114 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 114; and VL comprising the amino acid sequence of SEQ ID NO: 142 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 142 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full-length anti-FasL antibody comprising an IgG4 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 115 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 115; and VL comprising the amino acid sequence of SEQ ID NO: 143 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 143 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 116 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 116; and VL comprising the amino acid sequence of SEQ ID NO: 144 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 144 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 117 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 117; and VL comprising the amino acid sequence of SEQ ID NO: 145 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 145 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 118 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 118; and VL comprising the amino acid sequence of SEQ ID NO: 146 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 146 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 119 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119; and VL comprising the amino acid sequence of SEQ ID NO: 147 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 147 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising: VH comprising the amino acid sequence of SEQ ID NO: 120 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 120; and VL comprising the amino acid sequence of SEQ ID NO: 148 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 148 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light The chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 121 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 121; and VL comprising the amino acid sequence of SEQ ID NO: 149 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 149 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 122 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 122; and VL comprising the amino acid sequence of SEQ ID NO: 150 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 150 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 123 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 123; and VL comprising the amino acid sequence of SEQ ID NO: 151 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 151 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 124 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 124; and VL comprising the amino acid sequence of SEQ ID NO: 152 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 152 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises Contains or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 125 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 125; and VL comprising the amino acid sequence of SEQ ID NO: 153 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 153 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • a full length anti-FasL antibody comprising an IgG4 constant region comprising an IgG4 constant region, wherein the anti-FasL antibody comprises: VH comprising the amino acid sequence of SEQ ID NO: 126 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 126; and VL comprising the amino acid sequence of SEQ ID NO: 154 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 154 identity.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:156 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • Binding affinity is expressed as Kd, Koff, Kon or Ka.
  • Koff refers to the rate constant for dissociation of an antibody from an antigen/antibody complex, as determined by a kinetic selective device.
  • Kon refers to the association rate constant for the binding of an antibody to an antigen to form an antigen/antibody complex.
  • the equilibrium dissociation constant Kd used herein refers to the dissociation constant when a specific antibody-antigen interacts, and refers to the antigen concentration required when the antigen occupies half of all antibody binding sites and reaches equilibrium in the antibody molecule solution, which is equal to Koff/Kon. The determination of Kd assumes that all bound molecules are in solution.
  • the corresponding equilibrium dissociation rate constant is expressed in terms of EC50, which is a good approximation of Kd.
  • the affinity association constant Ka is the reciprocal of the dissociation constant Kd.
  • the dissociation constant (Kd) can be used as an indicator of the affinity of the antibody moiety for the antigen.
  • simple analysis can be performed by the Scatchard method using antibodies labeled with various markers, and a Biacore instrument (manufactured by Amersham Biosciences), and the interaction between biomolecules can be analyzed by surface plasmon resonance according to the user's manual or accompanying kit. use these methods
  • the Kd value obtained by the method is expressed in the unit M.
  • Antibodies that specifically bind to a target may have, for example, a Kd value of ⁇ 10 ⁇ 7 M, ⁇ 10 ⁇ 8 M, ⁇ 10 ⁇ 9 M, ⁇ 10 ⁇ 10 M, ⁇ 10 ⁇ 11 M, ⁇ 10 ⁇ 12 M, or ⁇ 10 ⁇ 13 M.
  • the binding specificity of an antibody can be determined experimentally by methods known in the art. These methods include, but are not limited to, Western blots, ELISA-, RIA-, ECL-, IRMA-, EIA-, BIAcore tests, and peptide scans, among others.
  • the anti-FasL antibody specifically binds a FasL target with a Kd value of 10 ⁇ 7 M to 10 ⁇ 13 M (e.g., 10 ⁇ 7 M to 10 ⁇ 13 M, 10 ⁇ 8 M to 10 ⁇ 13 M, 10 ⁇ 9 M to 10 ⁇ 13 M, or 10 ⁇ 10 M to 10 ⁇ 12 M).
  • a Kd value of 10 ⁇ 7 M to 10 ⁇ 13 M e.g., 10 ⁇ 7 M to 10 ⁇ 13 M, 10 ⁇ 8 M to 10 ⁇ 13 M, 10 ⁇ 9 M to 10 ⁇ 13 M, or 10 ⁇ 10 M to 10 ⁇ 12 M.
  • the Kd value for binding of the anti-FasL antibody to the non-target is higher than the Kd value of the anti-FasL antibody to the target, and in some embodiments cited herein, the binding affinity of the anti-FasL antibody to the target (e.g., FasL) is higher than the binding affinity of the anti-FasL antibody to the non-target.
  • non-target refers to an antigen other than FasL.
  • the Kd value of the anti-FasL antibody (for FasL) binding to a non-FasL target differs by at least 10 times, such as 10-100 times, 100-1000 times, 103-104 times , 104-105 times, 105-106 times, 106-107 times, 107-108 times, 108-109 times, 10 9 -10 10 times, 10 10 -10 11 times , 10 11 -10 12 times .
  • the non-target binding Kd value of the anti-FasL antibody is 10 ⁇ 1 M to 10 ⁇ 6 M (eg, 10 ⁇ 1 M to 10 ⁇ 6 M, 10 ⁇ 1 M to 10 ⁇ 5 M, 10 ⁇ 2 M to 10 ⁇ 4 M).
  • the non-target refers to an antigen other than FasL. ⁇ , ⁇ , ⁇ FasL ⁇ FasL ⁇ Kd ⁇ 10 -1 M ⁇ 10 -6 M ⁇ 1 ⁇ 10 -1 M ⁇ 5 ⁇ 10 -6 M ⁇ 10 -1 M ⁇ 10 -5 M ⁇ 1 ⁇ 10 -1 M ⁇ 5 ⁇ 10 -5 M ⁇ 10 -1 M ⁇ 10 -4 M ⁇ 1 ⁇ 10 -1 M ⁇ 5 ⁇ 10 -4 M ⁇ 10 -1 M ⁇ 10 -3 M ⁇ 1 ⁇ 10 -1 M ⁇ 5 ⁇ 10 -3 M ⁇ 10 -1 M ⁇ 10 -2 M ⁇ 10 -2 M ⁇ 10 -6 M ⁇ 1 ⁇ 10 -2 M ⁇ 5 ⁇ 10 -6 M ⁇ 10 -2 M ⁇ 10 -5 M ⁇ 1 ⁇ 10 -2 M ⁇ 5 ⁇ 10 -5 M ⁇ 10 -2 M ⁇ 10 -4 M ⁇ 1 ⁇ 10 -2 M ⁇ 10 -3 M ⁇ 10 -6 M ⁇ 10 -3 M ⁇ 10 -6 M ⁇ 10 -3 M ⁇ 10 -6 M ⁇ 10 -5 M ⁇ 1 ⁇ 10 -2 M ⁇ 5 ⁇ 10 -5 M ⁇
  • the Kd value of the anti-FasL antibody binding to the FasL target is 10 ⁇ 7 M to 10 ⁇ 13 M (for example, 10 ⁇ 7 M to 10 ⁇ 13 M, 10 ⁇ 8 M to 10 ⁇ 13 M, 10 ⁇ 9 M to 10 ⁇ 13 M, 10 ⁇ 10 M to 10 ⁇ 1 2 M), and the Kd value for non-target binding is 10 -1 M to 10 -6 M (eg, 10 -1 M to 10 -6 M, 10 -1 M to 10 -5 M, 10 -2 M to 10 -4 M).
  • the binding affinity of the anti-FasL antibody is compared to the binding affinity of a control anti-FasL antibody (eg, 119-4A or APG101 or MAB126-100).
  • a control anti-FasL antibody eg, 119-4A or APG101 or MAB126-100.
  • the Kd value of the binding between the control anti-FasL antibody and FasL may be at least 2 times, such as 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 10-100 times, 100-1000 times, 103-104 times the Kd value of the binding between the anti-FasL antibody described herein and FasL.
  • nucleic acid molecules encoding anti-FasL antibodies are also contemplated.
  • a nucleic acid (or set) encoding a full-length anti-FasL antibody is provided, including any one of the full-length anti-FasL antibodies described herein.
  • the nucleic acid (or a set of nucleic acids) of the anti-FasL antibody described herein may also include a nucleic acid sequence encoding a polypeptide tag (eg, protein purification tag, His tag, HA tag).
  • an isolated host cell comprising an anti-FasL antibody, an isolated nucleic acid encoding an anti-FasL antibody polypeptide component, or a vector comprising a nucleic acid encoding an anti-FasL antibody polypeptide component described herein.
  • a variant includes a nucleotide sequence that hybridizes to a nucleic acid sequence encoding an anti-FasL antibody of the present application at least under moderately stringent hybridization conditions.
  • the present application also provides a vector into which the nucleic acid sequence of the present application can be inserted.
  • the natural or synthetic nucleic acid encoding the anti-FasL antibody is inserted into a suitable expression vector, so that the nucleic acid is operably linked to the 5' and 3' end regulatory elements, such as including a promoter (such as a lymphocyte-specific promoter) and a 3' untranslated region (UTR), and the anti-FasL antibody (such as a full-length anti-FasL antibody) can be expressed.
  • the vectors are suitable for replication and integration in eukaryotic host cells. Typical cloning and expression vectors contain transcriptional and translational terminators, initiation sequences and promoters to regulate the expression of the nucleic acid sequence of interest.
  • nucleic acids described herein can also be used in nucleic acid immunization and gene therapy by using standard gene delivery protocols. Methods of nucleic acid delivery are known in the art. See, eg, U.S. Pat. Nos. 5,399,346, 5,580,859, 5,589,466, the entire contents of which are incorporated herein by reference. In some embodiments, the present application also provides gene therapy vectors.
  • Nucleic acids can be cloned into many types of vectors.
  • nucleic acids can be cloned into vectors including, but not limited to, plasmids, phagemids, phage derivatives, animal viruses, and cosmids.
  • Vectors of particular interest include expression vectors, replication vectors, probe generation vectors and sequencing vectors.
  • expression vectors can be provided to cells in the form of viral vectors.
  • Viral vector technology is well known in the art and described, for example, in Green and Sambrook (2013, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York), among other virology or molecular biology manuals.
  • Viruses that can be used as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpesviruses, and lentiviruses.
  • suitable vectors include an origin of replication functional in at least one organism, a promoter sequence, convenient restriction enzyme sites, and one or more selectable markers (see, e.g., WO 01/96584; WO 01/29058; and U.S. Pat. No. 6,326,193).
  • retroviruses provide a convenient platform for gene delivery systems.
  • the gene of choice can be inserted into a vector and packaged using techniques known in the art in retroviral particles.
  • the recombinant virus is then isolated and delivered to cells of the subject either in vivo or in vitro.
  • retroviral systems are known in the art.
  • adenoviral vectors are used.
  • Many adenoviral vectors are known in the art.
  • lentiviral vectors are used.
  • Vectors derived from retroviruses are suitable tools for long-term gene transfer because they allow long-term stable integration of the transgene and propagation in progeny cells.
  • Lentiviral vectors have an additional advantage over tumor-derived retroviruses such as murine leukemia virus in that they can transduce non-dividing cells such as hepatocytes. At the same time, it has the added advantage of low immunogenicity.
  • promoter elements such as enhancers, regulate transcription initiation frequency. Typically they are located 30-110 bp upstream of the initiation site, although it has recently been discovered that many promoters also contain functional elements downstream of the initiation site.
  • the spacing between promoter elements is usually flexible so that promoter function is maintained when elements are swapped or moved relative to each other. In the thymidine kinase (tk) promoter, activity begins to decline when the spacing between promoter elements increases to 50 bp.
  • tk thymidine kinase
  • a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence.
  • the promoter sequence is a strong constitutive promoter sequence, which can drive high-level expression of any polynucleotide sequence operably linked to it.
  • Another example of a suitable promoter is the elongation factor 1 alpha (EF-1 alpha) promoter.
  • constitutive promoters can also be used, including but not limited to Simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus long terminal repeat (HIV-LTR) promoter, MoMuLV promoter, avian leukemia virus promoter, Epstein-Barr virus immediate early promoter, Rous sarcoma virus promoter and human gene promoters, such as including but not limited to actin promoter, myosin promoter, hemoglobin promoter and creatine kinase promoter.
  • SV40 Simian virus 40
  • MMTV mouse mammary tumor virus
  • HV-LTR human immunodeficiency virus long terminal repeat
  • MoMuLV promoter avian leukemia virus promoter
  • Epstein-Barr virus immediate early promoter Epstein-Barr virus immediate early promoter
  • Rous sarcoma virus promoter Rous sarcoma virus promoter
  • human gene promoters such as including but not limited to actin promote
  • an inducible promoter provides a molecular switch that turns on expression of a polynucleotide sequence to which it is operably linked when such expression is desired and turns off expression when it is not.
  • Inducible promoters include, but are not limited to, the metallothionein promoter, the glucocorticoid promoter, the progesterone promoter, and the tetracycline promoter.
  • expression of anti-FasL antibodies is inducible.
  • the nucleic acid sequence encoding an anti-FasL antibody is operably linked to an inducible promoter, including any of the inducible promoters described herein.
  • an inducible promoter provides a molecular switch that turns on expression of a polynucleotide sequence to which it is operably linked when expression is desired and turns off expression when expression is not desired.
  • exemplary inducible promoters suitable for use in eukaryotic cells include, but are not limited to, hormone regulatory elements (see, e.g., Mader, S. and White, JH (1993) Proc. Natl. Acad. Sci. USA 90:5603-5607), synthetic ligand regulatory elements (see Spencer, DM et al (1993) Science 262:1019-1024), and ionizing radiation regulatory elements (see Man. Ome, Y. et al.
  • the inducible promoter system used to express the anti-FasL antibody is the Tet system. In some embodiments, the inducible promoter system used to express the anti-FasL antibody is the E. coli lac repression system.
  • an exemplary inducible promoter system employed herein is the Tet system.
  • the system is based on the Tet system described by Gossen et al. (1993).
  • the polynucleotide of interest is controlled by a promoter comprising one or more Tet operator (TetO) sites.
  • TetO Tet operator
  • TetR Tet repressor
  • the activated state for example, in the presence of an inducer such as tetracycline (Tc), anhydrotetracycline, doxycycline (Dox) or an active analog thereof, the inducer releases TetR from TetO, thereby causing transcription to occur.
  • an inducer such as tetracycline (Tc), anhydrotetracycline, doxycycline (Dox) or an active analog thereof.
  • Doxycycline is a member of the tetracycline antibiotic family and its chemical name is 1-dimethylamino-2,4a,5,7-pentahydroxy-11-methyl-4,6-dioxy-1,4a,11,11a,12,12a-hexahydrotetraene-3-carboxamide.
  • TetR is codon optimized for expression in mammalian cells, such as mouse or human cells. Due to the degeneracy of the genetic code, most amino acids are encoded by more than one codon, resulting in a large number of variants in the sequence of a given nucleic acid without any change in the amino acid sequence it encodes. However, many organisms differ in their codon usage, also known as "codon bias" (ie, the preference for a given amino acid to use a particular codon). Codon bias is often associated with the presence of dominant tRNA species for specific codons, which in turn increases the efficiency of mRNA translation. A coding sequence derived from a particular species (eg, prokaryotes) can thus be tailored by codon optimization to enhance its expression in a different species (eg, eukaryotes).
  • Tet-Off transcription is inactivated in the presence of Tc or Dox.
  • a tetracycline-regulated transcriptional activator consisting of TetR fused to the strong transcriptional activation domain of herpes simplex virus VP16, regulates the expression of target nucleic acids under the transcriptional control of a tetracycline-responsive promoter element (TRE).
  • the TRE element consists of a TetO sequence fused in tandem to a promoter (usually a minimal promoter sequence derived from the human cytomegalovirus immediate early promoter).
  • Tc or Dox binds TRE and activates transcription of target genes.
  • tTA cannot bind TRE and target genes cannot be expressed.
  • rtTA is a fusion protein consisting of the TetR repressor and the VP16 transcriptional activation domain.
  • a change of 4 amino acids in the DNA-binding region of TetR altered the binding properties of rtTA so that it could only recognize the tetO sequence on the target transgenic TRE in the presence of Dox. Therefore, in the Tet-On system, rtTA can activate the transcription of TRE-regulated target genes only in the presence of Dox.
  • lac repressor system of E. coli (see Brown et al., Cell 49:603-612 (1987)).
  • the Lac repressor system functions by regulating the transcription of a polynucleotide of interest operably linked to a promoter comprising the lac operator (lacO).
  • lacO lac operator
  • lacR lac repressor
  • lacR lacR
  • lacR lacR
  • Expression of the polynucleotide of interest is induced by a suitable inducer, for example, isopropyl- ⁇ -Dthiogalactopyranoside (IPTG).
  • IPTG isopropyl- ⁇ -Dthiogalactopyranoside
  • the expression vector to be introduced into the cells may also contain a selectable marker gene or a reporter gene or both to facilitate the identification and selection of expressing cells from a population of cells transfected or infected with the viral vector.
  • selectable markers can be carried on separate DNA fragments and used in co-transfection experiments. Either a selectable marker gene or a reporter gene can be flanked by appropriate regulatory sequences to enable its expression in the host cell.
  • Useful selectable markers include, for example, antibiotic resistance genes such as neo and the like.
  • Reporter genes can be used to identify potentially transfected cells and evaluate the function of regulatory sequences.
  • a reporter gene is a gene not present in or expressed by a recipient organism or tissue that encodes a polypeptide whose expression is manifested by some readily detectable property, such as enzymatic activity. After the DNA is introduced into the recipient cells, the expression of the reporter gene is detected at an appropriate time.
  • Suitable reporter genes may include genes encoding luciferase, ⁇ -galactosidase, chloramphenicol acetyltransferase, secreted alkaline phosphatase, or green fluorescent protein (see, Ui-Tel et al., 2000 FEBS Letters 479:79-82).
  • Suitable expression systems are known and can be prepared by known techniques or obtained commercially.
  • the construct with the smallest 5' flanking region that exhibits the highest expression level of the reporter gene is considered a promoter.
  • Such a promoter region can be linked to a reporter gene and used to assess the ability of certain substances to regulate transcription driven by the promoter.
  • nucleic acid encoding any of the full-length anti-FasL antibodies described herein is provided.
  • the nucleic acid comprises one or more nucleic acid sequences encoding full-length anti-FasL antibody heavy and light chains.
  • each of the one or more nucleic acid sequences is contained in a separate vector.
  • at least some of the nucleic acid sequences are contained within the same vector.
  • all nucleic acid sequences are contained within the same vector.
  • Vectors may be selected, for example, from mammalian expression vectors and viral vectors (such as vectors derived from retroviruses, adenoviruses, adeno-associated viruses, herpesviruses, and lentiviruses).
  • mammalian expression vectors such as vectors derived from retroviruses, adenoviruses, adeno-associated viruses, herpesviruses, and lentiviruses.
  • vectors can be readily introduced into host cells, such as mammalian, bacterial, yeast or insect cells, by any method in the art.
  • expression vectors can be introduced into host cells by physical, chemical or biological methods.
  • polynucleotides are introduced into host cells by calcium phosphate transfection.
  • Biological methods for introducing polynucleotides of interest into host cells include the use of DNA and RNA vectors.
  • Viral vectors especially retroviral vectors, have become the most widely used method for inserting genes into mammalian cells, such as human cells.
  • Other viral vectors can be derived from lentiviruses, poxviruses, herpes simplex virus type 1, adenoviruses, and adeno-associated viruses, among others. See, eg, U.S. Pat. Nos. 5,350,674 and 5,585,362.
  • Chemical methods for introducing polynucleotides into host cells include colloidal dispersion systems, such as polymer complexes, nanocapsules, microspheres, magnetic beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
  • colloidal dispersion systems such as polymer complexes, nanocapsules, microspheres, magnetic beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
  • An exemplary colloidal system used as a delivery vehicle in vivo and in vitro is a liposome (eg, an artificial membrane vesicle).
  • an exemplary delivery vehicle is a liposome.
  • lipid formulations to introduce nucleic acids into host cells (in vitro, ex vivo, or in vivo).
  • the nucleic acid can be bound to a lipid.
  • Lipid-associated nucleic acids can be encapsulated into the aqueous interior of liposomes, dispersed within the lipid bilayer of liposomes, attached to liposomes via linker molecules that bind liposomes and oligonucleotides, entrapped in liposomes, form complexes with liposomes, dispersed in lipid-containing solutions, mixed with lipids, associated with lipids, suspended in lipids, contained in or mixed with micelles, or otherwise associated with lipids.
  • Lipid, lipid/DNA or lipid/expression vector-related compositions are not limited to any particular structure in solution. For example, they may exist in bilayer structures, in micelles or in "collapsed" structures.
  • Lipids are fatty substances, either naturally occurring or synthetic.
  • lipids include fat droplets naturally present in the cytoplasm, as well as a class of compounds containing long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, aminoalcohols, and aldehydes.
  • experiments can be performed to confirm the presence of the recombinant DNA sequence in the host cell.
  • Such experiments include, for example, "molecular biology” experiments well known to those skilled in the art. For example, Southern and Northern blotting, RT-PCR and PCR; "biochemical” experiments, such as detecting the presence or absence of a particular polypeptide, such as identification by immunological methods (ELISAs and Western blots) or by the experiments described herein are all within the scope of this application.
  • the anti-FasL antibody is or is derived from a monoclonal antibody. In some embodiments, the anti-FasL antibody comprises VH and VL from a monoclonal antibody, or a variant thereof. In some embodiments, the anti-FasL antibody further comprises CH1 and CL regions from a monoclonal antibody, or a variant thereof.
  • Monoclonal antibodies can be prepared using, for example, methods known in the art, including hybridoma cell methods, phage display methods, or using recombinant DNA methods. Additionally, exemplary phage display methods are described herein and in the Examples below.
  • lymphocytes In the hybridoma cell method, hamsters, mice or other suitable host animals are usually immunized with an immunizing agent to induce lymphocytes that produce or are capable of producing antibodies that specifically bind to the immunizing agent.
  • lymphocytes can be immunized in vitro. Immunizing agents may include polypeptides or fusion proteins of the protein of interest.
  • PBLs peripheral blood lymphocytes
  • splenocytes or lymph node cells are used if cells of non-human mammalian origin are desired.
  • Lymphocytes are fused with an immortal cell line using an appropriate fusion agent, such as polyethylene glycol, to form hybridoma cells.
  • Immortal cell lines are usually transformed mammalian cells, especially myeloma cells of rodent, bovine and human origin. Typically rat or mouse myeloma cell lines are used.
  • Hybridoma cells can be cultured in a suitable medium, which preferably contains one or more substances that inhibit the growth or survival of unfused immortalized cells.
  • a suitable medium which preferably contains one or more substances that inhibit the growth or survival of unfused immortalized cells.
  • the parental cells lack hypoxanthine-guanine phosphoribosyltransferase (HGPRT or HPRT)
  • the hybridoma cell culture medium typically includes hypoxanthine, aminopterin, and thymidine (HAT medium), which prevents the growth of HGPRT-deficient cells.
  • the immortalized cell line fuses efficiently, ensures high level and stable expression of antibody by the selected antibody-producing cells, and is sensitive to certain medium, such as HAT medium.
  • the immortal cell line is a mouse myeloma cell line available from, eg, the Salk Cell Collection, San Diego, California, and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human hybrid myeloma cell lines are also described for the production of human monoclonal antibodies.
  • the medium in which the hybridoma cells are grown can then be assayed for the presence of monoclonal antibodies directed against the polypeptide.
  • the binding specificity of monoclonal antibodies produced by hybridoma cells can be determined by immunoprecipitation or in vitro binding assays, such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA). Such techniques or analytical methods are known in the art.
  • the binding affinity of monoclonal antibodies can be determined, for example, by Scatchard analysis as described in Munson and Pollard, Anal. Biochem., 107:220 (1980).
  • hybridoma cells After the desired hybridoma cells have been identified, the clones of interest can be subcloned by limiting dilution and cultured by standard methods. Suitable media for this purpose include, for example, Modified Eagle's Medium (DMEM) and RPMI-1640 medium. Alternatively, hybridoma cells can be grown in ascites in mammals.
  • DMEM Modified Eagle's Medium
  • RPMI-1640 medium RPMI-1640
  • Monoclonal antibodies secreted by subclones can be isolated or purified from culture medium or ascites fluid by conventional immunoglobulin purification methods, such as protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • the anti-FasL antibody comprises a sequence selected from a clone of an antibody library (eg, a phage library displaying scFv or Fab fragments).
  • a clone of an antibody library eg, a phage library displaying scFv or Fab fragments.
  • Such clones can be identified by screening a combinatorial library of antibody fragments having the desired activity. For example, various methods are known in the art for generating phage display libraries and screening these libraries for antibodies with desired binding properties.
  • VH and VL gene repertoires are cloned separately by polymerase chain reaction (PCR), randomly recombined in a phage library, and then screened for antigen-binding phage, as described in Winter et al., Ann. Rev. Immunol., 12:433-455 (1994). Phage typically display antibody fragments as scFv fragments or as Fab fragments. Immune-derived library phages provide high-affinity antibodies against the immunogen without the need to construct hybridoma cells.
  • PCR polymerase chain reaction
  • natural repertoires eg, from humans
  • natural repertoires can be cloned to provide a single source of antibodies against multiple non-self and self-antigens without any immunization, as described in Griffiths et al., EMBO J, 12:725-734 (1993).
  • natural libraries can also be prepared by cloning non-rearranged V-gene fragments from stem cells, using PCR primers containing random sequences encoding CDR3 hypervariable regions, and rearranging in vitro, as described in Hoogenboom and Winter, J. Mol. Biol., 227:381-388 (1992).
  • Patent publications describing human antibody phage libraries include, for example, US Pat. No. 5,750,373 and US Patent Publication Nos. 7/0292936 and 2009/0002360.
  • the anti-FasL antibody is prepared by phage display screening the anti-FasL antibody portion in the library that can specifically bind to the target FasL.
  • the library can be a human scFv phage display library of unique human antibody fragments having a diversity of at least 1 ⁇ 10 9 (eg, at least 1 ⁇ 10 9 , 2.5 ⁇ 10 9 , 5 ⁇ 10 9 , 7.5 ⁇ 10 9 , 1 ⁇ 10 10 , 2.5 ⁇ 10 10 , 5 ⁇ 10 10 , 7.5 ⁇ 10 10 , or 1 ⁇ 10 11 ).
  • the library is a natural human library constructed from DNA extracted from PMBCs and spleens of healthy subjects, comprising all human heavy and light chain subfamilies.
  • the library is a human natural library constructed by DNA extracted from PMBCs isolated from patients with various diseases, such as patients with autoimmune diseases, cancer patients and patients with infectious diseases.
  • the library is a semi-synthetic human library in which the heavy chain CDR3s are completely randomized, with all amino acids (except cysteine) present at any given position with equal probability. (See eg, Hoet, RM et al., Nat. Biotechnol. 23(3):344-348, 2005).
  • the heavy chain CDR3 of the semi-synthetic human library is between 5 and 24 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24) amino acids in length.
  • the library is a fully synthetic phage display library.
  • the library is a non-human phage display library.
  • Phage clones with high affinity to target FasL can be screened by iterative binding of phage to target FasL bound to a solid support (such as beads for solution panning or mammalian cells for cell panning), followed by removal of unbound phage and elution of specifically bound phage. Subsequently, bound phage clones are eluted and used to infect suitable host cells, such as E.coli XL1-Blue, for expression and purification. Phage clones that specifically bind FasL can be enriched by multiple rounds of panning (eg, 2, 3, 4, 5, 6 or more rounds), such as solution panning, cell panning, or a combination of both. Specific binding of the enriched phage clones to the target FasL can be detected by any method known in the art, including, for example, ELISA and FACS.
  • Another way to screen antibody libraries is to display proteins on the surface of yeast cells.
  • Wittrup et al. (US Patents 6,699,658 and 6,696,251) developed a method for displaying libraries in yeast cells.
  • one component includes the yeast lectin protein (Aga1) anchored on the yeast cell wall, and the other component includes the second subunit of the lectin protein Aga2, which can be combined with the Aga1 protein through a disulfide bond and then displayed on the yeast cell surface.
  • the Agal protein is expressed by integrating the Agal gene into the yeast chromosome.
  • VH and VK fragments Human antibody V gene repertoires ( VH and VK fragments) were obtained by the PCR method using a set of degenerate primers (Sblattero, D. and Bradbury, A. Immunotechnology 3, 271-278 1998).
  • PCR templates were derived from commercially available RNA or cDNA, including PBMC, spleen, lymph node, bone marrow and tonsil. After combining independent VH and VK PCR libraries, they were assembled into scFv format by overlap extension PCR (Sheets, MD et al, Proc. Natl. Acad. Sci. USA 95, 6157-6162 1998).
  • yeast scFv display library To construct a yeast scFv display library, the resulting scFv PCR product was cloned into a yeast display plasmid in yeast by homologous recombination. (Chao, G, et al, Nat Protoc. 2006; 1(2):755-68. Miller KD, et al. Current Protocols in Cytometry 4.7.1-4.7.30, 2008).
  • Anti-FasL antibodies can be screened using a mammalian cell display system, in which antibody portions are displayed on the cell surface and antibodies specifically targeting FasL are isolated by antigen-directed screening methods (as described in US Patent No. 7,732,195B2).
  • a library of Chinese hamster ovary (CHO) cells displaying a large number of human IgG antibody genes can be created and used to discover clones expressing high-affinity antibody genes.
  • An alternative display system has been developed that enables simultaneous cell surface display and secretion of the same protein through alternative splicing, where the displayed protein phenotype remains genotype-related, allowing the simultaneous characterization of the secreted soluble antibody in biophysical and cell function-based assays.
  • This method overcomes many limitations of previous mammalian cell displays and enables direct screening and maturation of antibodies in the form of full-length, glycosylated IgGs (Peter M. Bowers, et al, Methods 2014, 65:44-56).
  • Transient expression systems are suitable for single rounds of antigen selection prior to antibody gene restoration and are therefore useful for selection from smaller libraries. Select the most useful antibody.
  • Stable exosome vectors offer an attractive option. Exosome vectors can be efficiently transfected and stably maintained at low copy numbers, allowing multiple rounds of panning and resolution of more complex antibody repertoires.
  • the IgG library is constructed based on the ligation of germline sequence V gene segments isolated from a panel of human donors with rearranged (D)J regions. RNA collected from 2000 human blood samples was reverse transcribed into cDNA, V H and V K fragments were amplified using V H and V K specific primers, and purified by gel extraction. IgG libraries were prepared by subcloning VH and VK fragments into display vectors containing IgG1 or K constant regions, respectively, and then electroporating or transducing 293T into cells.
  • VH and VK were ligated to generate scFv, which was then subcloned into a display vector, which was then electroporated or transduced into 293T cells.
  • IgG libraries are constructed based on germline sequence V gene fragments and rearranged (D)J regions isolated from a group of donors, which can be mice, rats, rabbits or monkeys.
  • Monoclonal antibodies can also be prepared by recombinant DNA methods, such as described in U.S. Patent No. 4,816,567.
  • DNA encoding the monoclonal antibodies described in this application can be easily isolated and sequenced by conventional methods (eg, by oligonucleotide probes that can specifically bind to genes encoding the light and heavy chains of murine antibodies).
  • Hybridoma cells as described above or the FasL-specific phage clones of the present application can be used as a source of such DNA.
  • the DNA can be placed in an expression vector, which is then transfected into host cells, such as simian COS cells, Chinese hamster ovarian cancer (CHO) cells, or non-immunoglobulin-producing myeloma cells, to obtain monoclonal antibodies synthesized in recombinant host cells.
  • host cells such as simian COS cells, Chinese hamster ovarian cancer (CHO) cells, or non-immunoglobulin-producing myeloma cells.
  • the DNA may also be modified, for example, by substituting coding sequences for human heavy and light chain constant regions and/or by substituting framework regions for cognate non-human sequences (U.S. Patent No. 4,816,567; Morrison et al., supra), or by covalently linking all or part of the coding sequence of an immunoglobulin to the coding sequence of a non-immunoglobulin polypeptide.
  • This non-immunoglobulin polypeptide can replace
  • the antibody can be a monovalent antibody.
  • Methods of making monovalent antibodies are known in the art. For example, one method involves recombinant expression of an immunoglobulin light chain and a modified heavy chain. Heavy chains are typically truncated anywhere in the Fc region to prevent cross-linking of the heavy chains to each other. Alternatively, the relevant cysteine residues are substituted with other amino acid residues or deleted to prevent cross-linking.
  • In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce antibody fragments, particularly Fab fragments, can be accomplished using any method known in the art.
  • Antibody variable domains with the desired binding specificity can be fused to immunoglobulin constant regions.
  • the fusion is preferably to an immunoglobulin heavy chain constant region, which includes at least part of the hinge, CH2 and CH3 regions.
  • the first heavy chain constant region (CH1) comprising the site necessary for light chain binding is present in at least one fusion.
  • DNA encoding the fusion of the immunoglobulin heavy chain and, if desired, the DNA encoding the light chain of the immunoglobulin is inserted into a separate expression vector and co-transfected into a suitable host organism.
  • the anti-FasL antibody (such as a full-length anti-FasL antibody) can be a fully human antibody or a humanized antibody.
  • Humanized forms of non-human (e.g., mouse) antibody portions are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (e.g., Fv, Fab, Fab', F(ab') 2 , scFv, or other antigen-binding subsequences of antibodies), which generally include minimal sequence derived from the non-human immunoglobulin.
  • Humanized antibodies include human immunoglobulins, immunoglobulin chains or fragments thereof (receptor antibodies) in which residues from the CDRs of the receptor have been altered with desired characteristics.
  • non-human (donor antibody) CDR residues for specificity, affinity, and performance, eg, mouse, rat, or rabbit CDRs.
  • human immunoglobulin Fv framework region residues are substituted by corresponding non-human residues.
  • Humanized antibodies may also comprise amino acid residues that are found neither in the recipient antibody nor in imported CDR or framework region sequences.
  • a humanized antibody will comprise at least one, and usually two, variable domains in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are human immunoglobulin consensus sequences.
  • humanized antibodies typically contain one or more amino acid residues that have been introduced from a non-human source. Those non-human amino acid residues are often referred to as "imported” residues, usually from an "imported” variable domain.
  • humanization can be performed substantially as described by Winter and colleagues (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by using rodents. Animal CDRs or CDR sequences are substituted for the corresponding sequences of human antibodies.
  • “humanized” antibody portions U.S. Patent No.
  • a humanized antibody portion is that portion of a typically human antibody in which some CDR residues and possibly some framework region residues are substituted by residues from analogous sites in rodent antibodies.
  • Fully human antibodies are an alternative to humanization.
  • transgenic animals eg, mice
  • mice that are capable of producing a fully human antibody library upon immunization but not endogenous immunoglobulins are currently produced.
  • JH antibody heavy-chain joining region
  • human germline immunoglobulin gene arrays into such germline mutant mice produces human antibodies upon antigen stimulation, see, for example, akobovits et al., PNAS USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggemann et al., Year in Immunol., 7:33 (1993); U.S. Patent Nos. 5,545,806, 5,569,825, 5,591,669, 5,545,807; and WO 97/17852.
  • fully human antibodies can be prepared by introducing human immunoglobulin loci into transgenic animals (eg, mice in which endogenous immunoglobulin genes have been partially or fully silenced).
  • Fully human antibodies can also be produced by in vitro activation of B cells (see US Patents 5,567,610 and 5,229,275) or by using various techniques known in the art, including phage display libraries. Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991). The techniques of Cole et al. and Boerner et al. can also be used to prepare fully human monoclonal antibodies. See Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1):86-95 (1991).
  • the amino acid sequences of anti-FasL antibody variants provided herein are also contemplated.
  • the amino acid sequences of antibody variants can be prepared by introducing appropriate modifications into the antibody-encoding nucleotide sequence or by peptide synthesis. Such modifications include, for example, deletions and/or insertions and/or substitutions of residues in the antibody amino acid sequence.
  • the final construction can be accomplished by any combination of amino acid residue deletions, insertions, and substitutions to impart the desired characteristics. For example, antigen binding.
  • anti-FasL antibody variants having one or more amino acid substitutions are provided.
  • Target sites for substitution mutations include hypervariable regions (HVRs) and framework regions (FRs).
  • Amino acid substitutions can be introduced in the antibody of interest and the product screened for desired activity, for example, improved biological activity, retained/improved antigen binding ability, reduced immunogenicity, or improved ADCC or CDC.
  • Amino acids are divided into different classes according to their side chain properties:
  • Acidic amino acids aspartic acid Asp, glutamic acid Glu;
  • Aromatic amino acids tryptophan Trp, tyrosine Tyr, phenylalanine Phe.
  • Substitution of non-conservative amino acids involves substitution of one of the above classes for another class.
  • An exemplary substitution variant is an affinity matured antibody, which can be conveniently generated using, for example, phage display-based affinity maturation techniques. Briefly, one or more CDR residues are mutated, the variant antibody portions are displayed on phage, and the variants are screened for specific biological activities (eg, apoptosis-inhibiting activity or increased antibody affinity). Alterations (eg, substitutions) in regions of the HVRs can be made to achieve improved antibody affinity or biological activity. Alterations can be made in HVR "hotspots", i.e. residues encoded by codons that are highly mutated during somatic maturation (see, e.g., Chowdhury, Methods Mol. Biol.
  • variable genes selected for affinity maturation are introduced into the variable genes selected for affinity maturation by any of a variety of methods (eg, error-prone PCR, strand shuffling, or oligonucleotide-directed mutagenesis). Secondary libraries are then created. This library is screened to identify antibody variants with the desired affinity. Another method of introducing diversity involves an HVR-mediated approach, in which several HVR residues (eg, 4-6 residues at a time) are randomized. HVR residues involved in antigen binding are specifically identified, for example, using alanine scanning mutagenesis or modeling. Often the CDR-H3 and CDR-L3 regions in particular are key targets.
  • HVR-mediated approach in which several HVR residues (eg, 4-6 residues at a time) are randomized. HVR residues involved in antigen binding are specifically identified, for example, using alanine scanning mutagenesis or modeling. Often the CDR-H3 and CDR-L3 regions in particular are key targets.
  • substitutions, insertions, or deletions may occur within one or more of the HVRs, so long as such alterations do not substantially reduce the ability of the antibody to bind antigen.
  • conservative changes eg, conservative substitutions provided herein
  • HVRs that do not substantially reduce binding affinity. These changes may occur outside of HVR "hot spots" or SDRs.
  • each HVR is either unchanged or comprises no more than 1, 2 or 3 amino acid substitutions.
  • a useful method for identifying amino acid residues or regions of an antibody that can be targeted for mutation is called "alanine scanning mutagenesis" as described in Cunningham and Wells (1989) Science, 244:1081-1085.
  • residues of interest e.g., charged residues such as arginine, aspartic acid, histidine, lysine, and glutamic acid
  • neutral or negatively charged amino acids e.g., alanine or glutamic acid
  • Further substitutions can be introduced at the amino acid position to demonstrate that the position is functionally sensitive to the initial substitution.
  • the contact sites between the antibody and the antigen are identified by the crystal structure of the antigen-antibody complex. These contact residues and neighboring residues can be targeted or eliminated as candidates for substitution. Variants are screened to determine whether they possess the desired properties.
  • Amino acid sequence insertions range in length from 1 residue to polypeptides containing 100 or more residues, and also include intrasequence insertions of 1 or more amino acid residues.
  • terminal insertions include antibodies with a methionyl residue at the N-terminus.
  • Other insertional variants of antibody molecules include fusions to the N-terminus or C-terminus of the antibody molecule of an enzyme (eg, ADEPT) or a polypeptide that increases the serum half-life of the antibody.
  • one or more amino acid modifications are introduced into the Fc region of an antibody described herein (eg, a full-length anti-FasL antibody or an anti-FasL antibody fusion protein), resulting in an Fc region variant.
  • the Fc region variant has an enhanced ADCC potency is usually related to Fc-binding receptors (FcRs).
  • FcRs Fc-binding receptors
  • the Fc region variant has reduced ADCC potency.
  • changes or mutations in the Fc sequence affecting its potency for example, WO 00/42072 and Shields et al. J Biol. Chem. 9(2):6591-6604 (2001 ) describe antibody variants with enhanced or reduced binding to FcRs. The contents of these publications are incorporated herein by reference.
  • ADCC Antibody-dependent cell-mediated cytotoxicity
  • NK cells activated by antibodies.
  • NK cells express the Fc receptor CD16. This receptor recognizes and binds the Fc portion of an antibody molecule bound to the surface of a target cell.
  • the most common Fc receptors on the surface of NK cells are CD16 or Fc ⁇ RIII.
  • Binding of Fc receptors to the Fc region of an antibody results in activation of NK cells, release of cytolytic granules, and subsequent apoptosis of target cells.
  • the killing effect of ADCC on tumor cells can be determined by the specific experiment of NK-92 cells transfected with high-affinity FcR. The results were compared with wild-type NK-92 not expressing FcR.
  • the present application also provides anti-FasL antibody variants (such as full-length anti-FasL antibody variants), which comprise Fc regions with partial but not all effector functions, so that they have prolonged half-life in vivo, but specific effector functions (such as CDC or ADCC) are unnecessary or harmful, and such anti-FasL antibodies become ideal candidates for the present application.
  • anti-FasL antibody variants such as full-length anti-FasL antibody variants
  • specific effector functions such as CDC or ADCC
  • anti-FasL antibodies become ideal candidates for the present application.
  • the reduction/elimination of CDC and/or ADCC activity is confirmed by in vitro and/or in vivo cytotoxicity assays.
  • an Fc receptor (FcR) binding assay is used to confirm that the antibody lacks Fc ⁇ R binding (and thus likely lacks ADCC activity) but retains FcRn binding.
  • NK cells express only Fc ⁇ RIII, while monocytes express Fc ⁇ RI, Fc ⁇ RII, and Fc ⁇ RIII.
  • FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet Annu. Rev. Immunol.
  • Antibodies with reduced effector function include substitutions of one or more residues at residues 238, 265, 269, 270, 297, 327, and 329 of the Fc region (US Pat. No. 6,737,056). These Fc variants are included at 265, 269, 270, 297 and Fc variants with a substitution of two or more residues at position 327, including the Fc variant known as "DANA", which substitutes alanine at residues 265 and 297 (US Pat. No. 7,332,581).
  • a variant of an anti-FasL antibody comprising a variant Fc region with one or more amino acid substitutions capable of enhancing ADCC effect.
  • the Fc region variant comprises one or more amino substitutions capable of enhancing the ADCC effect, and these substitutions are at positions 298, 333 and/or 334 (EU residue numbering) of the Fc region.
  • the anti-FasL antibody (eg, full-length anti-FasL antibody) variant comprises amino acid substitutions at positions S298A, E333A, and K334A in the Fc region.
  • alterations in the Fc region result in altered (i.e., enhanced or decreased) Clq binding and/or complement-dependent cytotoxicity (CDC), as described in U.S. Pat. No. 6,194,551, WO 99/51642, and Idusogie et al., J. Immunol. 164:4178-4184 (2000).
  • CDC complement-dependent cytotoxicity
  • a variant of an anti-FasL antibody (eg, a full-length anti-FasL antibody) comprising a variant of the Fc region with one or more amino acid substitutions capable of extending half-life or enhancing binding to Fc receptors (FcRn) is provided.
  • Antibodies with extended half-life and improved FcRn binding are described in US 2005/0014934A1 (Hinton et al.). These antibody Fc regions contain one or more amino acid substitutions that enhance the binding of the Fc region to FcRn.
  • Fc variants comprise one or more substitutions in the Fc region at residues 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, or 434, for example a substitution of residue 434 in the Fc region (U .S.Pat.No. 7,371,826).
  • anti-FasL antibodies eg, full-length anti-FasL antibodies
  • Fc variants described herein or combinations thereof.
  • an anti-FasL antibody provided herein is altered to increase or decrease the degree of glycosylation of the anti-NGF antibody.
  • Addition or deletion of glycosylation sites on the anti-FasL antibody can be conveniently achieved by changing the amino acid sequence of the anti-NGF antibody or its polypeptide portion to add or remove one or more glycosylation sites.
  • the sugar attached to it can be changed.
  • Native antibodies produced by mammalian cells typically comprise branched biantennary oligosaccharides, usually N-linked to the Fc region CH2 domain Asn297, see e.g. Wright et al., TIBTECH 15:26-32 (1997).
  • the oligosaccharides may comprise a variety of sugars such as mannose, N-acetylglucosamine (GlcNAc), galactose and sialic acid, as well as trehalose linked to the GlcNAc in the "stem" of the biantennary oligosaccharide structure.
  • oligosaccharide modifications can be made to the anti-FasL antibodies of the present application to generate anti-FasL antibody variants with certain improved properties.
  • N-glycans linked to the CH2 domain of the Fc region are heterogeneous.
  • Antibodies or Fc fusion proteins produced in CHO cells are fucosylated by fucosyltransferase activity, see Shoji-Hosaka et al., J. Biochem. 2006, 140:777-83.
  • N-glycosylation of the Fc region is important for its binding to Fc ⁇ Rs; non-fucosylated N-glycans enhance the binding ability of Fc to Fc ⁇ RIIIa.
  • Enhanced binding to FcRIIIa results in enhanced ADCC effect, which is advantageous in certain antibody therapeutic applications where cytotoxicity is required.
  • enhanced effector functions may be detrimental when Fc-mediated cytotoxicity is not desired.
  • the Fc fragment or CH2 domain is aglycosylated.
  • glycosylation is prevented by mutating the N-glycosylation site in the CH2 domain.
  • anti-FasL antibody e.g., full-length anti-FasL antibody
  • anti-FasL antibody variants comprise an Fc region, wherein the carbohydrate structure attached to the Fc region has reduced fucose or lacks fucose, which may enhance ADCC function.
  • anti-FasL antibodies that have reduced fucose relative to the same anti-FasL antibodies produced by wild-type CHO cells. That is, they are characterized by having a lower amount of fucose than antibodies produced by native CHO cells (eg, CHO cells producing native glycosylated forms, CHO cells containing the native FUT8 gene).
  • the N-linked glycans of the anti-FasL antibody have less than 50%, 40%, 30%, 20%, 10%, or 5% fucose.
  • the fucose content of the anti-FasL antibody may be 1%-80%, 1%-65%, 5%-65%, or 20%-40%.
  • the N-linked glycans of the anti-FasL antibody do not comprise fucose, ie, wherein the anti-FasL antibody is completely fucose-free, or fucose-free, or afucosylated.
  • the content of fucose was determined by calculating the average content of fucose within the sugar chain attached to Asn297 relative to the total amount of all sugar structures (such as complex, hybrid or mannose structures) attached to Asn297 measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546.
  • Asn297 refers to the asparagine residue located at position 297 of the Fc region (EU Fc region residue numbering system). However, Asn297 can also be located ⁇ 3 amino acids upstream or downstream of position 297, ie between positions 294 and 300, due to minor sequence variations of the antibody. These fucosylated variants may have enhanced ADCC function. See, eg, US Patent Publication Nos.
  • Cell lines capable of producing afucosylated antibodies include Lec13 CHO cells lacking protein fucosylation function (Ripka et al. al., especially Example 11), and knockout cell lines, such as ⁇ -1,6-fucosyltransferase gene, FUT8 knockout CHO cells (see Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Kanda, Y. et al., Biotechnol. Bioeng., 94 (4): 680-688 (2006); and WO2003 /085107).
  • Anti-FasL antibody (eg, full-length anti-FasL antibody) variants further provide bisected oligosaccharides, eg, wherein the biantennary oligosaccharide attached to the Fc region of the anti-FasL antibody is bisected by GlcNAc.
  • Such anti-FasL antibody (eg, full-length anti-FasL antibody) variants may have reduced fucosylation and/or enhanced ADCC function. Examples of such antibody variants are in WO 2003/011878 (Jean-Mairet et al.); US Pat. No.
  • anti-FasL antibodies eg, full-length anti-FasL antibodies having at least one galactose residue in the oligosaccharide linked to the Fc region are also provided.
  • anti-FasL antibody variants may have enhanced CDC function. Such variants are described, for example, in WO 1997/30087 (Patel et al.); WO 1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.).
  • the anti-FasL antibody (eg, full length anti-FasL antibody) variant comprises an Fc region that binds FcyRIII.
  • said anti-FasL antibody (e.g., full-length anti-FasL antibody) variant comprising an Fc region has ADCC activity in the presence of human effector cells (e.g., T cells), or has enhanced ADCC activity in the presence of human effector cells as compared to an otherwise identical anti-FasL antibody (e.g., full-length anti-FasL antibody) having a human wild-type IgG1 Fc region.
  • cysteine engineered anti-FasL antibodies eg, full-length anti-FasL antibodies
  • the substituted residue occurs at a site accessible to an anti-FasL antibody.
  • reactive sulfhydryl groups are located at sites accessible to anti-FasL antibodies that can be used to conjugate the anti-FasL antibody to other moieties, such as drug moieties or linker-drug moieties, to prepare anti-FasL immunoconjugates as further described herein.
  • Cysteine-engineered anti-FasL antibodies eg, full-length anti-FasL antibodies
  • the anti-FasL antibodies provided herein can be further modified to include other non-protein moieties known in the art and readily available.
  • Moieties suitable for derivatizing anti-FasL antibodies include, but are not limited to, water soluble polymers.
  • Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol/propylene glycol copolymer, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyamino acid (homopolymer or random copolymer), dextran or poly(n-vinylpyrrolidone) polyethylene glycol, propylene glycol Homopolymers, propylene oxide/ethylene oxide copolymers, polyoxyethylated polyols (eg glycerol), polyvinyl alcohol and mixtures thereof.
  • PEG polyethylene glycol
  • ethylene glycol/propylene glycol copolymer carboxymethylcellulose
  • dextran polyvinyl alcohol
  • polyvinylpyrrolidone poly-1,3-dio
  • Polyethylene glycol propionaldehyde has advantages in manufacturing due to its stability in water.
  • the polymers can be of any molecular weight and can be branched or unbranched.
  • the number of polymers attached to the anti-FasL antibody can vary, and if more than one polymer is attached, they can be the same or different molecules. Generally, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the need to improve the properties or functions of the anti-FasL antibody, whether the anti-FasL antibody derivative is used for the treatment of a particular condition, and the like.
  • compositions comprising any of the anti-FasL antibodies (e.g., full-length anti-FasL antibodies), nucleic acids encoding the antibodies, vectors comprising nucleic acids encoding the antibodies, or host cells comprising the nucleic acids or vectors described herein.
  • a pharmaceutical composition comprising any anti-FasL antibody described herein and a pharmaceutically acceptable carrier.
  • Suitable anti-FasL antibody formulations can be obtained by mixing anti-FasL antibodies of the desired purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), prepared as lyophilized formulations or liquid formulations. ⁇ , ⁇ : ⁇ ; ⁇ , ⁇ ; ⁇ ( ⁇ ; ⁇ ; ⁇ ; ⁇ ; ⁇ ; ⁇ ; ⁇ ; ⁇ ; ⁇ ; ⁇ ;3- ⁇ ); ⁇ ( ⁇ 10 ⁇ ) ⁇ ; ⁇ , ⁇ ; ⁇ , ⁇ ; ⁇ ; ⁇ ; ⁇ ; ⁇ ; ⁇ ; ⁇ EDTA; ⁇ , ⁇ ; ⁇ ; ⁇ ( ⁇ - ⁇ ); ⁇ / ⁇ TWEEN TM ,PLURONICS TM ⁇ (PEG); ⁇ WO98/56418 ⁇ , ⁇ Lyophilized formulations suitable for subcutaneous administration are described in WO97/04801.
  • Such lyophilized formulations can be reconstituted with a suitable diluent into a high protein concentration formulation, and the reconstituted formulation can be administered subcutaneously to the individual to be treated herein.
  • Cationic liposomes or liposomes can be used to deliver the anti-FasL antibodies of the present application to cells.
  • the preparation described herein may also contain one or more other active substances necessary for the treatment of specific diseases, preferably substances with complementary activities and no adverse reactions to each other.
  • active substances preferably substances with complementary activities and no adverse reactions to each other.
  • These molecules are present in combination in amounts effective for the intended purpose. Effective amounts of other substances depend on the amount of anti-FasL antibody in the formulation, the type of disease or disorder or treatment, and other factors as described above. These agents are generally used at the same doses and routes of administration as described herein, or at 1% to 99% of the currently employed doses.
  • the anti-FasL antibody (e.g., full-length anti-FasL antibody) can also be embedded in microcapsules prepared, for example, by coacervation techniques and interfacial polymerization, such as hydroxymethylcellulose or gelatin-microcapsules and poly(methylmethacrylate) microcapsules in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or in macroemulsions, respectively. Sustained release formulations can be prepared.
  • colloidal drug delivery systems e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules
  • sustained release formulations of anti-FasL antibodies can be prepared.
  • suitable examples of sustained release formulations include semipermeable matrices of solid hydrophobic polymers containing the antibody (or fragment thereof) in the form of shaped articles, eg, films or microcapsules.
  • sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl methacrylate) or poly(vinyl alcohol)), polylactic acid (US Pat. No.
  • L-glutamic acid and ethyl L-glutamate copolymers non-degradable ethylene-vinyl acetate, degradable lactic-glycolic acid copolymers such as LUPRON DEPOTTM (injectable microspheres composed of lactic-co-glycolic acid and leuprolide acetate), and poly-D(-) -3-Hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid can release molecules for more than 100 days, certain hydrogels can release proteins for shorter periods of time.
  • the anti-FasL antibody (eg, a full-length anti-FasL antibody) is formulated in a buffer containing citrate, sodium chloride, acetate, succinate, glycine, polysorbate 80 (Tween 80), or any combination thereof.
  • Preparations for in vivo administration must be sterile. This is readily accomplished, for example, by filtration using sterile filtration membranes.
  • Anti-FasL antibodies e.g., full-length anti-FasL antibodies
  • compositions described herein can be administered to individuals (e.g., mammals, such as humans) to treat diseases and/or conditions (e.g., inflammatory diseases, autoimmune diseases, or cancer) associated with dysregulation of the FasL-Fas signaling pathway, including but not limited to pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatit
  • the cancer is a FasL positive cancer disease; in particular, a FasL positive cancer disease is characterized by the expression of FasL on its cell surface.
  • a cancer may be considered FasL positive if at least 1%, at least 2%, at least 5%, at least 10%, at least 20%, or at least 50% of the cells in the cancer sample express FasL.
  • the number of FasL positive cells can be detected by counting the cells in a microsection.
  • the present application provides a method for treating diseases and/or disorders (for example, inflammatory diseases, autoimmune diseases or cancer) caused by dysregulation of FasL signaling pathway, comprising administering to an individual an effective amount of a composition (for example, a pharmaceutical composition) comprising an anti-FasL antibody (for example, a full-length anti-FasL antibody), such as any anti-FasL antibody described herein (for example, a full-length anti-FasL antibody), and in some embodiments, the individual is a human.
  • a composition for example, a pharmaceutical composition
  • an anti-FasL antibody for example, a full-length anti-FasL antibody
  • the individual is a human.
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a pharmaceutical composition comprising a FasL antibody (for example, a full-length anti-FasL antibody) that specifically binds to an epitope on human FasL, wherein the epitope comprises a human FasL amino acid residue.
  • a FasL antibody for example, a full-length anti-FasL antibody
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • the cancer is a FasL positive cancer disease; in particular a FasL positive cancer disease is characterized by the expression of FasL on its cell surface. In some embodiments, if at least 1%, at least 2%, at least 5%, at least 10%, at least 20%, or at least FasL expression in fewer than 50% of the cells would allow the cancer to be considered FasL positive. In some embodiments, the number of FasL positive cells can be detected by counting the cells in a microsection. In some embodiments, the individual is a human.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • the disease or condition is selected from
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO:99 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO:99; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 127 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 127.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • VL light chain variable domain
  • said VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:51, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:68, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:78, or a variant of said VL comprising a substitution of up to about 5 amino acids in its LC-CDRs.
  • the anti-FasL antibody is a full length antibody. In some embodiments, the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 100 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 100; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 128 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 128.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion Injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • the disease or condition is selected from
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 101 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 101; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 129 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 129.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • pemphigus transplant
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: VH , the VH comprising the amino acid sequence shown in SEQ ID NO: 102 or a variant thereof, the variant being the same as the amino acid sequence set forth in SEQ ID NO: 102 has at least about 80% sequence identity; and a VL comprising the amino acid sequence set forth in SEQ ID NO: 130 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 130.
  • a disease associated with the FasL-Fas signaling pathway for example, an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • pemphigus transplant
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 103 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 103; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 131 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 131.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the heavy chain constant region comprises or consists of amino Acid sequence SEQ ID NO:156 composition.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • the disease or condition is selected from
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 104 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 104; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 132 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 132.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • V H light chain variable domain
  • said VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:54, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:70, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:83, or a variant of said VL comprising a substitution of up to about 5 amino acids in its LC-CDRs.
  • the anti-FasL antibody is a full length antibody. In some embodiments, the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 105 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 105; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 133 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 133.
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion Injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • the disease or condition is selected from
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 106 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 106; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 134 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 134.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • pemphigus transplant
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: VH , the VH comprising the amino acid sequence shown in SEQ ID NO: 107 or a variant thereof, the variant being the same as the amino acid sequence set forth in SEQ ID NO: 107 has at least about 80% sequence identity; and a VL comprising the amino acid sequence set forth in SEQ ID NO: 135 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 135.
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • pemphigus transplant
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 108 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 108; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 136 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 136.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the heavy chain constant region comprises or consists of amino Acid sequence SEQ ID NO:156 composition.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • pemphigus transplant
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 109 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 109; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 137 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 137.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • V H light chain variable domain
  • said VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:55, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:72, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:85, or a variant of said VL comprising a substitution of up to about 5 amino acids in its LC-CDRs.
  • the anti-FasL antibody is a full length antibody. In some embodiments, the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 110 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 110; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 138 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 138.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion Injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • the disease or condition is selected from
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 111 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 111; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 139 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 139.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • pemphigus transplant
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: VH , the VH comprising the amino acid sequence shown in SEQ ID NO: 112 or a variant thereof, the variant being the same as the amino acid sequence set forth in SEQ ID NO: 112 has at least about 80% sequence identity; and a VL comprising the amino acid sequence set forth in SEQ ID NO: 140 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 140.
  • a disease associated with the FasL-Fas signaling pathway for example, an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • the disease or condition is selected from
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 113 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 113; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 141 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 141.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 113 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the heavy chain constant region comprises or consists of amino Acid sequence SEQ ID NO:156 composition.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • pemphigus transplant
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 114 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 114; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 142 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 142.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • VL light chain variable domain
  • said VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:73, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:88, or a variant of said VL comprising a substitution of up to about 5 amino acids in its LC-CDRs.
  • the anti-FasL antibody is a full length antibody. In some embodiments, the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 115 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 115; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 143 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 143.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a pharmaceutical composition comprising an anti-FasL antibody (eg, a full-length anti-FasL antibody), a heavy chain variable domain (V h ), the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO: 10, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO: 20, and HC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 41, or the V h variants comprising up to about 5 amino acid substitutions in their HC-CDRs; and the light chain variable domain (V L ), the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:59,
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic Reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • the cancer is a FasL positive cancer disease.
  • the individual is a human.
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 116 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 116; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 144 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 144.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 116 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • pemphigus transplant
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: VH , the VH comprising the amino acid sequence shown in SEQ ID NO: 117 or a variant thereof, the variant being the same as the amino acid sequence set forth in SEQ ID NO: 117 has at least about 80% sequence identity; and a VL comprising the amino acid sequence set forth in SEQ ID NO: 145 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 145.
  • a disease associated with the FasL-Fas signaling pathway for example, an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a pharmaceutical composition comprising an anti-FasL antibody (eg, a full-length anti-FasL antibody), a heavy chain variable domain (V h ), the V h Comprising: HC-CDR1, which comprises the amino acid sequence of SEQ ID NO: 11, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO: 28, and HC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 42, or the V h variants comprising up to about 5 amino acid substitutions in their HC-CDRs; and the light chain variable domain (V L ), the V L comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:60,
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • the cancer is a FasL positive cancer disease.
  • the individual is a human.
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 118 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 118; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 146 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 146.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the heavy chain constant region comprises or consists of amino Acid sequence SEQ ID NO:156 composition.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • pemphigus transplant
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 119 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 119; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 147 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 147.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • V H ⁇ , ⁇ , ⁇ FasL-Fas ⁇ ( ⁇ , ⁇ ) ⁇ , ⁇ FasL ⁇ ( ⁇ , ⁇ FasL ⁇ ) ⁇ , ⁇ (V H ), ⁇ V H ⁇ :HC-CDR1, ⁇ SEQ ID NO:12,HC-CDR2, ⁇ SEQ ID NO:29, ⁇ HC-CDR3, ⁇ SEQ ID NO:44, ⁇ V H ⁇ , ⁇ HC-CDRs ⁇ 5 ⁇ and a light chain variable domain (V L ), said V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:62, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:75, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:93, or a variant of said V L comprising a substitution of up to about 5 amino acids in its LC-CDRs.
  • the anti-FasL antibody is a full length antibody. In some embodiments, the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis,
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 120 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 120; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 148 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 148.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic Reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • the disease or condition is selected from,
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 121 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 121; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 149 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 149.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • the disease or condition is selected from
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: VH , the VH comprising the amino acid sequence shown in SEQ ID NO: 122 or a variant thereof, the variant being the same as the amino acid sequence set forth in SEQ ID NO: 122 has at least about 80% sequence identity; and a VL comprising the amino acid sequence set forth in SEQ ID NO: 150 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 150.
  • a disease associated with the FasL-Fas signaling pathway for example, an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • pemphigus transplant
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 123 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 123; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 151 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 151.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:155.
  • the heavy chain constant region comprises or consists of amino Acid sequence SEQ ID NO:156 composition.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • the disease or condition is selected from
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 124 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 124; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 152 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 152.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • V H ⁇ , ⁇ , ⁇ FasL-Fas ⁇ ( ⁇ , ⁇ ) ⁇ , ⁇ FasL ⁇ ( ⁇ , ⁇ FasL ⁇ ) ⁇ , ⁇ (V H ), ⁇ V H ⁇ :HC-CDR1, ⁇ SEQ ID NO:17,HC-CDR2, ⁇ SEQ ID NO:28, ⁇ HC-CDR3, ⁇ SEQ ID NO:49, ⁇ V H ⁇ , ⁇ HC-CDRs ⁇ 5 ⁇ and a light chain variable domain (V L ), said V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:66, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:74, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:98, or a variant of said V L comprising a substitution of up to about 5 amino acids in its LC-CDRs.
  • the anti-FasL antibody is a full length antibody. In some embodiments, the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute Viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis,
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 125 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 125; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 153 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 153.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the anti-FasL antibody is a full length antibody.
  • the full length anti-FasL antibody is an IgGl or IgG4 antibody.
  • the disease or condition is selected from, for example, pemphigus, transplant rejection, graft versus host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic Reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • the disease or condition is selected from,
  • a method for treating an individual with a disease associated with the FasL-Fas signaling pathway comprising administering to the individual an effective amount of a composition comprising an anti-FasL antibody, wherein the antibody comprises: V h , the V h comprising the amino acid sequence set forth in SEQ ID NO: 126 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 126; and V L , the V L Comprising the amino acid sequence set forth in SEQ ID NO: 154 or a variant thereof having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 154.
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer
  • the anti-FasL antibodies described herein are full-length anti-FasL antibodies comprising an IgGl or IgG4 constant region.
  • the IgG1 is human IgG1.
  • the IgG4 is human IgG4.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 155.
  • the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 156.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 157.
  • the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 158.
  • the individual is a mammal (eg, a human, non-human primate, rat, mouse, cow, horse, pig, sheep, goat, dog, cat, etc.). In some embodiments, the individual is a human. In some embodiments, the individual is a clinical patient, a clinical trial volunteer, an experimental animal, or the like. In some embodiments, the individual is less than 60 years old (including, for example, less than 50, 40, 30, 25, 20, 15, or 10 years old). In some embodiments, the individual is greater than 60 years old (including, for example, greater than 70, 80, 90, or 100 years old).
  • the individual is diagnosed with, or is genetically predisposed to, one or more diseases or conditions described herein (eg, inflammatory disease, autoimmune disease, or cancer). In some embodiments, the individual has one or more risk factors associated with one or more diseases or conditions described herein.
  • diseases or conditions described herein eg, inflammatory disease, autoimmune disease, or cancer.
  • the individual has one or more risk factors associated with one or more diseases or conditions described herein.
  • the present application provides a method of delivering an anti-FasL antibody (e.g., any of the anti-FasL antibodies described herein, e.g., an isolated anti-FasL antibody) to a cell in an individual that expresses FasL on its surface, the method comprising administering to the individual a composition comprising the anti-FasL antibody.
  • an anti-FasL antibody e.g., any of the anti-FasL antibodies described herein, e.g., an isolated anti-FasL antibody
  • inflammatory diseases include, but are not limited to, eg, immunohistochemistry, PCR, and fluorescence in situ hybridization (FISH).
  • FISH fluorescence in situ hybridization
  • the anti-FasL antibodies described herein are used in combination with second, third or fourth agents (including, for example, immunosuppressants, anti-inflammatory drugs, anti-tumor agents, growth inhibitors, cytotoxic agents, chemotherapeutic agents or blood vessel inhibitors) to treat diseases related to the FasL-Fas signaling pathway.
  • second, third or fourth agents including, for example, immunosuppressants, anti-inflammatory drugs, anti-tumor agents, growth inhibitors, cytotoxic agents, chemotherapeutic agents or blood vessel inhibitors
  • Dosages of anti-FasL antibody (eg, isolated anti-FasL antibody) compositions administered to an individual may vary depending on the particular composition, mode of administration, and type of disease being treated.
  • the composition e.g., comprising an anti-FasL anti- An amount effective to produce an objective response (eg, a partial response or a complete response) in the treatment of an inflammatory disease, an autoimmune disease, or cancer.
  • the amount of anti-FasL antibody composition is sufficient to produce a complete response in an individual.
  • the amount of anti-FasL antibody composition is sufficient to produce a partial response in an individual.
  • the dose of the anti-FasL antibody composition administered is sufficient to produce an overall response rate of greater than 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 64%, 65%, 70%, 75%, 80%, 85%, or 90% in a population of individuals treated with the anti-FasL antibody composition.
  • the amount of the composition is sufficient to prolong progression-free survival in the individual. In some embodiments, the amount of the composition is sufficient to prolong the overall survival of the individual. In some embodiments, the amount of the composition (eg, when administered alone) is sufficient to produce greater than 50%, 60%, 70%, or 77% clinical benefit in a population of individuals treated with an anti-FasL antibody composition.
  • the amount of a composition is an amount sufficient to control symptoms and reduce the risk of exacerbation of the disease prior to treatment or compared to corresponding activity in other subjects not receiving treatment.
  • the magnitude of this therapeutic effect can be measured using standard methods, such as in vitro assays of purified enzymes, cell-based assays, animal models, or human trials.
  • the amount of anti-FasL antibody (e.g., full-length anti-FasL antibody) in the composition is below a level that causes a toxic effect (i.e., an effect that is greater than a clinically acceptable level of toxicity), or is at a level at which potential side effects can be managed or tolerated.
  • the amount of the composition approximates the maximum tolerated dose (MTD) of the composition. In some embodiments, the amount of the composition is greater than 80%, 90%, 95%, or 98% of the MTD.
  • the amount of anti-FasL antibody (eg, full-length anti-FasL antibody) in the composition ranges from 0.001 ⁇ g to 1000 ⁇ g.
  • the effective amount of the anti-FasL antibody (eg full-length anti-FasL antibody) in the composition is in the range of 0.1 ⁇ g/kg to 100 mg/kg based on body weight.
  • Anti-FasL antibody compositions can be administered to an individual (e.g., a human) by a variety of routes including, for example, intravenous, intraarterial, intraperitoneal, intrapulmonary, oral, inhalational, intravascular, intramuscular, intratracheal, subcutaneous, intraocular, intrathecal, mucosal, or transdermal.
  • sustained release formulations of the compositions are used.
  • the composition is administered intravenously.
  • the composition is administered arterially.
  • the composition is administered intraperitoneally.
  • the composition is administered intrahepatically.
  • the composition is administered by hepatic artery infusion.
  • the composition is administered at a site remote from the first lesion.
  • an article of manufacture comprising a substance that can be used to treat a disease associated with the FasL-Fas signaling pathway (e.g., an inflammatory disease, an autoimmune disease, or cancer), or to deliver an anti-FasL antibody (e.g., a full-length anti-FasL antibody) to cells expressing FasL on the surface.
  • the article may include a container to and the label or package insert on or accompanying the container. Suitable containers include, for example, bottles, vials, syringes, and the like. Containers can be made from a variety of materials such as glass or plastic.
  • the container contains a composition effective to treat a disease or condition described herein and has a sterile port (eg, the container may be an IV bag or a vial with a hypodermic needle-pierceable cap). At least one active substance in the composition is the anti-FasL antibody described in this application.
  • the label or package insert identifies the particular condition that the composition may be used to treat.
  • the label or package insert further comprises instructions for administering the anti-FasL antibody composition to a patient. Articles of manufacture and kits comprising combination therapies are contemplated herein.
  • Package insert refers to the instructions commonly included in commercial packages of therapeutic products that contain indications, usage, dosage, administration, contraindications and/or warning information pertaining to the use of such therapeutic products.
  • the package insert indicates that the composition can be used to treat diseases related to FasL-Fas signaling pathway (such as inflammatory diseases, autoimmune diseases or cancer).
  • the package insert indicates that the composition can be used to treat diseases including pemphigus, transplant rejection, graft-versus-host disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute lung injury, acute respiratory distress syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury , acute viral hepatitis B, acute viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, nonalcoholic steatohepatitis, liver cirrhosis, drug-induced liver injury/liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, cancer.
  • diseases including pemphigus, transplant rejection, graft-versus-host disease, systemic inflammatory response syndrome,
  • the article of manufacture may further comprise a second container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate buffered saline, Greene's solution, or dextrose solution.
  • a pharmaceutically acceptable buffer such as bacteriostatic water for injection (BWFI), phosphate buffered saline, Greene's solution, or dextrose solution.
  • kits that can be used for various purposes, such as for treating diseases associated with the FasL-Fas signaling pathway (such as inflammatory diseases, autoimmune diseases or cancer), or for delivering anti-FasL antibodies (such as full-length anti-FasL antibodies) to cells expressing FasL on the surface, optionally in combination with a preparation.
  • the kits of the present application include one or more containers comprising an anti-FasL antibody composition (or single dosage form and/or preparation), and in some embodiments, further comprising another medicament (such as a medicament described herein) and/or instructions for use consistent with any of the methods described herein.
  • the kit may further include instructions for selecting an individual for treatment.
  • the instructions for use attached to the kit in the present application are usually written instructions on the label or package insert (such as paper sheets included in the kit), and machine-readable instructions (such as instructions on magnetic or optical storage discs) are also acceptable.
  • the kit includes a composition comprising an anti-FasL antibody (eg, a full-length anti-FasL antibody).
  • the kit comprises: a) a composition comprising any one of the anti-FasL antibodies described herein, and b) at least one effective amount of another agent capable of enhancing the effect (e.g., therapeutic effect, detection effect) of the anti-FasL antibody.
  • the kit includes: a) a composition comprising any one of the anti-FasL antibodies described herein, and b) instructions for administering the anti-FasL antibody composition to an individual for treating a disease associated with the FasL-Fas signaling pathway (such as an inflammatory disease, an autoimmune disease, or cancer).
  • a disease associated with the FasL-Fas signaling pathway such as an inflammatory disease, an autoimmune disease, or cancer.
  • the kit includes: a) a composition comprising any of the anti-FasL antibodies described herein, and b) at least one effective amount of other agent capable of enhancing the effect of the anti-FasL antibody (e.g., therapeutic effect, detection effect) and c) administering the anti-FasL antibody composition and other substances to an individual for the treatment of a disease associated with the FasL-Fas signaling pathway (e.g., inflammatory disease, autoimmune autoimmune disease or cancer).
  • the anti-FasL antibody and other substances may be present in separate containers or in the same container.
  • the kit may include one particular composition or two or more compositions, wherein one composition includes an anti-FasL antibody and the other composition includes another agent.
  • the kit comprises a nucleic acid (or set) encoding an anti-FasL antibody (eg, a full-length anti-FasL antibody).
  • the kit comprises: a) a nucleic acid (or set of nucleic acids) encoding an anti-FasL antibody (eg, a full-length anti-FasL antibody), and b) a host cell expressing the nucleic acid (or set of nucleic acids).
  • the kit comprises: a) a nucleic acid (or a set) encoding an anti-FasL antibody (e.g., a full-length anti-FasL antibody), and b) instructions for use, suitable for: i) expressing the anti-FasL antibody in a host cell, ii) preparing a composition comprising the anti-FasL antibody, and iii) administering the composition comprising the anti-FasL antibody to an individual to treat a disease associated with the FasL-Fas signaling pathway (e.g., an inflammatory disease, an autoimmune disease, or cancer).
  • a disease associated with the FasL-Fas signaling pathway e.g., an inflammatory disease, an autoimmune disease, or cancer.
  • the kit comprises: a) a nucleic acid (or a set) encoding an anti-FasL antibody (e.g., a full-length anti-FasL antibody), b) a host cell expressing the nucleic acid (or a set of nucleic acids), and c) instructions for use, suitable for: i) expressing the anti-FasL antibody in the host cell, ii) preparing a composition comprising the anti-FasL antibody, and iii) administering the composition comprising the anti-FasL antibody to an individual for the treatment of a disease associated with the FasL-Fas signaling pathway (e.g., inflammatory disease, autoimmune autoimmune disease or cancer).
  • a disease associated with the FasL-Fas signaling pathway e.g., inflammatory disease, autoimmune autoimmune disease or cancer.
  • kits described herein are packaged in a suitable form.
  • suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (eg, sealed mylar or plastic bags), and the like. Kits may optionally provide other components, such as buffers and instructional information. Accordingly, the present application also provides articles of manufacture including vials, bottles, jars, flexible packaging (eg, sealed mylar or plastic bags), and the like.
  • the instructions for use of the anti-FasL antibody composition usually include some information, such as dose, administration cycle and administration route.
  • the container can be unit dose, bulk (eg, multi-dose package) or subunit dose.
  • a kit comprising a sufficient dose of an anti-FasL antibody as described herein (e.g., a full-length anti-FasL antibody) is provided for long-term effective treatment of an individual, e.g., one week, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months or more.
  • Kits may also comprise multiple unit doses of anti-FasL antibody, pharmaceutical compositions and instructions for use, and be packaged in quantities sufficient for storage and use in pharmacies, eg, hospital pharmacies and compounding pharmacies.
  • the cDNA encoding the extracellular region of human FasL (human FasL, hFasL; GenBank ID number: 356) (synthesized by Beijing Sino Biological Technology Co., Ltd.) was respectively constructed into eukaryotic expression vectors by subcloning.
  • the above plasmids were transfected into 293F cells for expression to produce fusion proteins containing the extracellular region of FasL, such as His-hFasL, hFc-hFasL, wherein "His” stands for His tag, and "hFc” stands for human Fc fragment.
  • a vector containing the coding sequence of the extracellular region of human Fas (human Fas, hFas; GenBank ID number: 355) was constructed, and transfected into 293F cells to express a fusion protein containing the extracellular region of human Fas, such as His-hFas, wherein "His" represents a His tag.
  • Recombinant proteins with His tags were purified by immobilized metal affinity chromatography (IMAC) using a nickel (Ni) column-HisCap Smart 6FF 5ml prepacked column (Changzhou Tiandi Renhe Biotechnology Co., Ltd., SA036C15) according to the manufacturer's instructions.
  • IMAC immobilized metal affinity chromatography
  • the specific operation is as follows: first, equilibrate the nickel column with buffer A1 (50mM Na 3 PO 4 , 0.15M NaCl, pH 7.2) at a flow rate of 150cm/h, adjust the pH of the solution containing the fusion protein (such as cell culture supernatant) to 7.2, and load the sample at room temperature at a flow rate of 150cm/h.
  • the column was re-equilibrated with 6 column volumes of Al buffer at a flow rate of 150 cm/h.
  • 10 column volumes of 50 mM PB solution (containing 0.15 M NaCl and 0.2 M imidazole, pH 7.2) were used for elution, and the eluate was collected.
  • the above eluate was ultrafiltered and exchanged into PBS using an ultrafiltration tube, and concentrated to a certain concentration.
  • the fusion protein with Fc fragment was purified by protein A column-MabCap At 4FF 5ml prepacked column (Changzhou Tiandi Renhe Biotechnology Co., Ltd., SA023C15).
  • the specific operation is as follows: first, equilibrate the protein A column with 6 times the column volume of PBS buffer (including 50mM PBS and 0.15M NaCl, pH7.2), and the flow rate is 5ml/min. The pH of the culture supernatant was adjusted to 7.2, and the sample was loaded at room temperature with a flow rate of 5 ml/min. Subsequently, the column was re-equilibrated with 6-10 column volumes of PBS buffer at a flow rate of 5 ml/min.
  • eluent comprising 0.1M Gly and 150mM NaCl, pH3.2
  • eluent comprising 0.1M Gly and 150mM NaCl, pH3.2
  • mice were immunized with an equal volume (v/v) of adjuvant using the extracellular domain of human FasL as antigen.
  • the immunized mouse serum was taken, and the total IgG titer in the immunized mouse serum was detected by ELISA.
  • mouse spleens were used to establish phage display libraries.
  • the spleen of immunized mice was extracted, RNA was extracted, cDNA was obtained by reverse transcription, V H and V K fragments were amplified with V H and V K specific primers, after gel recovery and purification, V H and V K were connected, scFv was constructed, and it was cloned into a phage display plasmid. Then, the plasmid was electrotransferred into E. coli TG1, and the scFv antibody phage display library was obtained by infecting E. coli TG1 with phage.
  • the scFv that specifically binds hFasL was isolated and obtained from a phage display library. Briefly, 2x10 11 PFU of the phage scFv library was added to the ELISA plate coated with His-hFasL antigen, and incubated at 37°C for 2 hours. Wash 8-15 times with PBST solution (as the number of rounds of screening increases, the number of washes increases), the phages bound to the hFasL antigen are captured by the FasL antigen coated on the ELISA plate, while the unbound phages are washed away.
  • the phage specifically binding to the hFasL antigen were eluted with 0.1M Glycine-HCl solution (pH 2.2). Infect the TG1 cells in the exponential growth phase with the above phages, add ampicillin and culture for 1 hour, then add The helper phage was cultivated overnight at 28°C and 220rpm on a shaker. The culture medium was collected the next day, and the supernatant was obtained after centrifugation, which was used for the next round of screening. A positive scFv antibody library was obtained after multiple rounds of panning.
  • the enriched phages after panning were screened by ELISA. Briefly, His-hFasL antigen was dissolved in PBS solution, coated with 0.1 ⁇ g/well of 96-well plate, and left overnight at 4°C. After washing once with PBST solution, 90 ⁇ L of PBS containing 4% skimmed milk powder was added to each well. Subsequently, 10 ⁇ L of phage-scFv culture supernatant was added to the corresponding wells, and incubated at 37° C. for 1-2 hours. After washing with PBST solution 8 times, anti-M13-HRP antibody (Sino Biological, 11973-MM05T-H) diluted 1:4000 was added, 100 ⁇ L/well.
  • V L and V H were amplified from the phage display vectors, and constructed into eukaryotic expression vectors pTTa1-L (comprising human ⁇ constant region), pTT5-H1 (comprising human IgG1 heavy chain constant region) or pTTa1-H4 (comprising human IgG4 heavy chain constant region), respectively.
  • the plasmid expressing the light chain and the plasmid expressing the heavy chain were co-transfected into 293F cells, cultured at 37° C., 5% CO 2 , 120 rpm for 6 days, and the culture solution was purified by Protein A affinity chromatography.
  • the antibody purification method was the same as that using protein A column purification in Example 1. After concentration by ultrafiltration, the antibody concentration was determined and further biochemical and biological activity assays were performed.
  • the constructed full-length anti-FasL chimeric antibody (reconstructed into human IgG4 form) was tested for binding to human FasL to reflect the binding activity of the anti-FasL antibody to human FasL antigen.
  • human hFc-hFasL antigen was dissolved in PBS solution, coated with 0.1 ⁇ g/well of 96-well plate, and left overnight at 4°C. Block with 5% milk at 37°C for 1 hour, and wash 6 times with PBST solution. Each antibody sample was first diluted to 66.67nM, followed by a 1:4 serial dilution. The samples after serial dilution were added to 96-well plates, 100 ⁇ L per well, and incubated at 37° C.
  • the results are shown in Table 5.
  • FL-M71, FL-M76, FL-M77 have good binding to human FasL antigen ability.
  • the binding ability of the above anti-FasL antibodies to human FasL is significantly better than that of the FasL antagonist APG101 (Fas fusion protein, Apogenix); it is also better than the control antibody MAB126-100 (commercialized anti-FasL antibody, RD) or equivalent.
  • Anti-FasL antibody neutralizes ligand-receptor binding:
  • This assay was used to identify the ability of anti-FasL chimeric antibodies (reconstituted into human IgG4 form) to neutralize the binding of ligand FasL to its receptor Fas. Briefly, the His-hFas prepared in Example 1 was coated on a 96-well plate at 0.1 ⁇ g/well, and left overnight at 4°C. After washing with PBST solution, 100 ⁇ L of 2% milk was added to each well. Block at 37°C for 1 hour, and then wash with PBST solution. Each anti-FasL antibody sample was diluted to 12.0 ⁇ g/ml, followed by serial dilution at a ratio of 1:4.
  • the hFc-hFasL antigen (1.25ug/mL) prepared in Example 1 was mixed with each anti-FasL antibody in serial dilution, and premixed at 37°C for 30 minutes. Add the above antigen-antibody premix into a 96-well plate, 100 ⁇ L/well, and incubate at 37° C. for 1 h. Add 100 ⁇ L of anti-human IgG1 Fc-AP antibody (SouthernBiotech, 9054-04, 1:3000) to each well, and incubate at 37° C. for 1 hour. After washing 6 times with PBST solution, add 100 ⁇ L pNPP solution to each well and incubate at 37°C for 10-20 minutes. The absorbance value at 405nm was read, and the neutralization curve was generated by GraphPad Prism software.
  • Anti-FasL antibody inhibits FasL antigen-induced apoptosis in Jurkat cells:
  • exogenous FasL can activate the signal transduction pathway of apoptosis and mediate apoptosis, and the amount of ATP in cells is directly proportional to the number of cells in culture. Based on the above principles, the amount of ATP in cells can be used to reflect the level of apoptosis, and then the activity of anti-FasL chimeric antibody (reconstructed into human IgG4 form) to inhibit FasL antigen-induced apoptosis in Jurkat cells can be determined.
  • Jurkat cells in the logarithmic growth phase (purchased from the Cell Bank of Peking Union Medical College, 1101HUM-PUMC000075) were seeded in a 96-well plate at 5 ⁇ 10 4 cells/well. Each antibody sample was diluted to 6.667nM followed by a 1:3 serial dilution.
  • actinomycin D (Hanhui Pharmaceutical Co., Ltd., H20023504)
  • 25 ⁇ L hFc-FasL recombinant fusion protein and 25 ⁇ L serially diluted anti-FasL antibody into a 96-well plate containing Jurkat cells, so that the final concentrations of actinomycin D and hFc-FasL recombinant fusion protein were 32 ng/mL and 5 ng/mL, respectively.
  • Luminescent Cell Viability Assay Kit detects the amount of ATP that exists, and the amount of ATP that exists is proportional to the luminescent signal generated, that is, adding to the 96-well cell culture plate Reagent, 50 ⁇ L per well, mix and incubate at room temperature for 10 min. Read the fluorescence value with a microplate reader. The curve was generated by GraphPad Prism software, and the IC50 value of each anti-FasL antibody was calculated.
  • Anti-FasL antibody inhibits FasL antigen-induced apoptosis in HepG2 cells:
  • the principle of the experiment is the same as above, and the amount of ATP in the cells is used to reflect the level of apoptosis, and then the activity of the anti-FasL chimeric antibody (reconstructed into human IgG4 form) to inhibit the apoptosis of HepG2 cells induced by FasL antigen is determined.
  • HepG2 cells in the logarithmic growth phase (purchased from the Cell Bank of Peking Union Medical College, 1101HUM-PUMC000035) were seeded in 96-well plates at 2 ⁇ 10 4 cells/well. Each antibody sample was diluted to 6.667nM followed by a 1:3 serial dilution.
  • the ability of the above anti-FasL antibodies to inhibit the apoptosis of HepG2 cells induced by FasL antigen was significantly better than that of the control APG101; and among the above anti-FasL antibodies, except FL-M27, FL-M46, FL-M52, and FL-M65 which were basically equivalent to the control antibody MAB126-100, the rest of the antibodies were significantly better than the control antibody MAB126-100.
  • Anti-FasL antibody inhibits FasL antigen-induced activation of NF- ⁇ B signaling pathway:
  • exogenous FasL can not only activate the signaling pathway of apoptosis, but also activate the NF- ⁇ B signaling pathway. After blocking the apoptosis pathway with Caspase inhibitors, exogenous FasL can only induce the activation of NF- ⁇ B signaling pathway.
  • HepG2-Dual (InvivoGen, hepg2d-nfis) is a dual reporter cell line of NF- ⁇ B-SEAP and IRF-Lucia, in which exogenous FasL induces the activation of NF- ⁇ B pathway, and then promotes the expression of secreted embryonic alkaline phosphatase (SEAP), which can be measured by the conversion rate of QUANTI-Blue TM substrate.
  • SEAP embryonic alkaline phosphatase
  • HepG2-Dual cells in the logarithmic growth phase were seeded in 96-well plates at 1 ⁇ 10 5 cells/well. Each antibody sample was diluted to 625 nM followed by serial dilutions. Add hFc-FasL (final concentration of 700ng/ml), actinomycin D, Caspase inhibitor Z-VAD-FMK (Beyond, C1202-5mg) and serially diluted anti-FasL antibody to the 96-well plate containing HepG2-Dual cells, and culture at 37°C, 5% CO 2 for 24 hours.
  • Anti-FasL chimeric antibodies FL-M06, FL-M39 ⁇ FL-M46, FL-M51, FL-M52, FL-M55, FL-M58, FL-M60 ⁇ FL-M62, FL-M65, FL-M68, and FL-M69 all had significant inhibitory effects on FasL antigen-induced activation of NF- ⁇ B signaling pathway.
  • anti-FasL antibodies except FL-M55 which was basically equivalent to the control APG101, the other antibodies were significantly better than the control APG101.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

本发明公开特异性识别FasL的抗体或抗原结合片段，及其制备方法和用途。

Description

特异性识别FasL的抗体及其应用
相关申请的交叉引用
本申请要求申请号为202210069822.X，申请日为2022.01.21，发明名称为“特异性识别FasL的抗体及其应用”的中国专利申请的优先权，且该申请的全部内容以引用方式并入本文中。
对电子序列表的引用
电子序列表(文本名称：CN_202201070662_SEQLIST.xml，记录日期：2022.08.03，大小：137KB)的内容通过整体引用并入本文中。
技术领域
本申请涉及特异性识别FasL的抗体或抗原结合片段，及其制备方法和用途。
背景技术
FasL(CD95L)是肿瘤坏死因子(TNF)超家族的跨膜蛋白和促凋亡成员之一。FasL胞外区包含一个配体二聚体和受体结合区(TNF同源结构域，THD)，而FasL胞内区参与多种信号通路，尤其是作为T细胞激活过程中的T细胞受体共刺激分子(
Calmon-Hamaty,Flavia et al.Cytokine vol.75,2(2015):228-33.)。FasL的胞内部分包含延伸的多聚脯氨酸区域，能够与具有脯氨酸结合基序的蛋白质相互作用，例如Src同源3(SH3)和WW结构域(Wenzel,J et al.FEBS letters vol.509,2(2001):255-62.；Blott,E J et al.Journal of cell science vol.114,Pt 13(2001):2405-16.)。此外，还存在几个酪氨酸磷酸化位点和一个“双”酪蛋白激酶磷酸化基序。FasL蛋白有膜结合蛋白和可溶性蛋白两种形式。可溶性形式是通过选择性剪接或将膜结合形式的蛋白水解而产生。在生理条件下，FasL在先天性和适应性免疫系统细胞以及免疫特权部位，如眼睛、胎盘或睾丸中的表达受到严格的控制和限制(Stenqvist,Ann-Christin et al.Journal of immunology(Baltimore,Md.:1950)vol.191,11(2013):5515-23.)。FasL在两种主要的免疫效应细胞的表面表达，即活化T细胞和自然杀伤(NK)细胞，但在巨噬细胞、中性粒细胞和树突状细胞表面也有表达(Kiener,P A et al.The Journal of experimental medicine vol.185,8(1997):1511-6.；Liles,W C et al.The Journal of experimental medicine vol.184,2(1996):429-40.doi:10.1084/jem.184.2.429.)。可以通过TCR(T细胞受体)激活诱导FasL的表达，也可以在细胞因子刺激，特别是干扰素(INF)刺激后，通过转录调控其表达(Tsutsui,H et al.Journal of immunology(Baltimore,Md.:1950)vol.157,9(1996):3967-73.)。
Fas受体(CD95/APO-1)是TNF受体超家族的成员之一。Fas蛋白有膜结合蛋白和可溶性蛋白两种形式，Fas主要以膜结合形式存在。而可溶性Fas蛋白由于缺乏跨膜结构域，不能与FasL相互作用诱导细胞凋亡，因此它在细胞凋亡中发挥调节作用，例如抑制膜结合Fas(mFas)诱导的细胞凋亡(Jee,Youngheun et al.Journal of veterinary science vol.11,2(2010):115-9.)。mFas蛋白的胞 外结构域包含三个富含半胱氨酸的结构域(CRD)，这是TNF受体家族的结构特征(Zhang,Gongyi.Current opinion in structural biology vol.14,2(2004):154-60.)。Fas蛋白胞内结构域的C-末端包含死亡结构域(DD)，该结构域是凋亡诱导所必需的，也是该死亡受体亚群的特征(Chan,F K et al.Science(New York,N.Y.)vol.288,5475(2000):2351-4.)。Fas在多器官组织中均有表达，尤其是在外周血T和B淋巴细胞、NK细胞、单核细胞细胞、成纤维细胞、内皮细胞、上皮细胞等(Wang,Mei,and Ping Su.Systems biology in reproductive medicine vol.64,2(2018):93-102.)。
在Fas介导的凋亡途径中，FasL的结合驱动Fas聚集以及Fas与Fas结合蛋白(FADD)的结合。FADD招募caspase-8和caspase-10形成死亡诱导信号复合物(DISC)(Wilson,Nicholas S et al.Nature immunology vol.10,4(2009):348-55.)。DISC被死亡受体(DR)的特定翻译后修饰激活，如棕榈酰化和O-连接糖基化(Muppidi,Jagan R,and Richard M Siegel.Nature immunology vol.5,2(2004):182-9.；Wagner,Klaus W et al.Nature medicine vol.13,9(2007):1070-7)。DISC介导半胱天冬酶-8和半胱天冬酶-10的自催化处理和激活，它们通过半胱天冬酶-3、半胱天冬酶-6和半胱天冬酶-7等效应半胱天冬酶的蛋白水解扩大死亡信号。在I型细胞(如胸腺细胞)中，半胱氨酸蛋白酶的作用足以诱导细胞凋亡。相比之下，在II型细胞(如B细胞)中，细胞凋亡需要半胱氨酸蛋白酶-8介导的BH3相互作用域死亡激动剂(Bid)的裂解，Bid是一种仅含BH3的蛋白质，其可提高线粒体外膜的通透性以及细胞色素c的释放。细胞色素c从线粒体释放后，可以作为一种辅助因子参与被称为凋亡体的细胞溶质半胱天冬酶激活复合物的装配，该复合物可放大半胱天冬酶级联激活(Wagner,Klaus W et al.Nature medicine vol.13,9(2007):1070-7.)。
细胞死亡不是Fas激活引起的唯一细胞反应。Fas也能诱导NF-κB信号传导。作用于Fas信号通路中细胞型caspase-8样抑制蛋白(cFLIP)和TRAF2的下游，可通过NF-κB激活诱导T细胞增殖(Kataoka,Takao,and Jürg Tschopp.Molecular and cellular biology vol.24,7(2004):2627-36.)。cFLIP N-末端的裂解产物p43FLIP和p22FLIP通过结合IKK复合物诱导NF-κB活化(Golks,Alexander et al.The Journal of experimental medicine vol.203,5(2006):1295-305.；Krammer,Peter H et al.Nature reviews.Immunology vol.7,7(2007):532-42.)。此外，cFLIP的过度表达抑制Fas诱导的活化T细胞的凋亡(Van Parijs,L et al.“Autoimmunity as a consequence of retrovirus-mediated expression of C-FLIP in lymphocytes.”Immunity vol.11,6(1999):763-70.；Kirchhoff,S et al.Journal of immunology(Baltimore,Md.:1950)vol.165,11(2000):6293-300.)。此外，Fas信号通过调节增殖和细胞死亡之间的平衡来调节外周T细胞内稳态，例如，在原始和记忆性T细胞亚群中(Jaleco,Sara et al.Journal of immunology(Baltimore,Md.:1950)vol.171,1(2003):61-8.)。因此，外周T细胞的内环境稳定可能由FasL/Fas信号传导的双重效果来维持。
Fas-FasL信号通路与多种疾病的发生发展相关，包括自身免疫性疾病、移植排斥、脊髓损伤、败血病等。因此，开发针对FasL靶点的抑制剂至关重要。
目前，已有针对FasL抑制剂的报道，例如中国专利CN1283662C中披露了拮抗性抗hFAS配基抗体及其应用；中国专利CN108290950B中披露了抗FasL抗体119-4A(在本申请实施例部分作 为对照抗体)及其应用；中国专利CN104662039B中披露了Fas-Fc融合蛋白APG101(在本申请实施例部分作为对照)及其应用。现有治疗领域中仍需要高亲和力、高生物活性的抗FasL抗体。
本文提及的所有出版物、专利、专利申请和已公开的专利申请中披露的内容，以引用方式全部并入本文中。
申请概述
在一些实施例中，提供一种分离的抗FasL抗体，其包含：(i)VH，其包含如氨基酸序列SEQ ID NO:99所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:127所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(ii)VH，其包含如氨基酸序列SEQ ID NO:100所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:128所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(iii)VH，其包含如氨基酸序列SEQ ID NO:101所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:129所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(iv)VH，其包含如氨基酸序列SEQ ID NO:102所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:130所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(v)VH，其包含如氨基酸序列SEQ ID NO:103所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:131所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(vi)VH，其包含如氨基酸序列SEQ ID NO:104所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:132所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(vii)VH，其包含如氨基酸序列SEQ ID NO:105所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:133所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(viii)VH，其包含如氨基酸序列SEQ ID NO:106所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:134所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(ix)VH，其包含如氨基酸序列SEQ ID NO:107所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:135所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(x)VH，其包含如氨基酸序列SEQ ID NO:108所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:136所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xi)VH，其包含如氨基酸序列SEQ ID NO:109所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:137所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xii)VH，其包含如氨基酸序列SEQ ID NO:110所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:138所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xiii)VH，其包含如氨基酸序列SEQ ID NO:111所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:139所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xiv)VH，其包含 如氨基酸序列SEQ ID NO:112所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:140所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xv)VH，其包含如氨基酸序列SEQ ID NO:113所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:141所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xvi)VH，其包含如氨基酸序列SEQ ID NO:114所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:142所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xvii)VH，其包含如氨基酸序列SEQ ID NO:115所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:143所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xviii)VH，其包含如氨基酸序列SEQ ID NO:116所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:144所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xix)VH，其包含如氨基酸序列SEQ ID NO:117所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:145所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xx)VH，其包含如氨基酸序列SEQ ID NO:118所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:146所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xxi)VH，其包含如氨基酸序列SEQ ID NO:119所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:147所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xxii)VH，其包含如氨基酸序列SEQ ID NO:120所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:148所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xxiii)VH，其包含如氨基酸序列SEQ ID NO:121所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:149所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xxiv)VH，其包含如氨基酸序列SEQ ID NO:122所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:150所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xxv)VH，其包含如氨基酸序列SEQ ID NO:123所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:151所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xxvi)VH，其包含如氨基酸序列SEQ ID NO:124所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:152所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；(xxvii)VH，其包含如氨基酸序列SEQ ID NO:125所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:153所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；或(xxviii)VH，其包含如氨基酸序列SEQ ID NO:126所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:154所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，提供一种分离的抗FasL抗体，其包含：(i)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:1，HC-CDR2，其包含氨基酸序列SEQ ID NO:18，和HC-CDR3， 其包含氨基酸序列SEQ ID NO:32；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:67，和LC-CDR3，其包含氨基酸序列SEQ ID NO:77；(ii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:2，HC-CDR2，其包含氨基酸序列SEQ ID NO:19，和HC-CDR3，其包含氨基酸序列SEQ ID NO:32；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:78；(iii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:1，HC-CDR2，其包含氨基酸序列SEQ ID NO:18，和HC-CDR3，其包含氨基酸序列SEQ ID NO:32；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:67，和LC-CDR3，其包含氨基酸序列SEQ ID NO:79；(iv)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:3，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:33；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:52，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:80；(v)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:3，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:34；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:52，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:81；(vi)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:4，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:35；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:53，LC-CDR2，其包含氨基酸序列SEQ ID NO:69，和LC-CDR3，其包含氨基酸序列SEQ ID NO:82；(vii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:5，HC-CDR2，其包含氨基酸序列SEQ ID NO:21，和HC-CDR3，其包含氨基酸序列SEQ ID NO:36；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:54，LC-CDR2，其包含氨基酸序列SEQ ID NO:70，和LC-CDR3，其包含氨基酸序列SEQ ID NO:83；(viii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:6，HC-CDR2，其包含氨基酸序列SEQ ID NO:22，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:84；(ix)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:23，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85；(x)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85；(xi)VH，所述VH包含：HC-CDR1，其 包含氨基酸序列SEQ ID NO:8，HC-CDR2，其包含氨基酸序列SEQ ID NO:25，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85；(xii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:72，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85；(xiii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85；(xiv)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:8，HC-CDR2，其包含氨基酸序列SEQ ID NO:25，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:56，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85；(xv)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:86；(xvi)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:9，HC-CDR2，其包含氨基酸序列SEQ ID NO:26，和HC-CDR3，其包含氨基酸序列SEQ ID NO:39；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:57，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:87；(xvii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:2，HC-CDR2，其包含氨基酸序列SEQ ID NO:27，和HC-CDR3，其包含氨基酸序列SEQ ID NO:40；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:58，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:88；(xviii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:10，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:41；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:59，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:89；(xix)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:6，HC-CDR2，其包含氨基酸序列SEQ ID NO:22，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:90；(xx)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:11，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:42；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:60，LC-CDR2，其包含氨基酸序列SEQ ID  NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:91；(xxi)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:12，HC-CDR2，其包含氨基酸序列SEQ ID NO:29，和HC-CDR3，其包含氨基酸序列SEQ ID NO:43；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:61，LC-CDR2，其包含氨基酸序列SEQ ID NO:75，和LC-CDR3，其包含氨基酸序列SEQ ID NO:92；(xxii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:12，HC-CDR2，其包含氨基酸序列SEQ ID NO:29，和HC-CDR3，其包含氨基酸序列SEQ ID NO:44；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:62，LC-CDR2，其包含氨基酸序列SEQ ID NO:75，和LC-CDR3，其包含氨基酸序列SEQ ID NO:93；(xxiii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:13，HC-CDR2，其包含氨基酸序列SEQ ID NO:30，和HC-CDR3，其包含氨基酸序列SEQ ID NO:45；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:63，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:94；(xxiv)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:14，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:46；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:95；(xxv)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:15，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:47；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:64，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:96；(xxvi)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:16，HC-CDR2，其包含氨基酸序列SEQ ID NO:31，和HC-CDR3，其包含氨基酸序列SEQ ID NO:48；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:65，LC-CDR2，其包含氨基酸序列SEQ ID NO:76，和LC-CDR3，其包含氨基酸序列SEQ ID NO:97；(xxvii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:17，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:49；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:66，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:98；或(xxviii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:17，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:50；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:60，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:91。
在一些实施例中，如上所述任一种分离的抗FasL抗体，其包含：VH，其包含SEQ ID NO:99所示的氨基酸序列或其变体，所述变体与SEQ ID NO:99所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:127所示的氨基酸序列或其变体，所述变体与SEQ ID NO:127所示的氨基酸序列具有至少约80％序列同一性；(ii)VH，其包含SEQ ID NO:100所示的氨基酸序列或其变体，所述变体与SEQ ID NO:100所示的氨基酸序列具有至少约80％序列同一性；以及VL， 其包含SEQ ID NO:128所示的氨基酸序列或其变体，所述变体与SEQ ID NO:128所示的氨基酸序列具有至少约80％序列同一性；(iii)VH，其包含SEQ ID NO:101所示的氨基酸序列或其变体，所述变体与SEQ ID NO:101所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:129所示的氨基酸序列或其变体，所述变体与SEQ ID NO:129所示的氨基酸序列具有至少约80％序列同一性；(iv)VH，其包含SEQ ID NO:102所示的氨基酸序列或其变体，所述变体与SEQ ID NO:102所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:130所示的氨基酸序列或其变体，所述变体与SEQ ID NO:130所示的氨基酸序列具有至少约80％序列同一性；(v)VH，其包含SEQ ID NO:103所示的氨基酸序列或其变体，所述变体与SEQ ID NO:103所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:131所示的氨基酸序列或其变体，所述变体与SEQ ID NO:131所示的氨基酸序列具有至少约80％序列同一性；(vi)VH，其包含SEQ ID NO:104所示的氨基酸序列或其变体，所述变体与SEQ ID NO:104所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:132所示的氨基酸序列或其变体，所述变体与SEQ ID NO:132所示的氨基酸序列具有至少约80％序列同一性；(vii)VH，其包含SEQ ID NO:105所示的氨基酸序列或其变体，所述变体与SEQ ID NO:105所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:133所示的氨基酸序列或其变体，所述变体与SEQ ID NO:133所示的氨基酸序列具有至少约80％序列同一性；(viii)VH，其包含SEQ ID NO:106所示的氨基酸序列或其变体，所述变体与SEQ ID NO:106所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:134所示的氨基酸序列或其变体，所述变体与SEQ ID NO:134所示的氨基酸序列具有至少约80％序列同一性；(ix)VH，其包含SEQ ID NO:107所示的氨基酸序列或其变体，所述变体与SEQ ID NO:107所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:135所示的氨基酸序列或其变体，所述变体与SEQ ID NO:135所示的氨基酸序列具有至少约80％序列同一性；(x)VH，其包含SEQ ID NO:108所示的氨基酸序列或其变体，所述变体与SEQ ID NO:108所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:136所示的氨基酸序列或其变体，所述变体与SEQ ID NO:136所示的氨基酸序列具有至少约80％序列同一性；(xi)VH，其包含SEQ ID NO:109所示的氨基酸序列或其变体，所述变体与SEQ ID NO:109所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:137所示的氨基酸序列或其变体，所述变体与SEQ ID NO:137所示的氨基酸序列具有至少约80％序列同一性；(xii)VH，其包含SEQ ID NO:110所示的氨基酸序列或其变体，所述变体与SEQ ID NO:110所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:138所示的氨基酸序列或其变体，所述变体与SEQ ID NO:138所示的氨基酸序列具有至少约80％序列同一性；(xiii)VH，其包含SEQ ID NO:111所示的氨基酸序列或其变体，所述变体与SEQ ID NO:111所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:139所示的氨基酸序列或其变体，所述变体与SEQ ID NO:139所示的氨基酸序列具有至少约80％序列同一性；(xiv)VH，其包含SEQ ID NO:112所示的氨基酸序列或其变体，所述变体与SEQ ID NO:112所示的氨基酸序列 具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:140所示的氨基酸序列或其变体，所述变体与SEQ ID NO:140所示的氨基酸序列具有至少约80％序列同一性；(xv)VH，其包含SEQ ID NO:113所示的氨基酸序列或其变体，所述变体与SEQ ID NO:113所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:141所示的氨基酸序列或其变体，所述变体与SEQ ID NO:141所示的氨基酸序列具有至少约80％序列同一性；(xvi)VH，其包含SEQ ID NO:114所示的氨基酸序列或其变体，所述变体与SEQ ID NO:114所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:142所示的氨基酸序列或其变体，所述变体与SEQ ID NO:142所示的氨基酸序列具有至少约80％序列同一性；(xvii)VH，其包含SEQ ID NO:115所示的氨基酸序列或其变体，所述变体与SEQ ID NO:115所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:143所示的氨基酸序列或其变体，所述变体与SEQ ID NO:143所示的氨基酸序列具有至少约80％序列同一性；(xviii)VH，其包含SEQ ID NO:116所示的氨基酸序列或其变体，所述变体与SEQ ID NO:116所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:144所示的氨基酸序列或其变体，所述变体与SEQ ID NO:144所示的氨基酸序列具有至少约80％序列同一性；(xix)VH，其包含SEQ ID NO:117所示的氨基酸序列或其变体，所述变体与SEQ ID NO:117所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:145所示的氨基酸序列或其变体，所述变体与SEQ ID NO:145所示的氨基酸序列具有至少约80％序列同一性；(xx)VH，其包含SEQ ID NO:118所示的氨基酸序列或其变体，所述变体与SEQ ID NO:118所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:146所示的氨基酸序列或其变体，所述变体与SEQ ID NO:146所示的氨基酸序列具有至少约80％序列同一性；(xxi)VH，其包含SEQ ID NO:119所示的氨基酸序列或其变体，所述变体与SEQ ID NO:119所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:147所示的氨基酸序列或其变体，所述变体与SEQ ID NO:147所示的氨基酸序列具有至少约80％序列同一性；(xxii)VH，其包含SEQ ID NO:120所示的氨基酸序列或其变体，所述变体与SEQ ID NO:120所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:148所示的氨基酸序列或其变体，所述变体与SEQ ID NO:148所示的氨基酸序列具有至少约80％序列同一性；(xxiii)VH，其包含SEQ ID NO:121所示的氨基酸序列或其变体，所述变体与SEQ ID NO:121所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:149所示的氨基酸序列或其变体，所述变体与SEQ ID NO:149所示的氨基酸序列具有至少约80％序列同一性；(xxiv)VH，其包含SEQ ID NO:122所示的氨基酸序列或其变体，所述变体与SEQ ID NO:122所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:150所示的氨基酸序列或其变体，所述变体与SEQ ID NO:150所示的氨基酸序列具有至少约80％序列同一性；(xxv)VH，其包含SEQ ID NO:123所示的氨基酸序列或其变体，所述变体与SEQ ID NO:123所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:151所示的氨基酸序列或其变体，所述变体与SEQ ID NO:151所示的氨基酸序列具有至少约80％序列同一性；(xxvi)VH，其包含SEQ ID NO:124所示的氨基酸序列 或其变体，所述变体与SEQ ID NO:124所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:152所示的氨基酸序列或其变体，所述变体与SEQ ID NO:152所示的氨基酸序列具有至少约80％序列同一性；(xxvii)VH，其包含SEQ ID NO:125所示的氨基酸序列或其变体，所述变体与SEQ ID NO:125所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:153所示的氨基酸序列或其变体，所述变体与SEQ ID NO:153所示的氨基酸序列具有至少约80％序列同一性；或(xxviii)VH，其包含SEQ ID NO:126所示的氨基酸序列或其变体，所述变体与SEQ ID NO:126所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:154所示的氨基酸序列或其变体，所述变体与SEQ ID NO:154所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，提供一种分离的抗FasL抗体，其与上述任一种分离的抗FasL抗体竞争与FasL的特异性结合。在一些实施例中，提供一种分离的抗FasL抗体，其与上述任一种分离的抗FasL抗体特异性地结合相同的表位。
在一些实施例中，如上所述任一种分离的抗FasL抗体，所述分离的抗FasL抗体包含Fc片段。在一些实施例中，所述分离的抗FasL抗体是全长的IgG抗体。在一些实施例中，所述分离的抗FasL抗体是全长的IgG1或IgG4抗体。在一些实施例中，所述分离的抗FasL抗体是嵌合的、全人的或人源化的抗体。在一些实施例中，所述分离的抗FasL抗体是抗原结合片段，所述抗原结合片段选自Fab、Fab’、F(ab)’2、Fab’-SH、单链Fv(scFv)、Fv片段、dAb、Fd、纳米抗体(nanobody)、双链抗体(diabody)和线性抗体组成的组中。
在一些实施例中，提供一种分离的核酸分子，所述核酸分子编码如上所述任一种抗FasL抗体。在一些实施例中，提供一种载体，所述载体包含如上所述任一种核酸分子。在一些实施例中，提供一种宿主细胞，所述宿主细胞包含如上所述任一种抗FasL抗体、如上所述任一种核酸分子或如上所述任一种载体。在一些实施例中，提供一种制备抗FasL抗体的方法，其包含：a)在能有效表达抗FasL抗体的条件下培养上述任一种宿主细胞；和b)从宿主细胞中获得表达的抗FasL抗体。
在一些实施例中，提供一种治疗所需个体疾病或病症的方法，包括向所述个体施用有效量的如上所述的任一种抗FasL抗体。在一些实施例中，提供如上所述的任一种抗FasL抗体在制备用于治疗所需个体疾病或病症的药物组合物中的用途。在一些实施例中，提供如上所述的任一种抗FasL抗体或包含抗FasL抗体的药物组合物在制备用于治疗疾病或病症的药物中的用途。在一些实施例中，所述疾病或病症与FasL-Fas信号通路有关，包括炎性疾病、癌症或自体免疫性疾病或病症。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免 性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症。
同时还提供包含如上所述的任一种抗FasL抗体的药物组合物、试剂盒以及生产制品。
本申请的详细描述
本申请一方面提供抗FasL抗体分子。通过天然scFv噬菌体库筛选、适当设计的生物化学及生物学实验的组合以及抗体人源化，已经鉴定出能够结合人FasL并抑制人FasL与其受体作用的高效抗体分子。本文给出的结果表明，与已知抗FasL抗体相比，本申请中的抗体具有更好的生物学活性。
本申请所提供的抗FasL抗体包括，例如，全长抗FasL抗体、抗FasL单链抗体(scFvs)、抗FasL Fc融合蛋白、多特异性(如双特异性)抗FasL抗体、抗FasL免疫偶联物以及诸如此类的。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:99所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:127所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:100所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:128所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:101所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:129所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:102所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:130所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:103所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:131所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:104所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:132所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:105所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:133所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:106所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:134所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:107所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:135所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:108所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:136所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:109所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:137所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:110所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:138所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:111所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:139所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:112所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:140所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:113所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:141所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:114所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:142所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:115所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:143所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:116所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:144所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:117所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:145所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:118所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:146所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:119所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:147所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:120所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:148所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:121所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:149所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:122所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:150所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:123所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:151所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:124所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:152所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:125所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:153所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
另一方面，本申请提供抗FasL抗体，所述抗FasL抗体包含：VH，其包含如氨基酸序列SEQ ID NO:126所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:154所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
同时还提供编码抗FasL抗体的核酸，包含抗FasL抗体的组合物，以及制备和使用抗FasL抗体的方法。
定义
如本文所述，“治疗(treatment)”或“治疗(treating)是一种获得有益的或期望的结果的方法，包括临床结果。鉴于本申请的目的，所述有益的或期望的临床结果，包括但不限于以下一种或多种：缓解由疾病引起的一种或多种症状，减轻疾病程度，稳定疾病(例如，预防或延迟疾病恶化)，预防或延迟疾病的扩散(例如，转移)，预防或延迟疾病复发，延迟或减缓疾病进展，改善疾病状态，缓解疾病(部分或全部)，减少治疗疾病所需的一种或多种其他药物的剂量，延迟疾病进展，改善或提高生活质量，增加体重，和/或延长生存期。同时，“治疗”还包括疾病病理结果的减少(例如，对癌症而言，肿瘤体积)。本申请的方法考虑了这些治疗的任何一个或多个方面。
术语“抗体”包括全长抗体及其抗原结合片段。全长抗体包括两条重链和两条轻链。轻链和重链的可变区负责抗原的结合。两条链中的可变区通常包括3个高变的环，被称为互补决定区(CDRs)(轻链(LC)CDRs包括LC-CDR1、LC-CDR2和LC-CDR3，重链(HC)CDRs包括HC-CDR1、HC-CDR2和HC-CDR3)。本文所披露的抗体或抗原结合片段的CDR边界可以通过Kabat，Chothia或Al-Lazikani惯例来定义或识别(Al-Lazikani 1997；Chothia 1985；Chothia 1987；Chothia 1989；Kabat 1987；Kabat 1991)。重链或轻链的3个CDR区插入到被称为框架区(FRs)的侧翼区段之间，所述框架区比CDR区具有更高的保守性，并形成支撑高变环的支架。重链和轻链的恒定区并不参与抗原结合，但展示出多种效应功能。抗体是基于它们重链恒定区的氨基酸序列进行分类的。抗体的五种主要类别或同种型是IgA、IgD、IgE、IgG和IgM，其特征在于分别具有α、δ、ε、γ和μ型重链。几种主要的抗体类别被分为亚类，如IgG1(γ1重链)、IgG2(γ2重链)、IgG3(γ3重链)、IgG4(γ4重链)、IgA1(α1重链)或IgA2(α2重链)。
如本文所述，术语“抗原结合片段”包括抗体片段，例如，双链抗体(diabody)、Fab、Fab’、F(ab’)2、Fv片段、二硫键稳定的Fv片段(dsFv)、(dsFv)2、双特异性dsFv(dsFv-dsFv’)、二硫键稳定的双链抗体(ds双链抗体)、单链Fv(scFv)、scFv二聚体(二价双链抗体)，由包含一个或多个CDRs的抗体片段组成的多特异性抗体、单域抗体、纳米抗体(nanobody)、域抗体、二价域抗体或者能够与抗原结合但不包含完整抗体结构的任何其他抗体片段。抗原结合片段能够与亲本抗体或亲本抗体片段(如亲本scFv)结合相同的抗原。抗原结合片段还包括包含上述抗体片段的融合蛋白。在一些实施例中，抗原结合片段可能包括来自特定人抗体的一个或多个CDRs，该CDRs被移植到来自一个或多个不同人抗体的框架区。
如本文所述，术语“表位”是指抗体或抗体部分结合的抗原上特定的原子或氨基酸组。如果两种抗体或抗体部分表现出与某抗原竞争性结合，则它们可能结合抗原上的相同表位。
如本文所用，当第一抗体在等摩尔浓度下抑制第二抗体与FasL靶标结合至少50％(例如至少55％、60％、65％、70％、75％、80％、85％、90％、95％、98％或99％)时，第一抗体与第二抗体“竞争”结合FasL靶标，反之亦然。PCT出版物WO 03/48731描述了基于交叉竞争的高通量抗体“表位归类”方法。
如本文所述，术语“特异性地结合”、“特异性地识别”或“对..来说是特异性的”是指可测量的和可再现的相互作用，例如抗体与靶标的结合可以确定在异质分子群，包括生物分子中存在该靶标。例如，抗体能够特异性地识别某靶标(可以是表位)是指，与其它靶标结合相比，该抗体与该靶标的结合具有更高的亲和力，亲合力，更容易和/或更持久。在一些实施例中，特异性地识别抗原的抗体与抗原的一个或多个抗原决定簇反应，其结合亲和力是其与其它靶标结合亲和力的至少10倍。
如本文所述，一种“分离的”抗FasL抗体是指一种抗FasL抗体，其(1)与天然存在的蛋白无关，(2)不含相同来源的其他蛋白，(3)由不同种属的细胞所表达，或(4)自然界中不存在。
如本文所述，术语“分离的核酸”，是指基因组、cDNA或合成来源的核酸或其组合。根据其来源，所述“分离的核酸”是指(1)与自然界中发现的“分离的核酸”中的全部或部分多核苷酸无关，(2)可与自然状态下不与之相连的多核苷酸可操作性地连接，或(3)在自然界中不作为较长序列的一部分而存在。
如本文所用，术语“CDR”或“互补决定区”意指重链和轻链多肽的可变结构域内发现的非连续抗原结合位点。在文献Kabat et al.,J.Biol.Chem.252:6609-6616(1977)；Kabat et al.,U.S.Dept.of Health and Human Services,“Sequences of proteins of immunological interest”(1991)；Chothia et al.,J.Mol.Biol.196:901-917(1987)；Al-Lazikani B.et al.,J.Mol.Biol.,273:927-948(1997)；MacCallum et al.,J.Mol.Biol.262:732-745(1996)；Abhinandan and Martin,Mol.Immunol.,45:3832-3839(2008)；Lefranc M.P.et al.,Dev.Comp.Immunol.,27:55-77(2003)；和Honegger and Plückthun,J.Mol.Biol.,309:657-670(2001)中已经描述这些特殊的区域，其中当彼此之间互相比较时，这些定义包括氨基酸残基的重合或子集。然而，采用任何一种定义方式来指示抗体或移植抗体或其变体的CDR，均包括在本文所定义和使用的术语范围之内。表1中列了由上述引用的各篇参考文献所定义的CDR所包括的氨基酸残基的位置，以示比较。CDR预测的算法和结合界面在本领域是已知的，包括，例如Abhinandan and Martin,Mol.Immunol.,45:3832-3839(2008)；Ehrenmann F.et al.,Nucleic Acids Res.,38:D301-D307(2010)；和Adolf-Bryfogle J.et al.,Nucleic Acids Res.,43:D432-D438(2015)中均有描述。本段中所引用的参考文献的内容以其整体引用并入本文中，以用于本申请和可能包含在本文中的一个或多个权利要求中。
表1:CDR定义


1氨基酸残基编号参照上述Kabat et al.中的命名方法
2氨基酸残基编号参照上述Chothia et al.中的命名方法
3氨基酸残基编号参照上述MacCallum et al.中的命名方法
4氨基酸残基编号参照上述Lefranc et al.中的命名方法
5氨基酸残基编号参照上述Honegger and Plückthun中的命名方法
术语“嵌合抗体”是指，重链和/或轻链的一部分与来自特定种属或属于特定抗体种类或亚类的抗体中的相应序列一致或具有同源性，而这个(些)链的剩余部分与来自另一种属或属于其它抗体种类或亚类的抗体中的相应序列一致或具有同源性的抗体，以及此类抗体的片段，只要其具有本申请中的生物学活性(见U.S.Patent No.4,816,567；and Morrison et al.,Proc.Natl.Acad.Sci.USA,81:6851-6855(1984))。
“Fv”是包含完整抗原识别及结合位点的最小抗体片段。该片段是由一个重链可变结构域和一个轻链可变结构域紧密非共价连接形成的二聚体。通过这两个域的折叠衍生出6个高变环(轻链和重链中各3个环)，所述高变环为抗体提供了用于结合抗原的氨基酸残基，并且赋予抗体与抗原结合的特异性。然而，即使单个可变结构域(或Fv片段的一半，其仅包含对抗原具有特异性的3个CDRs)也具有识别和结合抗原的能力，尽管其亲和力低于完整的结合位点。
“单链Fv”，也可简写成“sFv”或“scFv”，是包含被连接成单一多肽链的VH和VL抗体域的抗体片段。在一些实施例中，scFv多肽进一步包括VH和VL域之间的连接多肽，该连接多肽使得scFv形成抗原结合的理想结构。关于scFv的概述，见Pluckthun in The Pharmacology of Monoclonal Antibodies,vol.113,Rosenburg and Moore eds.,Springer-Verlag,New York,pp.269-315(1994)。
术语“双链抗体(diabody)”是在VH和VL域之间采用短接头(例如5～10个残基)，构建scFv片段(见上段内容)制备而成的一种小抗体片段，这样就使得可变结构域在链间而不是链内进行配对，产生一个双价片段，即具有两个抗原结合位点的片段。双特异性的双链抗体是两个“交叉”scFv片段的异二聚体，其中两个抗体的VH和VL域位于不同的多肽链上。在EP 404,097；WO 93/11161；Hollinger et al.,Proc.Natl.Acad.Sci.USA,90:6444-6448(1993)中全面描述了双链抗体。
非人源(如啮齿类)抗体的“人源化”形式是嵌合抗体，其包括最少的来自非人源抗体的序列。大多数情况下，人源化抗体是人源免疫球蛋白(受体抗体)，其中受体抗体的高变区(HVR)残基被来自非人源种属例如小鼠、大鼠、兔或非人类哺乳动物的且具有理想的抗体特异性，亲和力和性能的高变区残基所取代(供体抗体)。在某些情况下，人源免疫球蛋白框架区中的残基被相应的非人源残基所取代。另外，人源化抗体可以包括在受体抗体或供体抗体中均不存在的残基。这些修饰能够进一步改善抗体的性能。通常，人源化抗体会包含基本上所有，至少一个，通常两个可变结构域，其中所有或基本上所有的高变环均与非人免疫球蛋白的高变环相对应，以及所有或基本上所有的框架区均是人免疫球蛋白序列。人源抗体任选地也还包括免疫球蛋白恒定区(Fc)的至少一部分，通常是人免疫球蛋白的恒定区。具体细节可以参考Jones et al.,Nature 321:522-525 (1986)；Riechmann et al.,Nature 332:323-329(1988)；和Presta,Curr.Op.Struct.Biol.2:593-596(1992)。
本文所鉴定的多肽和抗体序列的“氨基酸序列同一性百分比(％)”或“同源性”被定义：在认为保守性取代属于序列同一性的一部分的情况下进行序列对比，候选序列与待比较多肽序列中相同氨基酸残基所占的百分比。可以通过本领域技术范围内的多种比对方式来确定氨基酸序列同一性百分比，例如，使用如BLAST、BLAST-2、ALIGN、Megalign(DNASTAR)、或MUSCLE软件等可公开获得的计算机软件。本领域技术人员可以确定用于测量比对的合适的参数，包括在所比较序列的全长上实现最大化比对所需的任何算法。然而，为了本文的目的，氨基酸序列同一性百分比数值是使用序列比对电脑程序MUSCLE(Edgar,R.C.,Nucleic Acids Research 32(5):1792-1797,2004；Edgar,R.C.,BMC Bioinformatics 5(1):113,2004)生成的。
术语“Fc受体”或“FcR”用于描述结合抗体Fc区的受体。在一些实施例中，本申请所述的FcR是结合IgG抗体(一种γ受体)的FcR，包括FcγRI、FcγRII和FcγRIII亚类的受体，包括这些受体的等位基因变体和可变剪接形式。FcγRII受体包括FcγRIIA(“激活受体”)和FcγRIIB(“抑制受体”)，它们具有相似的氨基酸序列，主要在细胞质结构域有所不同。激活受体FcγRIIA的胞质结构域中含有免疫受体酪氨酸活化基序(ITAM)。抑制受体FcγRIIB的胞质结构域中含有免疫受体酪氨酸抑制基序(ITIM)(见M.inAnnu.Rev.Immunol.15:203-234(1997))。所述术语还包括同种异型，例如FcγRIIIA同种异型：FcγRIIIA-Phe158、FcγRIIIA-Val158、FcγRIIA-R131和/或FcγRIIA-H131。在Ravetch and Kinet,Annu.Rev.Immunol 9:457-92(1991)和Capel et al.,Immunomethods 4:25-34(1994)；以及de Haas et al.,J.Lab.Clin.Med.126:330-41(1995)中对FcRs进行了描述。本申请中术语FcR涵盖其他类型的FcRs，包括将来鉴定的FcRs。术语FcR同时还包括新生儿受体FcRn，其负责向新生儿转移母体IgGs(Guyer et al.,J.Immunol.117:587(1976)以及Kim et al.,J.Immunol.24:249(1994))。
术语“FcRn”指新生儿Fc受体(FcRn)。FcRn与主要组织相容性复合体(MHC)在结构上相似，由α链非共价结合到β2微球蛋白上组成。新生儿Fc受体FcRn的多种功能在Ghetie and Ward(2000)Annu.Rev.Immunol.18,739-766.中进行了综述。FcRn在免疫球蛋白IgGs从母体向新生儿的被动转运和调控血清IgG水平中起到重要作用。FcRn作为一种救助受体，可以在细胞内和细胞间以完整的形式结合和运输胞吞化的IgG，并使它们免于经受默认的降解途径。
人IgG重链恒定区的“CH1结构域”通常从118位氨基酸延伸到215位氨基酸(EU编号系统)。
“铰链区”通常被定义为从人IgG1的216位Glu延伸到230位Pro(Burton,Molec.Immunol.22:161-206(1985))。通过将形成重链间二硫键的第一个和最后一个半胱氨酸残基置于与IgG1相同位置后，可以使得其他IgG同种型的铰链区与IgG1序列比对。
人IgG Fc区的“CH2结构域”通常从231位氨基酸延伸到340位氨基酸。CH2结构域的独特之处在于，它不会与另一个区域紧密配对，而是在完整的天然IgG分子的两个CH2结构域之间插入 了两条N端连接的支链糖链。据推测，糖类可能作为域与域间配对的替代，有助于保持CH2结构域稳定。Burton,Molec.Immunol.22:161-206(1985)。
“CH3”结构域包括在Fc区内从C末端残基延伸到CH2结构域(从341位氨基酸到抗体序列的C末端，通常为IgG的第446或447位氨基酸残基)。
“功能性Fc片段”具有天然Fc区序列所具有的“效应功能”。示例性的“效应功能”包括C1q结合；补体依赖的细胞毒作用(CDC)；Fc受体结合；抗体依赖的细胞介导的细胞毒作用(ADCC)；吞噬作用；细胞表面受体的下调(如B细胞受体；BCR)等。这类效应功能通常需要Fc区与结合结构域(如抗体可变区)结合，并且可以使用本领域公知的多种实验方法进行评估。
具有“改变的”FcR结合亲和力或ADCC活性的IgG Fc变体的抗体，与亲本多肽或包含天然Fc序列的多肽相比，其FcR结合活性和/或ADCC活性增强或减弱。表现出与FcR“结合增强”的Fc变体与亲本多肽或包含天然IgG Fc序列的多肽相比，其与至少一种FcR具有更高的结合亲和力(例如更低的表观Kd或IC50值)。在一些实施例中，与亲本多肽相比，结合能力增强3倍，例如5、10、25、50、60、100、150、200，甚至高达500倍或结合力提高25％到1000％。表现出与FcR“结合降低”的Fc变体，与亲本多肽相比，其与至少一种FcR具有更低的亲和力(例如更高的表观Kd或IC50值)。与亲本多肽相比，其结合能力下降40％或更多。
“抗体依赖的细胞介导的细胞毒作用”或“ADCC”是一种细胞毒性形式，指分泌型的Ig与存在于某些细胞毒性细胞(例如自然杀伤细胞(NK)、中性粒细胞、和巨噬细胞)上的Fc受体(FcRs)结合，使这些细胞毒性效应细胞能够特异性结合携带抗原的靶细胞，随后使用细胞毒素杀死靶细胞。抗体“武装”细胞毒性细胞并且是这种杀伤所必需的。介导ADCC的主要细胞类型中，NK细胞只表达FcγRIII，而单核细胞表达FcγRI、FcγRII和FcγRIII。在Ravetch and Kinet,Annu.Rev.Immunol 9:457-92(1991)第464页的Table 3中总结了在造血细胞上FcR的表达。评估目标分子的ADCC活性，可以进行体外ADCC实验，在美国专利No.5,500,362或5,821,337中进行了描述。适用于此类实验的效应细胞包括外周血单核细胞(PBMC)和自然杀伤性细胞(NK)。可选地，或者此外，目标分子的ADCC活性也可以在体内进行评估，例如在如Clynes et al.PNAS(USA)95:652-656(1998)中所公开的动物模型中进行了描述。
包含Fc区变体的多肽与包含野生型IgG Fc多肽或亲本多肽相比，在人体效应细胞存在下表现出“增强的ADCC活性”或能够更有效的介导ADCC效应，所述包含Fc区变体的多肽在实验时与包含野生型IgG Fc多肽(或亲本多肽)数量上基本相同时，无论在体外或体内均能更有效的介导ADCC。通常采用本领域已知的任何体外ADCC实验方法来鉴定此类变体，例如用于鉴定ADCC活性的实验或方法，例如在动物模型中等。在一些实施例中，此类变体与野生型Fc(或亲代多肽)相比，介导ADCC的效率提高5到100倍，例如25到50倍。
“补体依赖的细胞毒作用”或“CDC”是指在补体存在的情况下裂解靶细胞。经典的补体途径的激活是由补体系统第一组分(C1q)与结合同源抗原的抗体(具有适宜结构的亚类)相结合而启动的。为了评估补体激活，可以进行CDC实验，如Gazzano-Santoro et al.,J.Immunol.Methods 202:163 (1996)中所描述的。在美国专利No.6,194,551B1和WO99/51642中描述了具有改变的Fc区氨基酸序列并增加或降低的C1q结合能力的多肽变体。这些专利出版物的内容通过引用明确地并入本文中。另见Idusogie et al.J.Immunol.164:4178-4184(2000)。
除非另有说明，一种“编码氨基酸序列的核苷酸序列”包括相互之间互为简并形式且编码相同氨基酸序列的所有核苷酸序列。编码蛋白质或RNA的核苷酸序列也可包括内含子，例如编码蛋白质的核苷酸序列在某些形式中包含内含子。
术语“可操作性地连接”是指调控序列与异源核苷酸序列之间的功能性连接，从而使后者表达。例如，当第一个核苷酸序列与第二个核苷酸序列处于功能性关系时，第一个核苷酸序列与第二个核苷酸序列为可操作性地连接。例如，如果启动子影响编码序列的转录或表达，该启动子与编码序列为可操作性地连接。通常，可操作性连接的DNA序列是连续的，并且在必要时，可以在同一个阅读框中连接两个蛋白质编码区。
“同源”是指两个多肽之间或两个核酸分子之间的序列相似性或序列同一性。如果两个比较序列的同一位置为相同的碱基或氨基酸单体亚基时，例如两个DNA分子的同一位置均为腺嘌呤，则这两个DNA分子在该位置是同源的。两个序列间的同源百分比是指两个序列中共有的匹配或同源位置的数量与位置总数之比再乘以100所得函数。例如，两个序列中如果10个位置中有6个位置是相匹配或同源的，则这两个序列的同源性为60％。举例来说，DNA序列ATTGCC和TATGGC具有50％的同源性。通常来说，在比对两个序列时，以得到最大同源性为目的来进行对比。
本文所公开的抗FasL抗体或组合物的“有效量”是指足以实现特定目的的量。“有效量”可以凭经验和通过已知的与所述目的相关的方法确定。
术语“治疗有效量”是指本文所公开的抗FasL抗体或其组合物能够有效治疗个体的疾病或者症状的用量，即足以减轻或改善疾病或其一种或多种症状的严重程度和/或持续时间的量；预防疾病发展，引起病症消退，预防与疾病相关的一种或多种症状的复发、发展、发作或进展，检测疾病，或增强/改善另一疗法(例如预防剂或治疗剂)的预防或治疗效果的量。例如在癌症的情况中，抗FasL抗体或其组合物的治疗有效量是指能够减少癌细胞数量；减小肿瘤的大小或重量；抑制(即在一定程度上减缓或优选停止)肿瘤细胞对周边器官的浸润；抑制(即在一定程度上减缓或优选停止)肿瘤转移；在一定程度上抑制肿瘤的生长，和/或在一定程度上缓解与癌症相关的一种或多种症状。本文所公开的抗FasL抗体或其组合物在某种程度上能够阻止或抑制FasL与其受体Fas的结合，除了细胞凋亡信号通路外，Fas介导的非细胞凋亡信号(诸如NF-kB、MAPK或PI3K)，该非细胞凋亡信号促进炎症、促成癌变并且调节免疫学参数(例如，肿瘤浸润T细胞群体)。所有这些活动都可能被本文所述的抗体所抑制。
如本文所用的，“药学上可接受的”或“药理学上相容的”是指无生物学活性或者其它不期望性质的材料，例如该材料能够加入到给予患者的药物组合物中，而不会引起显著的不良生物反应，或者，不与组合物中包含的任何其它组分以有害的方式相互作用。药学上可接受的载体或赋形剂优选满足毒理学或制造检测的所需标准和/或包含在美国食品和药品管理局编制的非活性成分指南中。
本文中描述的本申请的实施例应理解为包含“由……组成”和/或“基本上由……组成”的实施例。
本文中提及“约”为一个数值或参数，包含(和描述)针对该值或参数本身的变体。例如，涉及“约X”的描述，包括“X”的描述。
如本文所用的，提及“不是(not)”一个数值或参数，通常表示并描述“除了(other than)”某一数值或参数之外。例如，该方法不能用于治疗X型癌症，意味着该方法通常用于治疗除X型癌症之外的其他类型的癌症。
除非上下文另有明确说明，本文和所述权利要求中所采用的单数形式“一”，“一个”和“该”包括复数对象。
抗FasL抗体
一方面，本申请提供特异性结合人FasL的抗FasL抗体。所述抗FasL抗体包括，但不限于，人源化抗体，嵌合抗体，小鼠抗体，人抗体，以及本文所述的包含重链和/或轻链CDRs的抗体分子。一方面，本申请提供与FasL结合的分离的抗体。预期的抗FasL抗体包括，例如，全长抗FasL抗体(如全长IgG1或IgG4)，抗FasL单链抗体，抗FasL Fc融合蛋白，多特异性(如双特异性)抗FasL抗体，抗FasL免疫偶联物，以及诸如此类的。在一些实施例中，抗FasL抗体是全长抗体(如全长IgG1或IgG4)或其抗原结合片段，其特异性结合FasL。在一些实施例中，抗FasL抗体是Fab、Fab’、F(ab)’2、Fab’-SH、单链Fv(scFv)、Fv片段、dAb、Fd、纳米抗体(nanobody)、双链抗体(diabody)或线性抗体。在一些实施例中，特异性结合FasL的抗体是指抗体与FasL结合的亲和力至少是与非靶标结合亲和力的10倍以上(包括例如10、102、103、104、105、106、或107倍)。在一些实施例中，非靶标是指不是FasL的抗原。结合亲和力可通过本领域已知的方法来测定，如ELISA，荧光激活细胞分选(FACS)分析或放射免疫沉淀分析(RIA)。Kd值可以通过本领域已知的方法来测定，如表面等离子共振(SPR)技术或生物层干涉技术(BLI)。
尽管本文广泛地讨论了包含人序列的抗FasL抗体(例如，包含人CDR序列的人重链和轻链可变结构域)，但同时也考虑了非人抗FasL抗体。在一些实施例中，非人抗FasL抗体包括本文所述的抗FasL抗体的人CDR序列和非人框架区序列，在一些实施例中，非人框架区序列包括任何的用于使用如本文所述的一种或多种人CDR序列产生重链和/或轻链可变结构域的序列，包括例如哺乳动物，例如小鼠、大鼠、兔子、猪、牛(例如，牛、公牛、水牛)、鹿、绵羊、山羊、鸡、猫、狗、雪貂、灵长类(例如，小猿，猕猴)等。在一些实施例中，非人抗FasL抗体包括将一种或多种本文所述的人CDR序列移植到非人框架区中(例如，鼠或鸡的框架区序列)所产生的抗FasL抗体。
示例性人FasL的完整氨基酸序列包含SEQ ID NO：159所示的氨基酸序列或由SEQ ID NO：159所示的氨基酸序列组成。示例性人FasL胞外区氨基酸序列包含SEQ ID NO：160所示的氨基酸序列或由SEQ ID NO：160所示的氨基酸序列组成。
在一些实施例中，本文所述抗FasL抗体特异性识别人FasL中的表位。在一些实施例中，所述抗FasL抗体与除人之外其它物种的FasL发生交叉反应。在一些实施例中，所述抗FasL抗体对人FasL是完全特异性的，并且不与其它非人物种发生交叉反应。
在一些实施例中，所述抗FasL抗体与FasL蛋白(或其片段)的至少一种等位基因变体交叉反应。在一些实施例中，等位基因变体与天然存在的FasL蛋白(或其片段)相比，具有至多30个(如1、2、3、4、5、6、7、8、9、10、15、20、25或30个)的氨基酸取代(例如保守取代)。在一些实施例中，所述抗FasL抗体不与FasL蛋白(或其片段)的任何等位基因变体发生交叉反应。
在一些实施例中，所述抗FasL抗体与FasL蛋白的至少一种种间变体发生交叉反应。在一些实施例中，例如，FasL蛋白(或其片段)是人FasL，并且FasL蛋白(或其片段)的种间变体是食蟹猴中的变体。在一些实施例中，所述抗FasL抗体不与FasL蛋白的任何种间变体发生交叉反应。
在一些实施例中，如本文所述的任一抗FasL抗体，所述抗FasL抗体包含抗体重链恒定区和抗体轻链恒定区。在一些实施例中，所述抗FasL抗体包含IgG1型重链恒定区。在一些实施例中，所述抗FasL抗体包含IgG2型重链恒定区。在一些实施例中，所述抗FasL抗体包含IgG3型重链恒定区。在一些实施例中，所述抗FasL抗体包含IgG4型重链恒定区。在一些实施例中，所述重链恒定区包含(包括由…组成或基本上由…组成)氨基酸序列SEQ ID NO:155。在一些实施例中，所述重链恒定区包含(包括由…组成或基本上由…组成)氨基酸序列SEQ ID NO:156。在一些实施例中，所述抗FasL抗体包含κ轻链恒定区。在一些实施例中，所述轻链恒定区包含(包括由…组成或基本上由…组成)氨基酸序列SEQ ID NO:157。在一些实施例中，所述抗FasL抗体包含λ轻链恒定区。在一些实施例中，所述轻链恒定区包含(包括由…组成或基本上由…组成)氨基酸序列SEQ ID NO:158。在一些实施例中，所述抗FasL抗体包含抗体重链可变结构域和抗体轻链可变结构域。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:1，HC-CDR2，其包含氨基酸序列SEQ ID NO:18，HC-CDR3，其包含氨基酸序列SEQ ID NO:32，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:67，LC-CDR3，其包含氨基酸序列SEQ ID NO:77，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:1，HC-CDR2，其包含氨基酸序列SEQ ID NO:18，和HC-CDR3，其包含氨基酸序列SEQ ID NO:32；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:67，和LC-CDR3，其包含氨基酸序列SEQ ID NO:77。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:99所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:127所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:99或其变体，所述变体与氨基酸序列SEQ ID NO:99具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:127或其变体，所述变体与氨基酸序列SEQ ID NO:127具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:99，以及VL，所述VL包含氨基酸序列SEQ ID NO:127。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:2，HC-CDR2，其包含氨基酸序列SEQ ID NO:19，HC-CDR3，其包含氨基酸序列SEQ ID NO:32，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，LC-CDR3，其包含氨基酸序列SEQ ID NO:78，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:2，HC-CDR2，其包含氨基酸序列SEQ ID NO:19，和HC-CDR3，其包含氨基酸序列SEQ ID NO:32；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:78。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:100所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:128所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:100或其变体，所述变体与氨基酸序列SEQ ID NO:100具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:128或其变体，所述变体与氨基酸序列SEQ ID NO:128具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:100，以及VL，所述VL包含氨基酸序列SEQ ID NO:128。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:1，HC-CDR2，其包含氨基酸序列SEQ ID NO:18，HC-CDR3，其包含氨基酸序列SEQ ID NO:32，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:67，LC-CDR3，其包含氨基酸序列SEQ ID NO:79，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:1，HC-CDR2，其包含氨基酸序列SEQ ID NO:18，和HC-CDR3，其包含氨基酸序列 SEQ ID NO:32；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:67，和LC-CDR3，其包含氨基酸序列SEQ ID NO:79。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:101所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:129所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:101或其变体，所述变体与氨基酸序列SEQ ID NO:101具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:129或其变体，所述变体与氨基酸序列SEQ ID NO:129具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:101，以及VL，所述VL包含氨基酸序列SEQ ID NO:129。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:3，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，HC-CDR3，其包含氨基酸序列SEQ ID NO:33，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:52，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，LC-CDR3，其包含氨基酸序列SEQ ID NO:80，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:3，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:33；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:52，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:80。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:102所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:130所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:102或其变体，所述变体与氨基酸序列SEQ ID NO:102具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:130或其变体，所述变体与氨基酸序列SEQ ID NO:130具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:102，以及VL，所述VL包含氨基酸序列SEQ ID NO:130。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:3，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，HC-CDR3，其包含氨基酸序列SEQ ID NO:34，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:52，LC-CDR2，其包含氨基酸序列SEQ ID  NO:68，LC-CDR3，其包含氨基酸序列SEQ ID NO:81，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:3，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:34；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:52，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:81。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:103所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:131所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:103或其变体，所述变体与氨基酸序列SEQ ID NO:103具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:131或其变体，所述变体与氨基酸序列SEQ ID NO:131具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:103，以及VL，所述VL包含氨基酸序列SEQ ID NO:131。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:4，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，HC-CDR3，其包含氨基酸序列SEQ ID NO:35，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:53，LC-CDR2，其包含氨基酸序列SEQ ID NO:69，LC-CDR3，其包含氨基酸序列SEQ ID NO:82，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:4，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:35；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:53，LC-CDR2，其包含氨基酸序列SEQ ID NO:69，和LC-CDR3，其包含氨基酸序列SEQ ID NO:82。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:104所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:132所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:104或其变体，所述变体与氨基酸序列SEQ ID NO:104具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:132或其变体，所述变体与氨基酸序列SEQ ID NO:132具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:104，以及VL，所述VL包含氨基酸序列SEQ ID NO:132。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:5，HC-CDR2，其包含氨基酸序列SEQ ID NO:21，HC-CDR3，其包含氨基酸序列SEQ ID NO:36，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:54，LC-CDR2，其包含氨基酸序列SEQ ID NO:70，LC-CDR3，其包含氨基酸序列SEQ ID NO:83，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:5，HC-CDR2，其包含氨基酸序列SEQ ID NO:21，和HC-CDR3，其包含氨基酸序列SEQ ID NO:36；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:54，LC-CDR2，其包含氨基酸序列SEQ ID NO:70，和LC-CDR3，其包含氨基酸序列SEQ ID NO:83。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:105所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:133所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:105或其变体，所述变体与氨基酸序列SEQ ID NO:105具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:133或其变体，所述变体与氨基酸序列SEQ ID NO:133具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:105，以及VL，所述VL包含氨基酸序列SEQ ID NO:133。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:6，HC-CDR2，其包含氨基酸序列SEQ ID NO:22，HC-CDR3，其包含氨基酸序列SEQ ID NO:37，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，LC-CDR3，其包含氨基酸序列SEQ ID NO:84，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:6，HC-CDR2，其包含氨基酸序列SEQ ID NO:22，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:84。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:106所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:134所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:106或其变体，所述变体与氨基酸序列SEQ ID NO:106具有至少约80％(例如至少80％、85％、90％、 95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:134或其变体，所述变体与氨基酸序列SEQ ID NO:134具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:106，以及VL，所述VL包含氨基酸序列SEQ ID NO:134。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:23，HC-CDR3，其包含氨基酸序列SEQ ID NO:38，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，LC-CDR3，其包含氨基酸序列SEQ ID NO:85，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:23，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:107所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:135所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:107或其变体，所述变体与氨基酸序列SEQ ID NO:107具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:135或其变体，所述变体与氨基酸序列SEQ ID NO:135具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:107，以及VL，所述VL包含氨基酸序列SEQ ID NO:135。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，HC-CDR3，其包含氨基酸序列SEQ ID NO:37，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，LC-CDR3，其包含氨基酸序列SEQ ID NO:85，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:108所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:136所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:108或其变体，所述变体与氨基酸序列SEQ ID NO:108具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:136或其变体，所述变体与氨基酸序列SEQ ID NO:136具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:108，以及VL，所述VL包含氨基酸序列SEQ ID NO:136。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:8，HC-CDR2，其包含氨基酸序列SEQ ID NO:25，HC-CDR3，其包含氨基酸序列SEQ ID NO:38，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，LC-CDR3，其包含氨基酸序列SEQ ID NO:85，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:8，HC-CDR2，其包含氨基酸序列SEQ ID NO:25，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:109所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:137所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:109或其变体，所述变体与氨基酸序列SEQ ID NO:109具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:137或其变体，所述变体与氨基酸序列SEQ ID NO:137具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:109，以及VL，所述VL包含氨基酸序列SEQ ID NO:137。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，HC-CDR3，其包含氨基酸序列SEQ ID NO:38，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:72，LC-CDR3，其包含氨基酸序列SEQ ID NO:85，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:72，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:110所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:138所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:110或其变体，所述变体与氨基酸序列SEQ ID NO:110具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:138或其变体，所述变体与氨基酸序列SEQ ID NO:138具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:110，以及VL，所述VL包含氨基酸序列SEQ ID NO:138。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，HC-CDR3，其包含氨基酸序列SEQ ID NO:38，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，LC-CDR3，其包含氨基酸序列SEQ ID NO:85，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:111所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:139所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:111或其变体，所述变体与氨基酸序列SEQ ID NO:111具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:139或其变体，所述变体与氨基酸序列SEQ ID NO:139具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:111，以及VL，所述VL包含氨基酸序列SEQ ID NO:139。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:8，HC-CDR2，其包含氨基酸序列SEQ ID NO:25，HC-CDR3，其包含氨基酸序列 SEQ ID NO:38，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:56，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，LC-CDR3，其包含氨基酸序列SEQ ID NO:85，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:8，HC-CDR2，其包含氨基酸序列SEQ ID NO:25，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:56，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:112所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:140所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:112或其变体，所述变体与氨基酸序列SEQ ID NO:112具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:140或其变体，所述变体与氨基酸序列SEQ ID NO:140具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:112，以及VL，所述VL包含氨基酸序列SEQ ID NO:140。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，HC-CDR3，其包含氨基酸序列SEQ ID NO:38，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，LC-CDR3，其包含氨基酸序列SEQ ID NO:86，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:86。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:113所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:141所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:113或其变体，所述变体与氨基酸序列SEQ ID NO:113具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:141或其变体，所述变体与氨基酸序列SEQ ID NO:141具有至少约80％(例如至少80％、85％、90％、 95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:113，以及VL，所述VL包含氨基酸序列SEQ ID NO:141。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:9，HC-CDR2，其包含氨基酸序列SEQ ID NO:26，HC-CDR3，其包含氨基酸序列SEQ ID NO:39，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:57，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，LC-CDR3，其包含氨基酸序列SEQ ID NO:87，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:9，HC-CDR2，其包含氨基酸序列SEQ ID NO:26，和HC-CDR3，其包含氨基酸序列SEQ ID NO:39；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:57，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:87。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:114所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:142所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:114或其变体，所述变体与氨基酸序列SEQ ID NO:114具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:142或其变体，所述变体与氨基酸序列SEQ ID NO:142具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:114，以及VL，所述VL包含氨基酸序列SEQ ID NO:142。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:2，HC-CDR2，其包含氨基酸序列SEQ ID NO:27，HC-CDR3，其包含氨基酸序列SEQ ID NO:40，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:58，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，LC-CDR3，其包含氨基酸序列SEQ ID NO:88，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:2，HC-CDR2，其包含氨基酸序列SEQ ID NO:27，和HC-CDR3，其包含氨基酸序列SEQ ID NO:40；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:58，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:88。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:115所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:143所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:115或其变体，所述变体与氨基酸序列SEQ ID NO:115具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:143或其变体，所述变体与氨基酸序列SEQ ID NO:143具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:115，以及VL，所述VL包含氨基酸序列SEQ ID NO:143。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:10，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，HC-CDR3，其包含氨基酸序列SEQ ID NO:41，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:59，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，LC-CDR3，其包含氨基酸序列SEQ ID NO:89，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:10，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:41；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:59，LC-
CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:89。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:116所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:144所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:116或其变体，所述变体与氨基酸序列SEQ ID NO:116具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:144或其变体，所述变体与氨基酸序列SEQ ID NO:144具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:116，以及VL，所述VL包含氨基酸序列SEQ ID NO:144。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:6，HC-CDR2，其包含氨基酸序列SEQ ID NO:22，HC-CDR3，其包含氨基酸序列SEQ ID NO:37，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，LC-CDR3，其包含氨基酸序列SEQ ID NO:90，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:6，HC-CDR2，其包含氨基酸序列SEQ ID NO:22，和HC-CDR3，其包含氨基酸序列 SEQ ID NO:37；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:90。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:117所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:145所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:117或其变体，所述变体与氨基酸序列SEQ ID NO:117具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:145或其变体，所述变体与氨基酸序列SEQ ID NO:145具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:117，以及VL，所述VL包含氨基酸序列SEQ ID NO:145。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:11，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，HC-CDR3，其包含氨基酸序列SEQ ID NO:42，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:60，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，LC-CDR3，其包含氨基酸序列SEQ ID NO:91，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:11，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:42；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:60，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:91。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:118所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:146所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:118或其变体，所述变体与氨基酸序列SEQ ID NO:118具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:146或其变体，所述变体与氨基酸序列SEQ ID NO:146具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:118，以及VL，所述VL包含氨基酸序列SEQ ID NO:146。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:12，HC-CDR2，其包含氨基酸序列SEQ ID NO:29，HC-CDR3，其包含氨基酸序列SEQ ID NO:43，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:61，LC-CDR2，其包含氨基酸序列SEQ ID  NO:75，LC-CDR3，其包含氨基酸序列SEQ ID NO:92，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:12，HC-CDR2，其包含氨基酸序列SEQ ID NO:29，和HC-CDR3，其包含氨基酸序列SEQ ID NO:43；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:61，LC-CDR2，其包含氨基酸序列SEQ ID NO:75，和LC-CDR3，其包含氨基酸序列SEQ ID NO:92。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:119所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:147所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:119或其变体，所述变体与氨基酸序列SEQ ID NO:119具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:147或其变体，所述变体与氨基酸序列SEQ ID NO:147具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:119，以及VL，所述VL包含氨基酸序列SEQ ID NO:147。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:12，HC-CDR2，其包含氨基酸序列SEQ ID NO:29，HC-CDR3，其包含氨基酸序列SEQ ID NO:44，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:62，LC-CDR2，其包含氨基酸序列SEQ ID NO:75，LC-CDR3，其包含氨基酸序列SEQ ID NO:93，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:12，HC-CDR2，其包含氨基酸序列SEQ ID NO:29，和HC-CDR3，其包含氨基酸序列SEQ ID NO:44；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:62，LC-CDR2，其包含氨基酸序列SEQ ID NO:75，和LC-CDR3，其包含氨基酸序列SEQ ID NO:93。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:120所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:148所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:120或其变体，所述变体与氨基酸序列SEQ ID NO:120具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:148或其变体，所述变体与氨基酸序列SEQ ID NO:148具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:120，以及VL，所述VL包含氨基酸序列SEQ ID NO:148。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:13，HC-CDR2，其包含氨基酸序列SEQ ID NO:30，HC-CDR3，其包含氨基酸序列SEQ ID NO:45，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:63，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，LC-CDR3，其包含氨基酸序列SEQ ID NO:94，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:13，HC-CDR2，其包含氨基酸序列SEQ ID NO:30，和HC-CDR3，其包含氨基酸序列SEQ ID NO:45；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:63，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:94。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:121所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:149所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:121或其变体，所述变体与氨基酸序列SEQ ID NO:121具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:149或其变体，所述变体与氨基酸序列SEQ ID NO:149具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:121，以及VL，所述VL包含氨基酸序列SEQ ID NO:149。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:14，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，HC-CDR3，其包含氨基酸序列SEQ ID NO:46，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，LC-CDR3，其包含氨基酸序列SEQ ID NO:95，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:14，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:46；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:95。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:122所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:150所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:122或其变体，所述变体与氨基酸序列SEQ ID NO:122具有至少约80％(例如至少80％、85％、90％、 95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:150或其变体，所述变体与氨基酸序列SEQ ID NO:150具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:122，以及VL，所述VL包含氨基酸序列SEQ ID NO:150。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:15，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，HC-CDR3，其包含氨基酸序列SEQ ID NO:47，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:64，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，LC-CDR3，其包含氨基酸序列SEQ ID NO:96，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:15，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:47；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:64，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:96。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:123所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:151所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:123或其变体，所述变体与氨基酸序列SEQ ID NO:123具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:151或其变体，所述变体与氨基酸序列SEQ ID NO:151具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:123，以及VL，所述VL包含氨基酸序列SEQ ID NO:151。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:16，HC-CDR2，其包含氨基酸序列SEQ ID NO:31，HC-CDR3，其包含氨基酸序列SEQ ID NO:48，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:65，LC-CDR2，其包含氨基酸序列SEQ ID NO:76，LC-CDR3，其包含氨基酸序列SEQ ID NO:97，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:16，HC-CDR2，其包含氨基酸序列SEQ ID NO:31，和HC-CDR3，其包含氨基酸序列SEQ ID NO:48；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:65，LC-CDR2，其包含氨基酸序列SEQ ID NO:76，和LC-CDR3，其包含氨基酸序列SEQ ID NO:97。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:124所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:152所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:124或其变体，所述变体与氨基酸序列SEQ ID NO:124具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:152或其变体，所述变体与氨基酸序列SEQ ID NO:152具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:124，以及VL，所述VL包含氨基酸序列SEQ ID NO:152。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:17，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，HC-CDR3，其包含氨基酸序列SEQ ID NO:49，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:66，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，LC-CDR3，其包含氨基酸序列SEQ ID NO:98，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:17，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:49；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:66，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:98。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:125所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:153所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:125或其变体，所述变体与氨基酸序列SEQ ID NO:125具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:153或其变体，所述变体与氨基酸序列SEQ ID NO:153具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:125，以及VL，所述VL包含氨基酸序列SEQ ID NO:153。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:17，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，HC-CDR3，其包含氨基酸序列SEQ ID NO:50，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:60，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，LC-CDR3，其包含氨基酸序列SEQ ID NO:91，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。
在一些实施例中，所述抗FasL抗体包含VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:17，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:50；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:60，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:91。
在一些实施例中，所述抗FasL抗体包含VH，其包含如氨基酸序列SEQ ID NO:126所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；以及VL，其包含如氨基酸序列SEQ ID NO:154所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
在一些实施例中，所述抗FasL抗体包含：VH，所述VH包含氨基酸序列SEQ ID NO:126或其变体，所述变体与氨基酸序列SEQ ID NO:126具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及VL，所述VL包含氨基酸序列SEQ ID NO:154或其变体，所述变体与氨基酸序列SEQ ID NO:154具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述抗FasL抗体包含VH，所述VH包含氨基酸序列SEQ ID NO:126，以及VL，所述VL包含氨基酸序列SEQ ID NO:154。
在一些实施例中，上述氨基酸取代限于本文表4中所示的“示例性取代”。在一些实施例中，氨基酸取代限于本文表4中所示的“优选取代”。
在一些实施例中，功能性表位可通过组合丙氨酸扫描法来解析。在此过程中，组合丙氨酸扫描技术可用于鉴定FasL蛋白中与抗FasL抗体相互作用所必需的氨基酸。在一些实施例中，该表位是构象的，同时可以采用与FasL蛋白结合的抗FasL抗体的晶体结构来鉴定表位。
在一些实施例中，本申请提供与本文所述的任一种抗FasL抗体竞争性结合FasL的抗体。在一些实施例中，提供能够与本文所述的任一种抗FasL抗体竞争性地结合FasL上的表位的抗体。在一些实施例中，提供抗FasL抗体，其与包含VH和VL的抗FasL抗体分子结合相同的表位，其中所述VH包含SEQ ID NOs:99-126中任一所示的氨基酸序列，以及所述VL包含SEQ ID NOs:127-154中任一所示的氨基酸序列。在一些实施例中，提供抗FasL抗体，其与包含VH和VL的抗FasL抗体竞争性地结合FasL，其中所述VH包含SEQ ID NOs:99-126中任一所示的氨基酸序列，以及所述VL包含SEQ ID NOs:127-154中任一所示的氨基酸序列。
在一些实施例中，可以利用竞争实验来鉴定与本文所述的抗FasL抗体竞争性结合FasL的单克隆抗体。竞争实验可以通过识别相同的或空间上重叠的表位或者通过一个抗体竞争性抑制另一抗体与抗原结合来确定两个抗体是否结合相同的表位。在某些实施例中，这种竞争性抗体与本文所述的抗体结合相同的表位。一些示例性的竞争实验包括，但不限于如Harlow and Lane(1988)Antibodies:A Laboratory Manual ch.14(Cold Spring Harbor Laboratory，Cold Spring Harbor,N.Y.)中所提到的常规实验。用于解析抗体结合的表位的详细示例性方法如Morris(1996)"Epitope Mapping Protocols,"in Methods in Molecular Biology vol.66(Humana Press,Totowa,N.J.)中所述。在一些实施例中，如果每种抗体阻断另一种抗体结合的50％或更多，则称其结合相同的表位。在一些实施例中，与本文所述的抗FasL抗体竞争的抗体是嵌合抗体、人源化抗体或全人抗体。
示例性抗FasL抗体序列如表2、表3所示，其中根据Chothia定义方式进行CDR编号。本领域技术人员将认识到有多种已知算法(Chothia定义方式)来预测CDR的位置以及界定抗体轻、重链可变区。包含如本文所述抗体的CDRs、VH和/或VL序列，但基于预测算法而非下表中所示例的抗体也在本申请的范围内。
表2示例性抗FasL抗体CDR序列


表3示例性序列



全长抗FasL抗体
在一些实施例中，所述抗FasL抗体是全长抗FasL抗体。在一些实施例中，所述全长抗FasL抗体是IgA、IgD、IgE、IgG或IgM。在一些实施例中，所述全长抗FasL抗体包含IgG恒定区域，例如IgG1、IgG2、IgG3、IgG4或其变体的恒定区域。在一些实施例中，所述全长抗FasL抗体包 含λ轻链恒定区。在一些实施例中，所述全长抗FasL抗体包含κ轻链恒定区。在一些实施例中，所述全长抗FasL抗体是全长的人抗FasL抗体。在一些实施例中，所述全长抗FasL抗体包含小鼠免疫球蛋白Fc序列。在一些实施例中，所述全长抗FasL抗体包含已经改变的或以其他方式改变的Fc序列，使得其具有增强的抗体依赖的细胞介导的细胞毒作用(ADCC)和补体依赖的细胞毒作用(CDC)的效应功能。
因此，例如，在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，所述抗FasL抗体与FasL特异性结合。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG2恒定区的全长抗FasL抗体，所述抗FasL抗体与FasL特异性结合。在一些实施例中，所述IgG2是人IgG2。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG3恒定区的全长抗FasL抗体，所述抗FasL抗体与FasL特异性结合。在一些实施例中，所述IgG3是人IgG3。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，所述抗FasL抗体与FasL特异性结合。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含SEQ ID NOs:1-17中任一所示的氨基酸序列，HC-CDR2，其包含SEQ ID NOs:18-31中任一所示的氨基酸序列，和HC-CDR3，其包含SEQ ID NOs:32-50中任一所示的氨基酸序列，或者所述重链可变结构域的变体，其HC-CDR序列中包含至多约5个(例如1、2、3、4或5个)氨基酸的取代；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含SEQ ID NOs:51-66中任一所示的氨基酸序列，LC-CDR2，其包含SEQ ID NOs:67-76中任一所示的氨基酸序列，和LC-CDR3，其包含SEQ ID NOs: 77-98中任一所示的氨基酸序列，或者所述轻链可变结构域的变体，其LC-CDR序列中包含至多约5个(例如1、2、3、4或5个)氨基酸的取代。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含SEQ ID NOs:1-17中任一所示的氨基酸序列，HC-CDR2，其包含SEQ ID NOs:18-31中任一所示的氨基酸序列，和HC-CDR3，其包含SEQ ID NOs:32-50中任一所示的氨基酸序列，或者所述重链可变结构域的变体，其HC-CDR序列中包含至多约5个(例如1、2、3、4或5个)氨基酸的取代；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含SEQ ID NOs:51-66中任一所示的氨基酸序列，LC-CDR2，包含SEQ ID NOs:67-76中任一所示的氨基酸序列，和LC-CDR3，其包含SEQ ID NOs:77-98中任一所示的氨基酸序列，或者所述轻链可变结构域的变体，其LC-CDR序列中包含至多约5个(例如1、2、3、4或5个)氨基酸的取代。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含SEQ ID NOs:1-17中任一所示的氨基酸序列，HC-CDR2，其包含SEQ ID NOs:18-31中任一所示的氨基酸序列，和HC-CDR3，其包含SEQ ID NOs:32-50中任一所示的氨基酸序列；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含SEQ ID NOs:51-66中任一所示的氨基酸序列，LC-CDR2，其包含SEQ ID NOs:67-76中任一所示的氨基酸序列，和LC-CDR3，其包含SEQ ID NOs:77-98中任一所示的氨基酸序列。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含SEQ ID NOs:1-17中任一所示的氨基酸序列，HC-CDR2，其包含SEQ ID NOs:18-31中任一所示的氨基酸序列，和HC-CDR3，其包含SEQ ID NOs:32-50中任一所示的氨基酸序列；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含SEQ ID NOs:51-66中任一所示的氨基酸序列，LC-CDR2，其包含SEQ ID NOs:67-76中任一所示的氨基酸序列，和LC-CDR3，其包含SEQ ID NOs:77-98中任一所示的氨基酸序列。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:1，HC-CDR2，其包含氨基酸序列SEQ ID NO:18，和HC-CDR3，其包含氨基酸序列SEQ ID NO:32；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:67，和LC-CDR3，其包含氨基酸序列SEQ ID NO:77。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:2，HC-CDR2，其包含氨基酸序列SEQ ID NO:19，和HC-CDR3，其包含氨基酸序列SEQ ID NO:32；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:78。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:1，HC-CDR2，其包含氨基酸序列SEQ ID NO:18，和HC-CDR3，其包含氨基酸序列SEQ ID NO:32；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:67，和LC-CDR3，其包含氨基酸序列SEQ ID NO:79。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:3，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:33；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:52，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:80。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:3，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:34；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:52，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:81。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:4，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:35；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:53，LC-CDR2，其包含氨基酸序列SEQ ID NO:69，和LC-CDR3，其包含氨基酸序列SEQ ID NO:82。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:5，HC-CDR2，其包含氨基酸序列SEQ ID NO:21，和HC-CDR3，其包含氨基酸序列SEQ ID NO:36；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:54，LC-CDR2，其包含氨基酸序列SEQ ID NO:70，和LC-CDR3，其包含氨基酸序列SEQ ID NO:83。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:6，HC-CDR2，其包含氨基酸序列SEQ ID NO:22，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:84。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:23，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:8，HC-CDR2，其包含氨基酸序列SEQ ID NO:25，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:72，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:8，HC-CDR2，其包含氨基酸序列SEQ ID NO:25，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:56，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:86。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:9，HC-CDR2，其包含氨基酸序列SEQ ID NO:26，和HC-CDR3，其包含氨基酸序列SEQ ID NO:39；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:57，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:87。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:2，HC-CDR2，其包含氨基酸序列SEQ ID NO:27，和HC-CDR3，其包含氨基酸序列SEQ ID NO:40；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:58，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:88。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:10，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:41；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:59，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:89。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:6，HC-CDR2，其包含氨基酸序列SEQ ID NO:22，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:90。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:11，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:42；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:60，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:91。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:12，HC-CDR2，其包含氨基酸序列SEQ ID NO:29，和HC-CDR3，其包含氨基酸序列SEQ ID NO:43；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:61，LC-CDR2，其包含氨基酸序列SEQ ID NO:75，和LC-CDR3，其包含氨基酸序列SEQ ID NO:92。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:12，HC-CDR2，其包含氨基酸序列SEQ ID NO:29，和HC-CDR3，其包含氨基酸序列SEQ ID NO:44；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:62，LC-CDR2，其包含氨基酸序列SEQ ID NO:75，和LC-CDR3，其包含氨基酸序列SEQ ID NO:93。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:13，HC-CDR2，其包含氨基酸序列SEQ ID NO:30，和HC-CDR3，其包含氨基酸序列SEQ ID NO:45；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:63，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:94。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:14，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:46；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:95。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:15，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:47；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:64，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:96。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:16，HC-CDR2，其包含氨基酸序列SEQ ID NO:31，和HC-CDR3，其包含氨基酸序列SEQ ID NO:48；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:65，LC-CDR2，其包含氨基酸序列SEQ ID NO:76，和LC-CDR3，其包含氨基酸序列SEQ ID NO:97。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:17，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:49；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:66，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:98。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:17，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:50；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:60，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:91。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:1，HC-CDR2，其包含氨基酸序列SEQ ID NO:18，和HC-CDR3，其包含氨基酸序列SEQ ID NO:32；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:67，和LC-CDR3，其包含氨基酸序列SEQ ID NO:77。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:2，HC-CDR2，其包含氨基酸序列SEQ ID NO:19，和HC-CDR3，其包含氨基酸序列SEQ ID NO:32；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:78。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:1，HC-CDR2，其包含氨基酸序列SEQ ID NO:18，和HC-CDR3，其包含氨基酸序列SEQ ID NO:32；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:67，和LC-CDR3，其包含氨基酸序列SEQ ID NO:79。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:3，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:33；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:52，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:80。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:3，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:34；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:52，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:81。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:4，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:35；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:53，LC-CDR2，其包含氨基酸序列SEQ ID NO:69，和LC-CDR3，其包含氨基酸序列SEQ ID NO:82。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:5，HC-CDR2，其包含氨基酸序列SEQ ID NO:21，和HC-CDR3，其包含氨基酸序列SEQ ID NO:36；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:54，LC-CDR2，其包含氨基酸序列SEQ ID NO:70，和LC-CDR3，其包含氨基酸序列SEQ ID NO:83。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:6，HC-CDR2，其包含氨基酸序列SEQ ID NO:22，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:84。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:23，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:8，HC-CDR2，其包含氨基酸序列SEQ ID NO:25，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:72，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:8，HC-CDR2，其包含氨基酸序列SEQ ID NO:25，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:56，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:86。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:9，HC-CDR2，其包含氨基酸序列SEQ ID NO:26，和HC-CDR3，其包含氨基酸序列SEQ ID NO:39；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:57，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:87。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:2，HC-CDR2，其包含氨基酸序列SEQ ID NO:27，和HC-CDR3，其包含氨基酸序列SEQ ID NO:40；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:58，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:88。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:10，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:41；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:59，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:89。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:6，HC-CDR2，其包含氨基酸序列SEQ ID NO:22，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:90。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:11，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:42；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:60，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:91。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:12，HC-CDR2，其包含氨基酸序列SEQ ID NO:29，和HC-CDR3，其包含氨基酸序列SEQ ID NO:43；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:61，LC-CDR2，其包含氨基酸序列SEQ ID NO:75，和LC-CDR3，其包含氨基酸序列SEQ ID NO:92。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:12，HC-CDR2，其包含氨基酸序列SEQ ID NO:29，和HC-CDR3，其包含氨基酸序列SEQ ID NO:44；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:62，LC-CDR2，其包含氨基酸序列SEQ ID NO:75，和LC-CDR3，其包含氨基酸序列SEQ ID NO:93。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:13，HC-CDR2，其包含氨基酸序列SEQ ID NO:30，和HC-CDR3，其包含氨基酸序列SEQ ID NO:45；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:63，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:94。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:14，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:46；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:95。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:15，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:47；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:64，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:96。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:16，HC-CDR2，其包含氨基酸序列SEQ ID NO:31，和HC-CDR3，其包含氨基酸序列SEQ ID NO:48；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:65，LC-CDR2，其包含氨基酸序列SEQ ID NO:76，和LC-CDR3，其包含氨基酸序列SEQ ID NO:97。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:17，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:49；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:66，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:98。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中所述抗FasL抗体包含：a)重链可变结构域，所述重链可变结构域包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:17，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:50；以及b)轻链可变结构域，所述轻链可变结构域包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:60，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:91。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：重链可变结构域(VH)，所述VH包含SEQ ID NOs:99-126中任一所示的氨基酸序列或其变体，所述变体与SEQ ID NOs:99-126中任一所示的氨基酸序列具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及轻链可变结构域(VL)，所述VL包含SEQ ID NOs:127-154中任一所示的氨基酸序列或其变体，所述变体与SEQ ID NOs:127-154中任一所示的氨基酸序列具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG2恒定区的全长抗FasL抗体，其中抗FasL抗体包含：重链可变结构域(VH)，所述VH包含SEQ ID NOs:99-126中任一所示的氨基酸序列或其变体，所述变体与SEQ ID NOs:99-126中任一所示的氨基酸序列具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及轻链可变结构域(VL)，所述VL包含SEQ ID NOs:127-154中任一所示的氨基酸序列或其变体，所述变体与SEQ ID NOs:127-154中任一所示的氨基酸序列具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述IgG2是人IgG2。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG3恒定区的全长抗FasL抗体，其中抗FasL抗体包含：重链可变结构域(VH)，所述VH包含SEQ ID NOs:99-126中任一所示的氨基酸序列或其变体，所述变体与SEQ ID NOs:99-126中任一所示的氨基酸序列具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及轻链可变结构域(VL)，所述VL包含SEQ ID NOs:127-154中任一所示的氨基酸序列或其变体，所述变体与SEQ ID NOs:127-154中任一所示的氨基酸序列具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性。在一些实施例中，所述IgG3是人IgG3。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：重链可变结构域(VH)，所述VH包含SEQ ID NOs:99-126中任一所示的氨基酸序列或其变体，所述变体与SEQ ID NOs:99-126中任一所示的氨基酸序列具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列同一性；以及轻链可变结构域(VL)，所述VL包含SEQ ID NOs:127-154中任一所示的氨基酸序列或其变体，所述变体与SEQ ID NOs:127-154中任一所示的氨基酸序列具有至少约80％(例如至少80％、85％、90％、95％、96％、97％、98％或99％)序列 同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：重链可变结构域(VH)，所述(VH)包含SEQ ID NOs:99-126中任一所示的氨基酸序列，以及轻链可变结构域(VL)，所述(VL)包含SEQ ID NOs:127-154中任一所示的氨基酸序列。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：重链可变结构域(VH)，所述VH包含SEQ ID NOs:99-126中任一所示的氨基酸序列，以及轻链可变结构域(VL)，所述VL包含SEQ ID NOs:127-154中任一所示的氨基酸序列。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:99或其变体，所述变体与氨基酸序列SEQ ID NO:99具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:127或其变体，所述变体与氨基酸序列SEQ ID NO:127具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:100或其变体，所述变体与氨基酸序列SEQ ID NO:100具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:128或其变体，所述变体与氨基酸序列SEQ ID NO:128具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:101或其变体，所述变体与氨基酸序列SEQ ID NO:101具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:129或其变体，所述变体与氨基酸序列SEQ ID NO:129具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:102或其变体，所述变体与氨基酸序列SEQ ID NO:102具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:130或其变体，所述变体与氨基酸序列SEQ ID NO:130具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:103或其变体，所述变体与氨基酸序列SEQ ID NO:103具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:131或其变体，所述变体与氨基酸序列SEQ ID NO:131具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻 链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:104或其变体，所述变体与氨基酸序列SEQ ID NO:104具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:132或其变体，所述变体与氨基酸序列SEQ ID NO:132具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:105或其变体，所述变体与氨基酸序列SEQ ID NO:105具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:133或其变体，所述变体与氨基酸序列SEQ ID NO:133具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:106或其变体，所述变体与氨基酸序列SEQ ID NO:106具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:134或其变体，所述变体与氨基酸序列SEQ ID NO:134具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:107或其变体，所述变体与氨基酸序列SEQ ID NO:107具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:135或其变体，所述变体与氨基酸序列SEQ ID NO:135具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包 含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:108或其变体，所述变体与氨基酸序列SEQ ID NO:108具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:136或其变体，所述变体与氨基酸序列SEQ ID NO:136具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:109或其变体，所述变体与氨基酸序列SEQ ID NO:109具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:137或其变体，所述变体与氨基酸序列SEQ ID NO:137具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:110或其变体，所述变体与氨基酸序列SEQ ID NO:110具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:138或其变体，所述变体与氨基酸序列SEQ ID NO:138具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:111或其变体，所述变体与氨基酸序列SEQ ID NO:111具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:139或其变体，所述变体与氨基酸序列 SEQ ID NO:139具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:112或其变体，所述变体与氨基酸序列SEQ ID NO:112具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:140或其变体，所述变体与氨基酸序列SEQ ID NO:140具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:113或其变体，所述变体与氨基酸序列SEQ ID NO:113具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:141或其变体，所述变体与氨基酸序列SEQ ID NO:141具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:114或其变体，所述变体与氨基酸序列SEQ ID NO:114具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:142或其变体，所述变体与氨基酸序列SEQ ID NO:142具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:115或其变体，所述变体与氨基酸序列SEQ ID NO:115具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:143或其变体，所述变体与氨基酸序列SEQ ID NO:143具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:116或其变体，所述变体与氨基酸序列SEQ ID NO:116具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:144或其变体，所述变体与氨基酸序列SEQ ID NO:144具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:117或其变体，所述变体与氨基酸序列SEQ ID NO:117具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:145或其变体，所述变体与氨基酸序列SEQ ID NO:145具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:118或其变体，所述变体与氨基酸序列SEQ ID NO:118具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:146或其变体，所述变体与氨基酸序列SEQ ID NO:146具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻 链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:119或其变体，所述变体与氨基酸序列SEQ ID NO:119具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:147或其变体，所述变体与氨基酸序列SEQ ID NO:147具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:120或其变体，所述变体与氨基酸序列SEQ ID NO:120具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:148或其变体，所述变体与氨基酸序列SEQ ID NO:148具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:121或其变体，所述变体与氨基酸序列SEQ ID NO:121具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:149或其变体，所述变体与氨基酸序列SEQ ID NO:149具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:122或其变体，所述变体与氨基酸序列SEQ ID NO:122具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:150或其变体，所述变体与氨基酸序列SEQ ID NO:150具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包 含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:123或其变体，所述变体与氨基酸序列SEQ ID NO:123具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:151或其变体，所述变体与氨基酸序列SEQ ID NO:151具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:124或其变体，所述变体与氨基酸序列SEQ ID NO:124具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:152或其变体，所述变体与氨基酸序列SEQ ID NO:152具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:125或其变体，所述变体与氨基酸序列SEQ ID NO:125具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:153或其变体，所述变体与氨基酸序列SEQ ID NO:153具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG1恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:126或其变体，所述变体与氨基酸序列SEQ ID NO:126具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:154或其变体，所述变体与氨基酸序列 SEQ ID NO:154具有至少约80％序列同一性。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:99或其变体，所述变体与氨基酸序列SEQ ID NO:99具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:127或其变体，所述变体与氨基酸序列SEQ ID NO:127具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:100或其变体，所述变体与氨基酸序列SEQ ID NO:100具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:128或其变体，所述变体与氨基酸序列SEQ ID NO:128具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:101或其变体，所述变体与氨基酸序列SEQ ID NO:101具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:129或其变体，所述变体与氨基酸序列SEQ ID NO:129具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:102或其变体，所述变体与氨基酸序列SEQ ID NO:102具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:130或其变体，所述变体与氨基酸序列SEQ ID NO:130具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:103或其变体，所述变体与氨基酸序列SEQ ID NO:103具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:131或其变体，所述变体与氨基酸序列SEQ ID NO:131具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:104或其变体，所述变体与氨基酸序列SEQ ID NO:104具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:132或其变体，所述变体与氨基酸序列SEQ ID NO:132具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:105或其变体，所述变体与氨基酸序列SEQ ID NO:105具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:133或其变体，所述变体与氨基酸序列SEQ ID NO:133具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻 链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:106或其变体，所述变体与氨基酸序列SEQ ID NO:106具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:134或其变体，所述变体与氨基酸序列SEQ ID NO:134具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:107或其变体，所述变体与氨基酸序列SEQ ID NO:107具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:135或其变体，所述变体与氨基酸序列SEQ ID NO:135具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:108或其变体，所述变体与氨基酸序列SEQ ID NO:108具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:136或其变体，所述变体与氨基酸序列SEQ ID NO:136具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:109或其变体，所述变体与氨基酸序列SEQ ID NO:109具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:137或其变体，所述变体与氨基酸序列SEQ ID NO:137具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包 含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:110或其变体，所述变体与氨基酸序列SEQ ID NO:110具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:138或其变体，所述变体与氨基酸序列SEQ ID NO:138具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:111或其变体，所述变体与氨基酸序列SEQ ID NO:111具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:139或其变体，所述变体与氨基酸序列SEQ ID NO:139具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:112或其变体，所述变体与氨基酸序列SEQ ID NO:112具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:140或其变体，所述变体与氨基酸序列SEQ ID NO:140具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:113或其变体，所述变体与氨基酸序列SEQ ID NO:113具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:141或其变体，所述变体与氨基酸序列 SEQ ID NO:141具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:114或其变体，所述变体与氨基酸序列SEQ ID NO:114具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:142或其变体，所述变体与氨基酸序列SEQ ID NO:142具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:115或其变体，所述变体与氨基酸序列SEQ ID NO:115具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:143或其变体，所述变体与氨基酸序列SEQ ID NO:143具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:116或其变体，所述变体与氨基酸序列SEQ ID NO:116具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:144或其变体，所述变体与氨基酸序列SEQ ID NO:144具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:117或其变体，所述变体与氨基酸序列SEQ ID NO:117具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:145或其变体，所述变体与氨基酸序列SEQ ID NO:145具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:118或其变体，所述变体与氨基酸序列SEQ ID NO:118具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:146或其变体，所述变体与氨基酸序列SEQ ID NO:146具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:119或其变体，所述变体与氨基酸序列SEQ ID NO:119具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:147或其变体，所述变体与氨基酸序列SEQ ID NO:147具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:120或其变体，所述变体与氨基酸序列SEQ ID NO:120具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:148或其变体，所述变体与氨基酸序列SEQ ID NO:148具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻 链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:121或其变体，所述变体与氨基酸序列SEQ ID NO:121具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:149或其变体，所述变体与氨基酸序列SEQ ID NO:149具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:122或其变体，所述变体与氨基酸序列SEQ ID NO:122具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:150或其变体，所述变体与氨基酸序列SEQ ID NO:150具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:123或其变体，所述变体与氨基酸序列SEQ ID NO:123具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:151或其变体，所述变体与氨基酸序列SEQ ID NO:151具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:124或其变体，所述变体与氨基酸序列SEQ ID NO:124具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:152或其变体，所述变体与氨基酸序列SEQ ID NO:152具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包 含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:125或其变体，所述变体与氨基酸序列SEQ ID NO:125具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:153或其变体，所述变体与氨基酸序列SEQ ID NO:153具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，提供一种包含IgG4恒定区的全长抗FasL抗体，其中抗FasL抗体包含：VH，其包含氨基酸序列SEQ ID NO:126或其变体，所述变体与氨基酸序列SEQ ID NO:126具有至少约80％序列同一性；以及VL，其包含氨基酸序列SEQ ID NO:154或其变体，所述变体与氨基酸序列SEQ ID NO:154具有至少约80％序列同一性。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成以及轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
结合亲和力
结合亲和力采用Kd、Koff、Kon或Ka表示。如本文所用，术语Koff是指抗体从抗原/抗体复合物中解离的速率常数，通过动力学选择装置测定。术语Kon是指抗体与抗原结合形成抗原/抗体复合物的结合速率常数。本文所用的平衡解离常数Kd是指特定抗体抗原相互作用时的解离常数，是指在抗体分子溶液中，抗原占据所有抗体结合位点的一半并且达到平衡时所需的抗原浓度，等于Koff/Kon。Kd的测定假设所有的结合分子均在溶液中。抗体与细胞壁连接的情况，例如在酵母表达系统中，相应的平衡解离速率常数采用EC50来表示，其是Kd的一个良好的近似值。亲和结合常数Ka是解离常数Kd的倒数。
解离常数(Kd)可以作为反应抗体部分与抗原亲和力的指标。例如，可以通过Scatchard方法使用标记有各种标记物的抗体，和Biacore仪器(由Amersham Biosciences制造)进行简单分析，根据用户手册或附带试剂盒，通过表面等离子体共振来分析生物分子间的相互作用。使用这些方 法得到的Kd值，用单位M来表示。与靶标特异性结合的抗体可能具有，例如≤10-7M、≤10-8M、≤10-9M、≤10-10M、≤10-11M、≤10-12M或≤10-13M的Kd值。
抗体的结合特异性可以通过本领域已知的方法进行实验测定。这些方法包括，但不限于Western blots、ELISA-、RIA-、ECL-、IRMA-、EIA-、BIAcore测试和肽扫描等。
在一些实施例中，所述抗FasL抗体特异性结合FasL靶标，其Kd值为10-7M至10-13M(例如10-7M至10-13M、10-8M至10-13M、10-9M至10-13M或10-10M至10-12M)。因此，在一些实施例中，抗FasL抗体与FasL之间结合的Kd值为10-7M至10-13M、1×10-7M至5×10-13M、10- 7M至10-12M、10-7M至10-11M、10-7M至10-10M、10-7M至10-9M、10-8M至10-13M、1×10- 8M至5×10-13M、10-8M至10-12M、10-8M至10-11M、10-8M至10-10M、10-8M至10-9M、5×10- 9M至1×10-13M、5×10-9M至1×10-12M、5×10-9M至1×10-11M、5×10-9M至1×10-10M、10-9M至10-13M、10-9M至10-12M、10-9M至10-11M、10-9M至10-10M、5×10-10M至1×10-13M、5×10- 10M至1×10-12M、5×10-10M至1×10-11M、10-10M至10-13M、1×10-10M至5×10-13M、1×10-10M至1×10-12M、1×10-10M至5×10-12M、1×10-10M至1×10-11M、10-11M至10-13M、1×10-11M至5×10-13M、10-11M至10-12M、10-12M至10-13M。在一些实施例中，抗FasL抗体与FasL之间结合的Kd值为10-7M至10-13M。
在一些实施例中，抗FasL抗体与非靶标之间结合的Kd值高于抗FasL抗体与靶标的Kd值，并且本文中引用的一些实施例中，抗FasL抗体与靶标(例如，FasL)的结合亲和力高于抗FasL抗体与非靶标的结合亲和力。一些实施例中，非靶标是指非FasL的抗原。在一些实施例中，抗FasL抗体(针对FasL)与非FasL靶标结合的Kd值间至少相差10倍，例如10-100倍、100-1000倍、103-104倍、104-105倍、105-106倍、106-107倍、107-108倍、108-109倍、109-1010倍、1010-1011倍、1011-1012倍。
在一些实施例中，所述抗FasL抗体与非靶标结合的Kd值为10-1M至10-6M(例如10-1M至10-6M、10-1M至10-5M、10-2M至10-4M)。在一些实施例中，所述非靶标是指非FasL的抗原。因此，在一些实施例中，抗FasL抗体与非FasL靶标之间结合的Kd值为10-1M至10-6M、1×10-1M至5×10-6M、10-1M至10-5M、1×10-1M至5×10-5M、10-1M至10-4M、1×10-1M至5×10-4M、10-1M至10-3M、1×10-1M至5×10-3M、10-1M至10-2M、10-2M至10-6M、1×10-2M至5×10-6M、10-2M至10-5M、1×10-2M至5×10-5M、10-2M至10-4M、1×10-2M至5×10-4M、10-2M至10-3M、10-3M至10-6M、1×10-3M至5×10-6M、10-3M至10-5M、1×10-3M至5×10-5M、10-3M至10-4M、10-4M至10-6M、1×10-4M至5×10-6M、10-4M至10-5M、10-5M至10-6M。
在一些实施例中，当提及抗FasL抗体以高结合亲和力特异性地识别FasL靶标，并以低结合亲和力结合非靶标时，所述抗FasL抗体与FasL靶标结合的Kd值为10-7M至10-13M(例如10-7M至10-13M、10-8M至10-13M、10-9M至10-13M、10-10M至10-12M)，并且与非靶标结合的Kd值为10-1M至10-6M(例如10-1M至10-6M、10-1M至10-5M、10-2M至10-4M)。
在一些实施例中，当提及抗FasL抗体特异性地识别FasL时，将所述抗FasL抗体的结合亲和力与对照抗FasL抗体(例如119-4A or APG101or MAB126-100)的结合亲和力进行比较。在一些实施例中，对照抗FasL抗体与FasL之间结合的Kd值可以是本申请所述的抗FasL抗体与FasL之间结合的Kd值的至少2倍，例如2倍、3倍、4倍、5倍、6倍、7倍、8倍、9倍、10倍、10-100倍、100-1000倍、103-104倍。
核酸
编码抗FasL抗体的核酸分子也被考虑在内。在一些实施例中，提供一种(或一组)编码全长抗FasL抗体的核酸，包括本文所述的任一种全长抗FasL抗体。在一些实施例中，本文所述的抗FasL抗体的核酸(或一组核酸)还可以包括编码多肽标签的核酸序列(例如蛋白纯化标签，His标签、HA标签)。
同时本文还考虑了包含抗FasL抗体的分离的宿主细胞，编码抗FasL抗体多肽组分的分离的核酸，或者包含编码本文所述的抗FasL抗体多肽组分的核酸的载体。
本申请还包括这些核酸序列的变体。例如，变体包括至少在中等严格杂交条件下与编码本申请的抗FasL抗体的核酸序列杂交的核苷酸序列。
本申请同时还提供可将本申请中核酸序列插入到其中的载体。
简言之，将编码抗FasL抗体的天然或合成的核酸插入到合适的表达载体中，使得核酸可操作性的连接到5’和3’端调控元件，例如包括启动子(例如淋巴细胞特异性启动子)和3’非翻译区(UTR)，可表达抗FasL抗体(例如全长的抗FasL抗体)。所述载体可适用于在真核宿主细胞中复制和整合。典型的克隆与表达载体包含调控目标核酸序列的表达的转录和翻译终止子、起始序列和启动子。
本申请所述的核酸也可以通过使用标准的基因递送方案，用于核酸免疫和基因治疗。核酸递送方法是本领域已知的。例如参见U.S.Pat.Nos.5,399,346、5,580,859、5,589,466，通过引用其全部内容并入本文。在一些实施例中，本申请还提供基因治疗载体。
可以将核酸克隆到许多类型的载体中。例如，可以将核酸克隆到载体中，所述载体包括，但不限于，质粒、噬菌粒、噬菌体衍生物、动物病毒和柯斯质粒。特别感兴趣的载体包括表达载体、复制载体、探针生成载体和测序载体。
此外，表达载体可以以病毒载体的形式提供给细胞。病毒载体技术是本领域熟知的，并且描述于例如Green and Sambrook(2013,Molecular Cloning:A Laboratory Manual,Cold Spring Harbor Laboratory,New York)，以及其它病毒学或分子生物学手册中。可用作载体的病毒包括，但不限于，逆转录病毒、腺病毒、腺相关病毒、疱疹病毒和慢病毒。通常，合适的载体包括一个在至少一种生物体中起作用的复制起点、启动子序列、方便的限制性内切酶位点以及一个或多个选择标记物(参见例如，WO 01/96584；WO 01/29058；和U.S.Pat.No.6,326,193)。
已经开发了许多基于病毒的系统，用于将基因转移到哺乳动物细胞中。例如，逆转录病毒为基因递送系统提供了便利的平台。可以应用本领域已知的技术，将选择的基因插入载体中并包装 在逆转录病毒颗粒中。然后分离重组病毒，在体内或体外递送至受试者的细胞中。许多逆转录病毒系统在本领域中是已知的。在一些实施例中，使用腺病毒载体。许多腺病毒载体在本领域中是已知的。在一些实施例中，使用慢病毒载体。衍生自逆转录病毒的载体，例如慢病毒，是实现长期基因转移的合适工具，因为它们使得转基因长期稳定的整合以及在子代细胞中繁殖。慢病毒载体相对于衍生自肿瘤的逆转录病毒例如小鼠白血病病毒具有额外的优势，因为它们可以转导非分裂细胞，例如肝细胞。同时，其还具有低免疫原性的额外优势。
其它的启动子元件，例如，增强子，调控转录起始频率。通常它们位于起始位点上游30-110bp处，虽然最近发现很多启动子也包含起始位点下游的功能元件。启动子元件之间的间隔通常是灵活的，所以当元件彼此之间位置互换或移动时仍保持启动子的功能。在胸苷激酶(tk)启动子中，启动子元件之间的间隔增加到50bp活性才会开始下降。
合适启动子的一个示例是即时早期巨细胞病毒(CMV)启动子序列。该启动子序列是一个很强的组成型启动子序列，可以驱动任何与其可操作性连接的多核苷酸序列高水平表达。合适启动子的另一个示例是延伸因子1α(EF-1α)启动子。然而，也可以使用其它组成型启动子，包括但不限于猿猴病毒40(SV40)早期启动子、小鼠乳腺肿瘤病毒(MMTV)、人免病缺陷病毒长末端重复序列(HIV-LTR)启动子、MoMuLV启动子、禽类白血病病毒启动子、Epstein-Barr病毒即刻早期启动子、劳斯氏肉瘤病毒启动子以及人类基因启动子，例如包括但不限于肌动蛋白启动子、肌球蛋白启动子、血红蛋白启动子和肌酸激酶启动子。此外，不应将本申请局限在仅使用组成型启动子，诱导型启动子也是本申请考虑的部分。诱导型启动子的使用提供了一种分子开关，当需要这种表达时，能启动其与之可操作性连接的多核苷酸序列表达，当不需要时，则关闭表达。诱导型启动子包含，但不局限于，金属硫蛋白启动子、糖皮质激素启动子、孕酮启动子和四环素启动子。
在一些实施例中，抗FasL抗体的表达是可诱导的。在一些实施例中，编码抗FasL抗体的核酸序列可操作的连接到诱导型启动子上，包括本文所述的任一诱导型启动子。
诱导型启动子
诱导型启动子的使用提供了一种分子开关，当需要表达时，可启动与之可操作性连接的多核苷酸序列表达，而在不需要表达时，则关闭表达。真核细胞中适用的示例性诱导型启动子包括，但不限于，激素调节元件(例如，参见Mader,S.and White,J.H.(1993)Proc.Natl.Acad.Sci.USA 90:5603-5607)、合成配体调节元件(参见Spencer,D.M.et al(1993)Science 262:1019-1024)以及电离辐射调控元件(参见Manome,Y.et al.(1993)Biochemistry 32:10607-10613；Datta,R.et al.(1992)Proc.Natl.Acad.Sci.USA 89:1014-10153)。其它适用于体内或体外哺乳动物系统的示例性诱导型启动子参见Gingrich et al.(1998)Annual Rev.Neurosci 21:377-405。在一些实施例中，用于表达抗FasL抗体的诱导型启动子系统为Tet系统。在一些实施例中，用于表达抗FasL抗体的诱导型启动子系统为大肠杆菌lac抑制系统。
本申请所采用的一个示例性诱导型启动子系统为Tet系统。该系统是基于Gossen等(1993)描述的Tet系统。在一个示例性实施例中，目标多核苷酸由包含一个或多个Tet操纵子(TetO)位点的启动子控制。在非激活状态，Tet阻遏物(TetR)与TetO位点结合并抑制启动子的转录。在激活状态，例如，在存在诱导剂如四环素(Tc)、无水四环素、多西环素(Dox)或其活性类似物的情况下，诱导剂会使TetR从TetO上释放，从而导致转录发生。多西环素是四环素抗生素家族中的一员，其化学名为1-二甲氨基-2,4a,5,7-五羟基-11-甲基-4,6-二氧基-1,4a,11,11a,12,12a-六氢四烯-3-甲酰胺。
在一个实施例中，TetR经密码子优化适用于在哺乳动物细胞中表达，例如小鼠或人类细胞。由于遗传密码的简并性，大多数氨基酸由不止一个密码子编码，从而使得给定核酸的序列具有大量的变体，而其编码的氨基酸序列没有任何改变。然而，许多生物体在密码子使用方面存在差异，也称为“密码子偏好”(即，给定氨基酸使用特定密码子的偏好)。密码子偏好通常与特定密码子的优势tRNA种类的存在有关，反过来又提高了mRNA翻译的效率。因此可以通过密码子优化来定制源自特定物种的编码序列(例如，原核生物)，以提高其在不同物种(例如，真核生物)中的表达。
Tet系统的其它具体变体，包括以下的“Tet-Off”和“Tet-On”系统。在Tet-off系统中，转录在Tc或Dox存在下是失活的。在该系统中，由TetR与单纯疱疹病毒VP16强转录激活结构域融合组成的四环素调控的转录激活蛋白(tTA)，在四环素反应启动子元件(TRE)转录控制下调控靶核酸的表达。TRE元件由TetO序列串联与启动子(通常是来源于人巨细胞病毒即刻早期启动子的最小启动子序列)融合组成。在不存在Tc或Dox的情况下，tTA结合TRE并激活靶基因的转录。在存在Tc或Dox的情况下，tTA不能结合TRE，靶基因不能表达。
相反，在Tet-On系统中，转录在Tc或Dox存在下是激活的。Tet-On系统是基于反向四环素调控的转录激活因子rtTA。与tTA一样，rtTA是由TetR阻遏物与VP16转录激活结构域组成的融合蛋白。然而，TetR的DNA结合区中4个氨基酸的变化改变了rtTA的结合特性，使其在存在Dox的情况下只能识别靶转基因TRE上的tetO序列。所以在Tet-On系统中，只有在存在Dox的情况下，rtTA才能激活TRE调控的靶基因的转录。
另一种诱导型启动子系统是大肠杆菌的lac阻遏物系统(参见Brown et al.,Cell 49:603-612(1987))。Lac阻遏物系统通过调控与包含lac操纵子(lacO)的启动子可操作性连接的目标多核苷酸的转录发挥功能。Lac阻遏物(lacR)与LacO结合，进而阻止目标多核苷酸的转录。通过合适的诱导剂来诱导目标多核苷酸的表达，例如，异丙基-β-D硫代半乳糖吡喃苷(IPTG)。
为了评估多肽或其部分的表达，待导入细胞的表达载体还可包含选择标记基因或报告基因或二者都有，以便于从病毒载体转染或感染的细胞群体中识别和选择表达细胞。在其他方面，选择标记可以携带在单独的DNA片段上并在共转染实验中使用。选择标记基因或报告基因都可侧接于合适的调控序列，使其在宿主细胞中能够表达。有用的选择标记包括，例如，抗生素耐药基因，如neo以及类似基因。
报告基因可用于鉴定潜在的转染细胞和评价调控序列的功能。通常，报告基因是不存在于受体生物体或组织中或不由受体生物体或组织表达的基因，其编码一种多肽，其表达表现为一些易于检测的特性，例如酶活性。当DNA导入受体细胞后，在合适的时间检测报告基因的表达。合适的报告基因可包括编码荧光素酶、β-半乳糖苷酶、氯霉素乙酰转移酶、分泌碱性磷酸酶或绿色荧光蛋白的基因(参见,Ui-Tel et al.,2000FEBS Letters 479:79-82)。合适的表达系统是公知的，可以通过已知的技术制备或通过商业途径获得。通常，把可显示报告基因最高表达水平的最小5’侧翼区的构建体认定为启动子。此类启动子区可以与报告基因连接，并用于评估某些物质在调节启动子驱动的转录中能力。
在一些实施例中，提供编码本文所述的任一种全长抗FasL抗体的核酸。在一些实施例中，所述核酸包括编码全长抗FasL抗体重链和轻链的一个或多个核酸序列。在一些实施例中，所述一个或多个核酸序列中的每一个包含在单独的载体中。在一些实施例中，至少有一些核酸序列包含在同一载体中。在一些实施例中，所有核酸序列包含在同一载体中。载体可以选自，例如，哺乳动物表达载体和病毒载体(如源自逆转录病毒、腺病毒、腺相关病毒、疱疹病毒和慢病毒的载体)。
将基因导入细胞并表达的方法在本领域是已知的。在涉及表达载体的上下文中，通过本领域的任何方法载体可以很容易地导入宿主细胞中，如哺乳动物细胞、细菌、酵母或昆虫细胞。例如表达载体可以通过物理、化学或生物方法导入宿主细胞。
将多核苷酸导入宿主细胞的物理方法包括磷酸钙沉淀、脂质体转染、基因枪法、显微注射、电穿孔法以及诸如此类。制备包含载体和/或外源核酸的细胞的方法在本领域是熟知的。参见例如Green and Sambrook(2013,Molecular Cloning:A Laboratory Manual,Cold Spring Harbor Laboratory,New York)。在一些实施例中，通过磷酸钙转染法将多核苷酸导入宿主细胞。
将目标多核苷酸导入宿主细胞的生物学方法包括使用DNA和RNA载体。病毒载体，特别是逆转录病毒载体，已成为将基因插入哺乳动物细胞，例如人类细胞中的最广泛使用的方法。其它病毒载体可以源自慢病毒、痘病毒、单纯疱疹病毒1型、腺病毒和腺相关病毒等。参见如U.S.Pat.Nos.5,350,674和5,585,362。
将多核苷酸导入宿主细胞的化学方法包括胶体分散系统，例如高分子复合物、纳米胶囊、微球、磁珠和以脂质为基础的系统，其包括水包油乳剂、胶团、混合胶团和脂质体。一种在体内和体外被用作递送载体的示例性胶体系统是脂质体(例如，人工膜囊)。
在使用非病毒递送系统的情况下，示例性的递送载体是脂质体。考虑使用脂质制剂将核酸导入宿主细胞(体外、离体或体内)。在另一方面，所述核酸可以与脂质结合。与脂质结合的核酸可被包裹进脂质体的水性内部，散布在脂质体的脂质双层内，通过与脂质体和寡核苷酸结合的连接分子连接在脂质体，包埋在脂质体中，与脂质体形成复合物，分散在含有脂质的溶液中，与脂质混合，与脂质结合，悬浮在脂质中，包含在胶束中或与胶束混合，或以其它方式与脂质结合。脂质、脂质/DNA或脂质/表达载体相关的组合物在溶液中不限于任何特定结构。例如，它们可能以双分子层结构、以胶束或以“塌陷”结构存在。它们也可以简单的分散在溶液中，可能形成大小或形 状不均匀的聚集体。脂质是脂肪物质，可以是天然存在的或是合成的脂质。例如，脂质包括天然存在于细胞质中的脂肪滴，以及含有长链脂肪烃及其衍生物的一类化合物，例如脂肪酸、醇、胺、氨基醇和醛。
无论采用何种方法将外源核酸导入宿主细胞中或以其他方式将细胞暴露于本申请的抑制剂中，为了确认重组DNA序列存在于宿主细胞中，可以进行多种实验。这类实验包括例如本领域技术人员熟知的“分子生物学”实验。例如Southern和Northern blotting，RT-PCR和PCR；“生物化学”实验，例如检测某一特定多肽存在或不存在，例如通过免疫学方法(ELISAs和Western blots)或者通过本文所述的实验来进行鉴定均落入本申请范围内。
抗FasL抗体的制备
在一些实施例中，所述抗FasL抗体是单克隆抗体或源于单克隆抗体。在一些实施例中，所述抗FasL抗体包含来自单克隆抗体的VH和VL，或者其变体。在一些实施例中，所述抗FasL抗体进一步包括来自单克隆抗体的CH1和CL区域，或者其变体。单克隆抗体可以应用例如本领域已知的方法制备，包括杂交瘤细胞法、噬菌体展示方法或应用重组DNA法。此外，示例性的噬菌体展示法在本文及以下的实施例中进行了描述。
在杂交瘤细胞法中，通常采用免疫剂免疫仓鼠、小鼠或其他适合的宿主动物，以引发产生或能够产生与免疫剂特异性结合的抗体的淋巴细胞。或者，可以在体外免疫淋巴细胞。免疫剂可包括目标蛋白的多肽或融合蛋白。通常，如果需要人源细胞，采用外周血淋巴细胞(PBLs)，而如果需要非人哺乳动物来源细胞，则会使用脾细胞或淋巴结细胞。使用适当的融合剂将淋巴细胞与永生细胞系进行融合，例如聚乙二醇，以形成杂交瘤细胞。永生细胞系通常是转化的哺乳动物细胞，尤其是啮齿类、牛科和人源的骨髓瘤细胞。通常采用大鼠或小鼠骨髓瘤细胞系。杂交瘤细胞可以在合适的培养基中进行培养，所述培养基优选含有一种或多种抑制未融合永生细胞生长或存活的物质。例如，如果亲本细胞缺乏次黄嘌呤-鸟嘌呤磷酸核糖转移酶(HGPRT或HPRT)，则杂交瘤细胞培养基通常包括次黄嘌呤、氨蝶呤和胸苷(HAT培养基)，该培养基能阻止HGPRT缺陷细胞生长。
在一些实施例中，永生化细胞系有效融合，通过所选择的抗体生产细胞保证抗体高水平稳定表达，并且对某些培养基敏感，例如HAT培养基。在一些实施例中，永生细胞系是小鼠骨髓瘤细胞系，可以从例如，加利福尼亚圣地亚哥的索尔克细胞保藏中心和弗吉尼亚马纳萨斯的美国典型培养物保藏中心获得。同时还描述了人骨髓瘤和鼠-人杂交骨髓瘤细胞系用于制备人源单克隆抗体。
然后可以测定培养杂交瘤细胞的培养基中是否存在针对多肽的单克隆抗体。由杂交瘤细胞产生的单克隆抗体的结合特异性可以通过免疫沉淀法或体外结合实验确定，如放射性免疫测定法(RIA)或酶联免疫吸附法(ELISA)。此类技术或分析方法在本领域是已知的。单克隆抗体的结合亲和力可以通过例如Munson and Pollard,Anal.Biochem.,107:220(1980)中所述的斯卡查德(Scatchard)分析确定。
在鉴定出所需的杂交瘤细胞后，可以通过有限稀释法对目标克隆进行亚克隆，并通过标准方法进行培养。基于此目的适合的培养基包括，例如改良Eagle培养基(DMEM)和RPMI-1640培养基。或者，杂交瘤细胞可以在哺乳动物体内以腹水的形式生长。
亚克隆分泌的单克隆抗体可以通过常规免疫球蛋白纯化方法从培养基或腹水中分离或纯化，例如蛋白A-琼脂糖凝胶、羟基磷灰石色谱层析、凝胶电泳、透析或亲和层析。
在一些实施例中，根据本文所述的任一抗FasL抗体，所述抗FasL抗体包含选自抗体文库(例如展示scFv或Fab片段的噬菌体文库)的克隆的序列。所述克隆可以通过筛选具有所需活性的抗体片段组合文库的方法进行鉴定。例如，本领域已知多种方法用于产生噬菌体展示文库以及筛选这些文库来获得所需结合特性的抗体。这些方法在例如Hoogenboom et al.,Methods in Molecular Biology 178:1-37(O'Brien et al.,ed.,Human Press,Totowa,N.J.,2001)中进行了综述，并且在例如McCafferty et al.,Nature 348:552-554；Clackson et al.,Nature 352:624-628(1991)；Marks et al.,J.Mol.Biol.222:581-597(1992)；Marks and Bradbury,Methods in Molecular Biology 248:161-175(Lo,ed.,Human Press,Totowa,N.J.,2003)；Sidhu et al.,J.Mol.Biol.338(2):299-310(2004)；Lee et al.,J.Mol.Biol.340(5):1073-1093(2004)；Fellouse,Proc.Natl.Acad.Sci.USA 101(34):12467-12472(2004)；and Lee et al.,J.Immunol.Methods 284(1-2):119-132(2004)中进行了进一步描述。
在某些噬菌体展示方法中，通过聚合酶链式反应(PCR)分别克隆VH和VL基因的所有组成成分，并在噬菌体文库中随机重组，然后筛选能够结合抗原的噬菌体，如Winter et al.,Ann.Rev.Immunol.,12:433-455(1994)中所述。噬菌体通常以scFv片段或以Fab片段形式展示抗体片段。免疫来源的文库噬菌体提供针对免疫原的高亲和力抗体而不需要构建杂交瘤细胞。或者，可以克隆天然库(例如来自人)，来提供针对多种非自身抗原和自身抗原的单一抗体来源，而不需任何免疫，如Griffiths et al.,EMBO J,12:725-734(1993)中所述。最后，天然文库也可以通过克隆来自干细胞的非重排V-gene片段，并使用包含随机序列的PCR引物编码CDR3高变区并且在体外完成重排的方法进行制备，如Hoogenboom and Winter,J.Mol.Biol.,227:381-388(1992)中所述。描述人抗体噬菌体文库的专利出版物包括，例如U.S.Pat.No.5,750,373和US Patent Publication Nos.2005/0079574、2005/0119455、2005/0266000、2007/0117126、2007/0160598、2007/0237764、2007/0292936和2009/0002360。
通过噬菌体展示筛选文库中能够特异性结合靶标FasL的抗FasL抗体部分的方法来制备所述的抗FasL抗体。该文库可以是人scFv噬菌体展示文库，具有至少1×109(例如至少1×109、2.5×109、5×109、7.5×109、1×1010、2.5×1010、5×1010、7.5×1010或1×1011)种多样性的独特的人抗体片段。在一些实施例中，所述文库是人天然文库，通过从健康受试者的PMBCs和脾脏中提取的DNA构建，包含所有人重链和轻链亚家族。在一些实施例中，所述文库是人天然文库，通过从各种疾病患者体内分离的PMBCs中提取的DNA构建，例如自身免疫病的患者、癌症患者和感染性疾病的患者。在一些实施例中，所述文库是半合成的人文库，其中重链CDR3完全是随机的，所有氨基酸(除了半胱氨酸)以相同的概率存在于任何给定的位置。(参见例如,Hoet,R.M.et al., Nat.Biotechnol.23(3):344-348,2005)。在一些实施例中，半合成的人文库的重链CDR3长度在5到24个(例如5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23或24个)氨基酸之间。在一些实施例中，所述文库是全合成的噬菌体展示文库。在一些实施例中，所述文库是非人噬菌体展示文库。
与靶标FasL具有高亲和力的噬菌体克隆可以通过噬菌体与靶标FasL的迭代结合进行筛选，所述靶标FasL与固相支持物结合(例如用于溶液淘选的珠子或用于细胞淘选的哺乳动物细胞)，接下来去除未结合的噬菌体，并洗脱特异性结合噬菌体。随后，洗脱结合的噬菌体克隆并用于感染合适的宿主细胞，例如E.coli XL1-Blue，进行表达和纯化。可以通过多轮淘选(例如，2、3、4、5、6或更多轮)，例如溶液淘选、细胞淘选或两者结合以富集特异性结合FasL的噬菌体克隆。富集的噬菌体克隆与靶标FasL的特异性结合可以通过本领域已知的任何方法进行检测，包括例如ELISA和FACS。
筛选抗体文库的另一种方法是在酵母细胞表面展示蛋白质。Wittrup等(美国专利6,699,658和6,696,251)开发了一种酵母细胞展示文库的方法。在此酵母展示系统中，一个组分包括锚定在酵母细胞壁上的酵母凝集素蛋白(Aga1)，另一个组分包括凝集素蛋白Aga2的第二个亚基，该亚基可以通过二硫键与Aga1蛋白结合进而展示在酵母细胞表面上。通过将Aga1基因整合到酵母染色体中来表达Aga1蛋白。将单链可变片段(scFv)文库与酵母展示质粒中的Aga2基因融合，将其转化后，该文库由于附加的营养标记的存在可保留在酵母中。Aga1和Aga2蛋白均在半乳糖诱导型启动子的控制下表达。
人抗体V基因库(VH和VK片段)是使用一组简并引物通过PCR方法获得(Sblattero，D.and Bradbury,A.Immunotechnology 3,271-278 1998)。PCR模板来自可商购的RNA或cDNA，包括PBMC，脾脏，淋巴结，骨髓和扁桃体。将独立的VH和VK PCR文库合并后，通过重叠延伸PCR将其组装成scFv形式(Sheets，M.D.et al,Proc.Natl.Acad.Sci.USA 95,6157–6162 1998)。为了构建酵母scFv展示文库，通过同源重组将所得的scFv PCR产物克隆到酵母中的酵母展示质粒中。(Chao,G,et al,Nat Protoc.2006；1(2):755-68.Miller KD,et al.Current Protocols in Cytometry 4.7.1-4.7.30,2008)。
可以利用哺乳动物细胞展示系统来筛选抗FasL抗体，其中抗体部分展示在细胞表面上并通过抗原导向的筛选方法分离出特异性靶向FasL的抗体(如U.S.patent No.7,732,195B2中所述)。可以建立展示大量人类IgG抗体基因的中国仓鼠卵巢(CHO)细胞文库，并将其用于发现表达高亲和力抗体基因的克隆。已开发出另一种展示系统，该系统通过可变剪接使同一蛋白同时在细胞表面展示和分泌，其中展示的蛋白表型保持与基因型相关，使得可同时在生物物理和基于细胞功能的分析中表征该分泌的可溶性抗体。该方法克服了先前哺乳动物细胞展示的许多局限性，能够直接筛选和成熟化全长的、糖基化的IgGs形式的抗体(Peter M.Bowers,et al,Methods 2014,65：44-56)。瞬时表达系统适用于在抗体基因恢复之前进行的单轮抗原选择，因此对于从较小文库中选 择抗体最有用。稳定的外显体载体提供了一种有吸引力的选择。外显体载体可以高效转染并稳定地维持在低拷贝数，从而允许多轮淘选以及更复杂抗体库的解析。
IgG文库是基于分离自一群人类供体的种系序列V基因片段与重排的(D)J区域的连接构建而成。将从2000个人体血液样本中收集的RNA反转录为cDNA，使用VH和VK特异性引物扩增VH和VK片段，并通过凝胶提取纯化。将VH和VK片段分别亚克隆到包含IgG1或K恒定区的展示载体中，然后电穿孔或转导293T到细胞，从而制备IgG文库。为了制备scFv抗体展示文库，连接VH和VK以产生scFv，然后亚克隆到展示载体中，再将其电穿孔或转导293T细胞。众所周知，IgG文库是基于分离自一群供体的种系序列V基因片段与重排的(D)J区域构建而成，供体可以是小鼠，大鼠，兔或猴。
单克隆抗体也可以通过重组DNA方法进行制备，例如U.S.Patent No.4,816,567中所述。编码本申请中所述单克隆抗体的DNA可以通过常规方法(例如通过能特异性结合编码鼠源抗体轻链和重链基因的寡聚核苷酸探针)轻易的分离和测序。如上所述的杂交瘤细胞或本申请的FasL特异性噬菌体克隆可以作为这种DNA的来源。分离后，可将DNA置于表达载体中，然后该载体转染入宿主细胞，例如猿猴COS细胞、中华仓鼠卵巢癌(CHO)细胞或不产生免疫球蛋白的骨髓瘤细胞中，获得在重组宿主细胞中合成的单克隆抗体。所述DNA也可以被修饰，例如用编码序列取代人重链和轻链恒定区和/或用框架区替换同源非人序列(U.S.Patent No.4,816,567；Morrison et al.,supra)，或通过共价键连接免疫球蛋白的编码序列的全部或部分非免疫球蛋白多肽的编码序列。这种非免疫球蛋白多肽可以取代本申请中抗体的恒定区，或可以取代本申请中抗体可变结构域中的一个抗原结合位点，形成嵌合的二价抗体。
所述抗体可以是单价抗体。制备单价抗体的方法是本领域已知的。例如，一种涉及免疫球蛋白轻链和修饰重链的重组表达方法。通常在Fc区的任意位置截短重链，以阻止重链相互交联。或者，相关的半胱氨酸残基被其它氨基酸残基取代或被缺失以防止交联。
体外方法也适用于制备单价抗体。消化抗体产生抗体片段，特别是Fab片段，可以使用任何本领域已知的方法完成。
具有所需结合特异性(抗体-抗原结合位点)的抗体可变结构域可以与免疫球蛋白恒定区融合。优选与免疫球蛋白重链恒定区进行融合，其包括至少部分铰链，CH2和CH3区。在一些实施例中，包含轻链结合必要位点的第一重链恒定区(CH1)至少出现在一种融合体中。编码免疫球蛋白重链融合体的DNA，如果需要，还可以包括编码免疫球蛋白轻链的DNA，被插入进独立的表达载体中，并共转染至合适的宿主生物中。
全人和人源化抗体
所述抗FasL抗体(如全长的抗FasL抗体)可以是全人抗体或人源化抗体。非人(如小鼠)抗体部分的人源化形式是嵌合的免疫球蛋白、免疫球蛋白链或其片段(例如Fv、Fab、Fab’、F(ab’)2、scFv或抗体的其他抗原结合子序列)，其通常包括最少的源于非人免疫球蛋白的序列。人源化抗体包括人免疫球蛋白、免疫球蛋白链或其片段(受体抗体)，其中受体CDR的残基被具有所需特 异性、亲和力和性能的非人源(供体抗体)CDR残基取代，例如小鼠、大鼠或兔子的CDR。在一些实施例中，人免疫球蛋白Fv框架区残基被相应的非人源残基取代。人源化抗体还可以包含既不属于受体抗体也不在引入的CDR或框架区序列中的氨基酸残基。通常，人源化抗体包含至少一个，通常两个可变结构域，其中全部或基本上全部CDR区对应于非人免疫球蛋白的CDR区，全部或基本上全部框架区是人免疫球蛋白共有序列。
通常，人源化抗体含有一个或多个从非人源引入的氨基酸残基。那些非人源氨基酸残基通常被称为“移入”残基，通常来自“移入”可变结构域。根据一些实施例，人源化基本上可以按照Winter和其同事的如下方法进行(Jones et al.,Nature,321:522-525(1986)；Riechmann et al.,Nature,332:323-327(1988)；Verhoeyen et al.,Science,239:1534-1536(1988))，通过用啮齿动物CDRs或CDR序列取代人源抗体的相应序列。因此，这种“人源化”抗体部分(U.S.Patent No.4,816,567)，其基本上少于完整的人源抗体，其可变结构域已被来自非人源的相应序列所取代。在实际中，人源化抗体部分是典型的人源抗体部分，其中一些CDR残基和可能的一些框架区残基被来自啮齿类抗体中类似位点的残基所取代。
全人抗体是人源化的一种替代方式。例如，目前可以制备在免疫后能够产生完整的全人抗体文库而不产生内源性免疫球蛋白的转基因动物(例如，小鼠)。例如，已有报道，嵌合和种系突变小鼠中抗体重链连接区(JH)基因的纯合子缺失，完全抑制了内源性抗体的产生。将人种系免疫球蛋白基因阵列转移到这种种系突变小鼠体内，可在抗原刺激下产生人源抗体，参见，例如akobovits et al.,PNAS USA,90:2551(1993)；Jakobovits et al.,Nature,362:255-258(1993)；Bruggemann et al.,Year in Immunol.,7:33(1993)；U.S.Patent Nos.5,545,806,5,569,825,5,591,669,5,545,807；和WO 97/17852。或者，可以通过将人类免疫球蛋白基因座引入转基因动物中(例如内源性免疫球蛋白基因已经被部分或全部沉默的小鼠)来制备全人抗体。抗原刺激后，可以发现全人抗体的产生在各个方面都与其在人类中的产生非常相似，包括基因重排、组装和抗体文库。这种方法在例如U.S.Patent Nos.5,545,807；5,545,806；5,569,825；5,625,126；5,633,425；and 5,661,016,and Marks et al.,Bio/Technology,10:779-783(1992)；Lonberg et al.,Nature,368:856-859(1994)；Morrison,Nature,368:812-813(1994)；Fishwild et al.,Nature Biotechnology,14:845-851(1996)；Neuberger,Nature Biotechnology,14:826(1996)；Lonberg and Huszar,Intern.Rev.Immunol.,13:65-93(1995)中进行了描述。
全人抗体也以通过体外活化B细胞(见U.S.Patents 5,567,610and 5,229,275)或通过使用本领域已知的各种技术来产生，包括噬菌体展示文库。Hoogenboom and Winter,J.Mol.Biol.,227:381(1991)；Marks et al.,J.Mol.Biol.,222:581(1991).Cole et al.和Boerner et al.等人的技术也可以用于制备全人单克隆抗体。见Cole et al.,Monoclonal Antibodies and Cancer Therapy,Alan R.Liss,p.77(1985)and Boerner et al.,J.Immunol.,147(1):86-95(1991)。
抗FasL抗体变体
在一些实施例中，本文提供的抗FasL抗体变体(例如，全长的抗FasL抗体)的氨基酸序列也在考虑中。例如，可能需要改善抗体的结合亲和力和/或其它生物学活性。抗体变体的氨基酸序列可以通过在编码抗体的核苷酸序列中引入适当的修饰或通过肽合成来制备。此类修饰包括例如，抗体氨基酸序列中残基的缺失和/或插入和/或取代。可以通过氨基酸残基缺失、插入和取代的任一组合来完成最终的构建，使其具有所需的特征。例如，抗原结合性。
在一些实施例中，提供具有一个或多个氨基酸取代的抗FasL抗体变体。取代突变的目标位点包括高变区(HVRs)和框架区(FRs)。可以在目标抗体中引入氨基酸取代，筛选所需活性的产物，例如，改善的生物活性，保持/改善抗原结合能力，降低的免疫原性，或改善的ADCC或CDC。
保守取代如下表4所示。
表4保守取代
根据侧链性质将氨基酸分为不同类别：
a、疏水氨基酸：去甲亮氨酸Norleucine、蛋氨酸Met、丙氨酸Ala、缬氨酸Val、亮氨酸Leu、异亮氨酸Ile；
b、中性亲水性氨基酸：半胱氨酸Cys、丝氨酸Ser、苏氨酸Thr、天冬酰胺Asn、谷氨酰胺Gln；
c、酸性氨基酸：天冬氨酸Asp、谷氨酸Glu；
d、碱性氨基酸：组氨酸His、赖氨酸Lys、精氨酸Arg；
e、含有影响链方向的氨基酸：甘氨酸Gly、脯氨酸Pro；
f、芳香族氨基酸：色氨酸Trp、酪氨酸Tyr、苯丙氨酸Phe。
非保守氨基酸的取代包含将以上一种类别取代为另一种类别。
一种示例性的取代变体是亲和力成熟的抗体，可采用例如以噬菌体展示为基础的亲和力成熟技术而方便地产生。简言之，将一个或多个CDR残基进行突变，变体抗体部分展示在噬菌体上，并筛选具有特定生物活性(例如，抑制细胞凋亡的活性或抗体亲和力提高)的变体。可以在HVRs区进行改变(例如，取代)来获得改善的抗体亲和力或生物学活性。可以在HVR的“热点区”产生改变，即在体细胞成熟过程中发生高频突变的密码子编码的残基(参见，例如Chowdhury,Methods Mol.Biol.207:179-196(2008))，和/或在特异的决定性残基(SDRs)，检测所得变体VH和VL的结合亲和力。从二级文库中构建和重新选择亲和力成熟的方法已经在一些文献中进行描述，例如，Hoogenboom et al.in Methods in Molecular Biology 178:1-37(O'Brien et al.,ed.,Human Press,Totowa,NJ,(2001))。
在一些亲和力成熟的实施例中，通过多种方法中的任一种(例如易错PCR，链改组或寡核苷酸定向突变)，将多样性引入选择的用于亲和力成熟的可变基因中。然后创建二级文库。对该文库进行筛选，鉴定出具有所需亲和力的抗体变体。另一种引入多样性的方法包括HVR介导的方式，其中几个HVR残基(例如，一次4-6个残基)被随机化。涉及抗原结合的HVR残基被特异性地识别，例如，采用丙氨酸扫描诱变或建模。通常CDR-H3和CDR-L3区域尤其是重点靶标。
在一些实施例中，取代、插入或缺失可能发生在一个或多个HVRs内，只要这种改变基本上不降低抗体结合抗原的能力。例如，可以在HVRs中产生基本上不降低结合亲和力的保守性改变(例如，本文中提供的保守性取代)。这些改变可能发生在HVR“热点区”或SDRs区域之外。在一些实施例中上文提供的变体VH和VL序列，每一个HVR或者是未发生改变，或者包含不超过1个、2个或3个氨基酸取代。
一种有用的可以鉴定出抗体中能被靶向性突变的氨基酸残基或区域的方法称为“丙氨酸扫描突变”，如Cunningham and Wells(1989)Science,244:1081-1085中所述。在该方法中，一个或一组目标残基(例如，带电残基如精氨酸、天冬氨酸、组氨酸、赖氨酸和谷氨酸)被中性或带负电荷氨基酸(例如，丙氨酸或谷氨酸)取代，以此来确定抗体与抗原相互作用是否受到影响。可以在氨基酸的位置进一步引入取代，来证明该位置对初始取代具有功能敏感性。或者/另外，通过抗原-抗体复合物的晶体结构来鉴定抗体和抗原之间的接触位点。这些接触位点残基和邻近残基可作为取代候选物而被靶向或消除。筛选变体，确定它们是否具有所需要的性质。
氨基酸序列的插入，包括在氨基端和/或羧基末端的融合，长度范围从1个残基到包含100个或更多个残基的多肽，还包括在序列内插入1个或多个氨基酸残基。末端插入的例子包括N末端具有甲硫氨酰残基的抗体。抗体分子的其它插入变体，包括在抗体分子N-末端或C-末端融合一个酶(例如，ADEPT)或增加抗体血清半衰期的多肽。
Fc区变体
在一些实施例中，将一个或多个氨基酸修饰引入本文所述的抗体(例如，全长抗FasL抗体或抗FasL抗体融合蛋白)的Fc区，从而产生Fc区变体。在一些实施例中，Fc区变体具有增强的 ADCC效能，通常与结合Fc的受体(FcRs)有关。在一些实施例中，Fc区变体具有降低的ADCC效能。有很多关于Fc序列的改变或突变影响其效能的例子，例如，WO 00/42072和Shields et al.J Biol.Chem.9(2):6591-6604(2001)描述了与FcRs的结合增强或减弱的抗体变体。这些出版物的内容通过引用并入本文。
抗体依赖的细胞介导的细胞毒作用(ADCC)是治疗性抗体针对肿瘤细胞的作用机制。ADCC是细胞介导的免疫防御，当靶细胞膜表面的抗原被特异性抗体(例如，抗FasL抗体)结合，免疫系统的效应细胞主动裂解靶细胞(例如，癌细胞)。通常ADCC效应涉及由抗体激活的NK细胞。NK细胞表达Fc受体CD16。该受体识别并结合与靶细胞表面相结合的抗体分子的Fc部分。NK细胞表面最常见的Fc受体为CD16或FcγRIII。Fc受体与抗体Fc区的结合导致NK细胞的活化，释放细胞裂解颗粒，随后靶细胞凋亡。ADCC对肿瘤细胞的杀伤作用可以通过转染高亲和力FcR的NK-92细胞的特异性实验来测定。其结果与不表达FcR的野生型NK-92进行比较。
在一些实施例中，本申请还提供抗FasL抗体变体(例如全长抗FasL抗体变体)，其包含具有部分但不是全部的效应功能Fc区，使得其在体内具有延长的半衰期，然而特定的效应功能(例如CDC或ADCC)是非必需的或有害的，这种抗FasL抗体成为本申请理想的候选。通过在体外和/或体内进行细胞毒性检测来确认CDC和/或ADCC活性的减少/消除。例如，通过Fc受体(FcR)结合试验来确认抗体缺乏FcγR结合能力(因此可能缺乏ADCC活性)但依然保留FcRn的结合能力。介导ADCC的主要细胞中，NK细胞仅表达FcγRIII，而单核细胞表达FcγRI、FcγRII和FcγRIII。Ravetch and Kinet Annu.Rev.Immunol.9:457-492(1991)第464页的表3中总结了FcR在造血细胞上的表达。在体外评估目标分子的ADCC活性的非限制性实例在U.S.Pat.No.5,500,362中进行了描述(参见例如Hellstrom,I.et al.Proc.Nat'l Acad.Sci.USA 83:7059-7063(1986)and Hellstrom,I et al.,Proc.Nat'l Acad.Sci.USA 82:1499-1502(1985)；U.S.Pat.No.5,821,337(see Bruggemann,M.et al.,J.Exp.Med.166:1351-1361(1987))。或者，可以采用非放射性检测方法(参见，例如ACTITM流式细胞术非放射性细胞毒性检测(CellTechnology,Inc.Mountain View,Calif.)和CYTOTOX 96TM非放射性细胞毒性检测(Promega,Madison,Wis.))。此类检测实验采用的效应细胞包括外周血单核细胞(PBMC)和自然杀伤细胞(NK)。或者，另外地，目标分子的ADCC活性在体内进行检测，例如，在动物模型中，如Clynes et al.Proc.Nat'l Acad.Sci.USA 95:652-656(1998)中所述。同时还可以进行C1q结合试验来确认抗体不能与C1q结合，从而缺乏CDC活性。参见，例如WO 2006/029879和WO 2005/100402中C1q和C3c结合ELISA。为了评估补体激活情况，可进行CDC检测(参见，例如Gazzano-Santoro et al.,J.Immunol.Methods 202:163(1996)；Cragg,M.S.et al.,Blood 101:1045-1052(2003)；和Cragg,M.S.and M.J.Glennie,Blood 103:2738-2743(2004))。使用本领域已知的方法来测定FcRn结合和体内清除/半衰期(参见，例如，Petkova,S.B.et al.,Int'l.Immunol.18(12):1759-1769(2006))。
具有降低的效应功能的抗体，包括在Fc区残基238、265、269、270、297、327和329位进行一个或多个残基的取代(U.S.Pat.No.6,737,056)。这些Fc变体包括在265、269、270、297和 327位进行两个或多个残基的取代的Fc变体，包括被称为“DANA”的Fc变体，其在265和297位残基取代为丙氨酸(U.S.Pat.No.7,332,581)。
这类与FcRs结合能力提高或降低的抗体变体已有描述(参见例如U.S.Pat.No.6,737,056；WO2004/056312，和Shields et al.,J.Biol.Chem.9(2):6591-6604(2001))。
在一些实施例中，提供一种抗FasL抗体(例如全长的抗FasL抗体)变体，其包含具有一个或多个能够增强ADCC效应的氨基酸取代的Fc区变体。在一些实施例中，Fc区变体包含一个或多个能够增强ADCC效应的氨基取代，这些取代的位置在Fc区的298、333和/或334位(EU残基编号)。在一些实施例中，所述抗FasL抗体(例如，全长的抗FasL抗体)变体包括在Fc区的S298A，E333A和K334A位氨基酸取代。
在一些实施例中，Fc区的改变导致C1q结合和/或补体依赖性细胞毒作用(CDC)的改变(即增强或减弱)，参见U.S.Pat.No.6,194,551,WO 99/51642，和Idusogie et al.,J.Immunol.164:4178-4184(2000)中所述。
在一些实施例中，提供一种抗FasL抗体(例如全长的抗FasL抗体)变体，其包含具有一个或多个氨基酸取代的Fc区变体，能够延长半衰期或增强与Fc受体(FcRn)的结合。具有延长半衰期和改善FcRn结合的抗体在US 2005/0014934A1(Hinton等)中有所描述。这些抗体Fc区包含一个或多个氨基酸取代，增强了Fc区与FcRn的结合。这些Fc变体在Fc区包含238、256、265、272、286、303、305、307、311、312、317、340、356、360、362、376、378、380、382、413、424或434位的残基中的一个或多个取代，例如Fc区434位残基的取代(U.S.Pat.No.7,371,826)。
同时参见Duncan&Winter,Nature 322:738-40(1988)；U.S.Pat.No.5,648,260；U.S.Pat.No.5,624,821和WO 94/29351中提供其它Fc区变体的例子。
本申请考虑了包括本文所述的任一种Fc变体或其组合的抗FasL抗体(例如全长抗FasL抗体)。
糖基化变体
在一些实施例中，对本文所提供的抗FasL抗体(例如全长抗FasL抗体)进行改变，以增加或降低抗NGF抗体糖基化的程度。通过改变抗NGF抗体或其多肽部分的氨基酸序列以此来增加或去除一个或多个糖基化位点，可以方便地实现添加或删除抗FasL抗体上的糖基化位点。
其中抗FasL抗体包含Fc区，可以改变与其连接的糖。由哺乳动物细胞产生的天然抗体通常包含分支的双触角寡糖，该寡糖通常通过N-连接与Fc区CH2结构域Asn297连接，参见例如Wright et al.，TIBTECH 15:26-32(1997)。所述寡糖可包含多种糖类，例如甘露糖、N-乙酰氨基葡萄糖苷(GlcNAc)、半乳糖和唾液酸，以及与双触角寡糖结构“茎”部的GlcNAc相连接的海藻糖。在一些实施例中，可对本申请的抗FasL抗体进行寡糖修饰，从而产生具有某些改进特性的抗FasL抗体变体。
与Fc区的CH2结构域连接的N-聚糖是异质的。CHO细胞中产生的抗体或Fc融合蛋白通过岩藻糖基转移酶活性被岩藻糖基化，参见Shoji-Hosaka et al.,J.Biochem.2006,140:777-83。通常，可 以在人血清中检测出一小部分天然存在的非岩藻糖基化IgGs。Fc区的N-糖基化对于其与FcγR结合很重要；而非岩藻糖基化的N-聚糖增强了Fc与FcγRIIIa的结合能力。与FcRIIIa结合能力增强使得ADCC效应增强，这在需要细胞毒性的某些抗体治疗应用中是有利的。
在一些实施例中，当不需要Fc介导的细胞毒作用时，增强的效应功能可能是有害的。在一些实施例中，Fc片段或CH2结构域是非糖基化的。在一些实施例中，通过对CH2结构域中的N-糖基化位点进行突变以阻止其糖基化。
在一些实施例中，提供抗FasL抗体(例如全长的抗FasL抗体)变体，其包含Fc区，其中连接于Fc区的糖类结构具有减少的岩藻糖或缺乏岩藻糖，这可能会增强ADCC功能。具体地，本文提供抗FasL抗体，其相对于野生型CHO细胞产生的相同抗FasL抗体具有减少的岩藻糖。也就是说，它们的特征在于，与天然CHO细胞(例如，产生天然糖基化形式的CHO细胞，含有天然FUT8基因的CHO细胞)产生的抗体相比，具有更少量的岩藻糖。在一些实施例中，所述抗FasL抗体的N-连接聚糖具有少于50％、40％、30％、20％、10％或5％的岩藻糖。例如，该抗FasL抗体的岩藻糖含量可能是1％-80％、1％-65％、5％-65％或20％-40％。在一些实施例中，所述抗FasL抗体的N-连接聚糖不包含岩藻糖，即，其中抗FasL抗体完全不含岩藻糖，或没有岩藻糖或是去岩藻糖基化。岩藻糖的含量是通过计算连接到Asn297上的糖链内岩藻糖平均含量相对于通过MALDI-TOF质谱测量的所有连接在Asn297上的糖结构(如复合、杂交或甘露糖结构)的总量来确定的，如WO 2008/077546所述。Asn297是指位于Fc区297位的天冬酰胺残基(EU Fc区残基编号体系)。然而，由于抗体的微小序列变化，Asn297也可位于297位的上游或下游±3个氨基酸，即在294和300位之间。这些岩藻糖基化变体可能具有增强的ADCC功能。参见例如US Patent Publication Nos.US 2003/0157108(Presta,L.)，US 2004/0093621(Kyowa Hakko Kogyo Co.,Ltd)。与“去岩藻糖基化”或“岩藻糖缺乏”的抗体变体相关的出版物的实例包括，US 2003/0157108；WO 2000/61739；WO 2001/29246；US 2003/0115614；US 2002/0164328；US 2004/0093621；US 2004/0132140；US 2004/0110704；US 2004/0110282；US 2004/0109865；WO 2003/085119；WO 2003/084570；WO 2005/035586；WO 2005/035778；WO 2005/053742；WO 2002/031140；Okazaki et al.J.Mol.Biol.336:1239-1249(2004)；Yamane-Ohnuki et al.Biotech.Bioeng.87:614(2004)。能够产生去岩藻糖基化抗体的细胞系包括缺乏蛋白岩藻糖基化功能的Lec13CHO细胞(Ripka et al.Arch.Biochem.Biophys.249:533-545(1986)；US Pat Appl No US 2003/0157108A1,Presta,L；和WO 2004/056312A1,Adams et al.,尤其是实施例11)，和基因敲除细胞系，例如α-1,6-岩藻糖基转移酶基因，FUT8基因敲除的CHO细胞(参见Yamane-Ohnuki et al.Biotech.Bioeng.87:614(2004)；Kanda,Y.et al.,Biotechnol.Bioeng.,94(4):680-688(2006)；和WO2003/085107)。
抗FasL抗体(例如全长抗FasL抗体)变体进一步提供二等分寡糖，例如，其中连接于抗FasL抗体Fc区的双触角寡糖被GlcNAc等分。这种抗FasL抗体(例如全长的抗FasL抗体)变体可能具有减少的岩藻糖基化和/或增强的ADCC功能。这类抗体变体的实例在WO 2003/011878(Jean-Mairet et al.)；U.S.Pat.No.6,602,684(Umana et al.)；US 2005/0123546(Umana et al.)， 和Ferrara et al.,Biotechnology and Bioengineering,93(5):851-861(2006)中有所描述。还提供抗FasL抗体(例如全长的抗FasL抗体)变体，其在与Fc区连接的寡糖中具有至少一个半乳糖残基。这类抗FasL抗体变体可能具有增强的CDC功能。这类变体在例如WO 1997/30087(Patel et al.)；WO 1998/58964(Raju,S.)；和WO 1999/22764(Raju,S.)中有所描述。
在一些实施例中，所述抗FasL抗体(例如全长抗FasL抗体)变体包含能与FcγRIII结合的Fc区。在一些实施例中，包含Fc区的所述抗FasL抗体(例如全长抗FasL抗体)变体在人效应细胞(例如T细胞)存在下具有ADCC活性，或者与具有人野生型IgG1Fc区的其他相同抗FasL抗体(例如全长抗FasL抗体)相比，在人效应细胞存在下，具有增强的ADCC活性。
半胱氨酸工程变体
在一些实施例中，需要制备半胱氨酸工程化的抗FasL抗体(例如全长抗FasL抗体)，在该抗体中一个或多个氨基酸残基被半胱氨酸残基取代。在一些实施例中，取代残基出现在抗FasL抗体的可及位点。通过用半胱氨酸取代那些残基，具有活性的巯基基团位于抗FasL抗体的可及位点，可以用于将该抗FasL抗体与其它部分偶联，例如药物部分或接头-药物部分，来制备如本文中进一步描述的抗FasL免疫偶联物。半胱氨酸工程化的抗FasL抗体(例如，全长抗FasL抗体)可以按照例如U.S.Pat.No.7,521,541所述进行制备。
衍生物
在一些实施例中，本文所提供的抗FasL抗体(例如全长抗FasL抗体)可进一步修饰以包含本领域已知并且容易获得的其它非蛋白部分。适用于衍生化抗FasL抗体的部分包括，但不限于，水溶性聚合物。水溶性聚合物的非限制性实例包括，但不限于，聚乙二醇(PEG)、乙二醇/丙二醇共聚物、羧甲基纤维素、右旋糖酐、聚乙烯醇、聚乙烯吡咯烷酮、聚-1,3-二氧戊烷、聚-1,3,6-三氧杂环已烷、乙烯/马来酸酐共聚物、聚氨基酸(均聚物或无规共聚物)、右旋糖酐或聚(n-乙烯基吡咯烷酮)聚乙二醇、丙二醇均聚物、环氧丙烷/环氧乙烷共聚物、聚氧乙基化多元醇(例如甘油)、聚乙烯醇及其混合物。聚乙二醇丙醛由于其在水中的稳定性，在制造中具有优势。聚合物可以具有任意分子量，可以是支链或非支链的。连接在抗FasL抗体上的聚合物数量可以变化，并且如果连接多于一个多聚物，它们可以是相同的或不同的分子。通常，用于衍生化的聚合物的数量和/或类型可基于以下考虑因素来确定，包括但不限于，需要改进抗FasL抗体的特性或功能，抗FasL抗体衍生物是否用于特定条件下的治疗等。
药物组合物
本文还提供包含任一种抗FasL抗体(例如全长抗FasL抗体)、编码抗体的核酸、包含编码抗体的核酸的载体或者包含本文所述的核酸或载体的宿主细胞的组合物(例如药物组合物，在这里也称为制剂)。在一些实施例中，提供一种药物组合物，包含本文所述的任一种抗FasL抗体和药学上可接受的载体。
可通过混合具有所需纯度的抗FasL抗体与任选的药学上可接受的载体、赋形剂或稳定剂(Remington's Pharmaceutical Sciences 16th edition,Osol,A.Ed.(1980))获得合适的抗FasL抗体制剂，制备成冻干制剂或液体制剂形式。可接受的载体、赋形剂或稳定剂在所用剂量和浓度下对接受者无毒，包括缓冲剂如：磷酸盐、柠檬酸和其它有机酸；抗氧化剂，包括抗坏血酸和蛋氨酸；防腐剂(例如十八烷基二甲基苄基氯化铵；六甲基氯化铵；苯扎氯铵；苄索氯铵；苯酚；丁醇或苄醇；对羟基苯甲酸烷基酯，如对羟基苯甲酸甲酯或对羟基苯甲酸丙酯；邻苯二酚；间苯二酚；环己醇；3-戊醇和间甲酚)；低分子量(少于10个残基)多肽；蛋白质，例如血清白蛋白、明胶或免疫球蛋白；亲水性聚合物，如聚乙烯吡咯烷酮；氨基酸，例如甘氨酸、谷氨酰胺、天冬酰胺、组氨酸、精氨酸或赖氨酸；单糖、二糖和其它碳水化合物，包括葡萄糖、甘露糖或糊精；螯合剂如EDTA；糖类，如蔗糖、甘露醇、海藻糖或山梨糖醇；成盐反离子如钠；金属复合物(如锌-蛋白复合物)；和/或非离子表面活性剂如TWEENTM，PLURONICSTM或聚乙二醇(PEG)；示例性制剂如WO98/56418中所述，并通过引用明确并入本文。适合皮下给药的冻干制剂在WO97/04801中有所描述。这类冻干制剂可通过合适的稀释剂重构成高蛋白浓度的制剂，并且重构的制剂可以通过皮下给药的方式给予本文中待治疗个体。阳离子脂质体或脂质体可以用于将本申请中的抗FasL抗体递送至细胞。
本文所述的制剂除包含抗FasL抗体(例如全长抗FasL抗体)之外，还可以包含一种或多种治疗特定病症所必要的其它活性物质，优选具有活性互补且彼此无不良反应的物质。例如，除了抗FasL抗体之外，可能需要进一步包含抗肿瘤剂、生长抑制剂、细胞毒剂或化学治疗试剂。这些分子以对预期目的有效的量组合存在。其它物质的有效量取决于制剂中的抗FasL抗体的含量，疾病或病症或治疗的类型，以及如上所述的其它因素。这些药物通常以与本文描述的相同剂量和给药途径使用，或者以目前应用剂量的1％至99％使用。
所述抗FasL抗体(例如，全长抗FasL抗体)也可以包埋在例如通过凝聚技术和界面聚合制备的微胶囊中，例如分别在胶体药物递送系统(例如，脂质体、白蛋白微球、微乳液、纳米颗粒和纳米胶囊)中或粗乳液中的羟甲基纤维素或明胶-微胶囊和聚(甲基丙烯酸甲酯)微胶囊。可以制备缓释制剂。
可以制备抗FasL抗体(例如，全长抗FasL抗体)的缓释制剂。缓释制剂的适合的实例包括含有抗体(或其片段)的固体疏水聚合物半透性基质，这些基质是成型制品的形式，例如，薄膜或微胶囊。缓释基质的实例包括聚酯、水凝胶(例如，聚(2-羟乙基甲基丙烯酸酯)或聚(乙烯醇))、聚乳酸(U.S.Pat.No.3,773,919)，L-谷氨酸和L-谷氨酸乙酯共聚物，不可降解的乙烯-醋酸乙烯酯，可降解的乳酸-乙醇酸共聚物如LUPRON DEPOTTM(由乳酸-乙醇酸共聚物和醋酸亮丙瑞林组成的可注射微球)以及聚-D(-)-3-羟基丁酸。虽然诸如乙烯-醋酸乙烯酯和乳酸-乙醇酸之类的聚合物可以使分子的释放超过100天，某些水凝胶可以在更短的时间内释放蛋白质。当包封的抗体在体内长时间停留时，它们会因暴露于37℃的潮湿环境中发生变性或聚集，可能导致生物活性的丧失或免疫原性的改变。可以根据相应的机制，设计合理的策略来稳定抗FasL抗体。例如，如果发现聚 集机制是通过硫代二硫化物交换形成分子间S-S键，则可以通过修饰巯基残基、在酸性溶液中冻干、控制含水量、使用适当的添加剂、以及开发特定的聚合物基质组合物来实现稳定化。
在一些实施例中，所述抗FasL抗体(例如全长抗FasL抗体)配制在含有柠檬酸盐、氯化钠、乙酸盐、琥珀酸盐、甘氨酸、聚山梨酯80(吐温80)或上述任何组合的缓冲液中。
用于体内给药的制剂必须是无菌的。这可以通过例如应用无菌过滤膜过滤而容易地实现。
使用抗FasL抗体的治疗方法
抗FasL抗体(例如，全长的抗FasL抗体)和/或本申请所述的组合物可以施用于个体(例如，哺乳动物，如人类)来治疗与FasL-Fas信号通路失调导致的疾病和/或病症(例如，炎性疾病、自体免疫性疾病或癌症)，这些疾病包括但不限于天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病；特别地，FasL阳性癌症疾病的特征在于其细胞表面表达FasL。在一些实施例中，如果在癌症样品中至少1％、至少2％、至少5％、至少10％、至少20％或至少50％的细胞表达FasL则可以将癌症认作FasL阳性。在一些实施例中，可以通过在显微切片中计数细胞检测FasL阳性细胞的数量。因此，本申请在一些实施例中，提供一种治疗FasL信号通路失调导致的疾病和/或病症(例如，炎性疾病、自体免疫性疾病或癌症)的方法，包括向个体施用有效量的包含抗FasL抗体(例如，全长的抗FasL抗体)的组合物(例如，药物组合物)，例如本文所述的任一种抗FasL抗体(例如，全长的抗FasL抗体)，在一些实施例中，所述个体是人类。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含特异性结合人FasL上表位的FasL抗体(例如，全长抗FasL抗体)的药物组合物，其中所述表位包含人FasL的位氨基酸残基。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病；特别地FasL阳性癌症疾病其特征在于其细胞表面表达FasL。在一些实施例中，如果在癌症样品中至少1％、至少2％、至少5％、至少10％、至少20％或至 少50％的细胞表达FasL则可以将癌症认作FasL阳性。在一些实施例中，可以通过在显微切片中计数细胞检测FasL阳性细胞的数量。在一些实施例中，所述个体是人类。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:1，HC-CDR2，其包含氨基酸序列SEQ ID NO:18，和HC-CDR3，其包含氨基酸序列SEQ ID NO:32，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:67，和LC-CDR3，其包含氨基酸序列SEQ ID NO:77，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:99所示的氨基酸序列或其变体，所述变体与SEQ ID NO:99所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:127所示的氨基酸序列或其变体，所述变体与SEQ ID NO:127所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:2，HC-CDR2，其包含氨基酸序列SEQ ID NO:19，和HC-CDR3，其包含氨基酸序列SEQ ID NO:32，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代； 以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:78，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:100所示的氨基酸序列或其变体，所述变体与SEQ ID NO:100所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:128所示的氨基酸序列或其变体，所述变体与SEQ ID NO:128所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:1，HC-CDR2，其包含氨基酸序列SEQ ID NO:18，和HC-CDR3，其包含氨基酸序列SEQ ID NO:32，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:67，和LC-CDR3，其包含氨基酸序列SEQ ID NO:79，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌 注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:101所示的氨基酸序列或其变体，所述变体与SEQ ID NO:101所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:129所示的氨基酸序列或其变体，所述变体与SEQ ID NO:129所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:3，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:33，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:52，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:80，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:102所示的氨基酸序列或其变体，所述变体与 SEQ ID NO:102所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:130所示的氨基酸序列或其变体，所述变体与SEQ ID NO:130所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:3，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:34，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:52，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:81，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:103所示的氨基酸序列或其变体，所述变体与SEQ ID NO:103所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:131所示的氨基酸序列或其变体，所述变体与SEQ ID NO:131所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基 酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:4，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:35，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:53，LC-CDR2，其包含氨基酸序列SEQ ID NO:69，和LC-CDR3，其包含氨基酸序列SEQ ID NO:82，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:104所示的氨基酸序列或其变体，所述变体与SEQ ID NO:104所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:132所示的氨基酸序列或其变体，所述变体与SEQ ID NO:132所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:5，HC-CDR2，其包含氨基酸序列SEQ ID NO:21，和HC-CDR3，其包含氨基酸序列SEQ ID NO:36，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代； 以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:54，LC-CDR2，其包含氨基酸序列SEQ ID NO:70，和LC-CDR3，其包含氨基酸序列SEQ ID NO:83，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:105所示的氨基酸序列或其变体，所述变体与SEQ ID NO:105所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:133所示的氨基酸序列或其变体，所述变体与SEQ ID NO:133所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:6，HC-CDR2，其包含氨基酸序列SEQ ID NO:22，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:84，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌 注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:106所示的氨基酸序列或其变体，所述变体与SEQ ID NO:106所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:134所示的氨基酸序列或其变体，所述变体与SEQ ID NO:134所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:23，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:107所示的氨基酸序列或其变体，所述变体与 SEQ ID NO:107所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:135所示的氨基酸序列或其变体，所述变体与SEQ ID NO:135所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:108所示的氨基酸序列或其变体，所述变体与SEQ ID NO:108所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:136所示的氨基酸序列或其变体，所述变体与SEQ ID NO:136所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基 酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:8，HC-CDR2，其包含氨基酸序列SEQ ID NO:25，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:109所示的氨基酸序列或其变体，所述变体与SEQ ID NO:109所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:137所示的氨基酸序列或其变体，所述变体与SEQ ID NO:137所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代； 以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:72，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:110所示的氨基酸序列或其变体，所述变体与SEQ ID NO:110所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:138所示的氨基酸序列或其变体，所述变体与SEQ ID NO:138所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌 注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:111所示的氨基酸序列或其变体，所述变体与SEQ ID NO:111所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:139所示的氨基酸序列或其变体，所述变体与SEQ ID NO:139所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:8，HC-CDR2，其包含氨基酸序列SEQ ID NO:25，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:56，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:112所示的氨基酸序列或其变体，所述变体与 SEQ ID NO:112所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:140所示的氨基酸序列或其变体，所述变体与SEQ ID NO:140所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:86，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:113所示的氨基酸序列或其变体，所述变体与SEQ ID NO:113所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:141所示的氨基酸序列或其变体，所述变体与SEQ ID NO:141所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基 酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:9，HC-CDR2，其包含氨基酸序列SEQ ID NO:26，和HC-CDR3，其包含氨基酸序列SEQ ID NO:39，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:57，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:87，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:114所示的氨基酸序列或其变体，所述变体与SEQ ID NO:114所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:142所示的氨基酸序列或其变体，所述变体与SEQ ID NO:142所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:2，HC-CDR2，其包含氨基酸序列SEQ ID NO:27，和HC-CDR3，其包含氨基酸序列SEQ ID NO:40，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代； 以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:58，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:88，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:115所示的氨基酸序列或其变体，所述变体与SEQ ID NO:115所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:143所示的氨基酸序列或其变体，所述变体与SEQ ID NO:143所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:10，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:41，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:59，
LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:89，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性 再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:116所示的氨基酸序列或其变体，所述变体与SEQ ID NO:116所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:144所示的氨基酸序列或其变体，所述变体与SEQ ID NO:144所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:6，HC-CDR2，其包含氨基酸序列SEQ ID NO:22，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:90，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:117所示的氨基酸序列或其变体，所述变体与 SEQ ID NO:117所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:145所示的氨基酸序列或其变体，所述变体与SEQ ID NO:145所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:11，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:42，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:60，
LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:91，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:118所示的氨基酸序列或其变体，所述变体与SEQ ID NO:118所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:146所示的氨基酸序列或其变体，所述变体与SEQ ID NO:146所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基 酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:12，HC-CDR2，其包含氨基酸序列SEQ ID NO:29，和HC-CDR3，其包含氨基酸序列SEQ ID NO:43，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:61，LC-CDR2，其包含氨基酸序列SEQ ID NO:75，和LC-CDR3，其包含氨基酸序列SEQ ID NO:92，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:119所示的氨基酸序列或其变体，所述变体与SEQ ID NO:119所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:147所示的氨基酸序列或其变体，所述变体与SEQ ID NO:147所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:12，HC-CDR2，其包含氨基酸序列SEQ ID NO:29，和HC-CDR3，其包含氨基酸序列SEQ ID NO:44，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取 代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:62，LC-CDR2，其包含氨基酸序列SEQ ID NO:75，和LC-CDR3，其包含氨基酸序列SEQ ID NO:93，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:120所示的氨基酸序列或其变体，所述变体与SEQ ID NO:120所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:148所示的氨基酸序列或其变体，所述变体与SEQ ID NO:148所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:13，HC-CDR2，其包含氨基酸序列SEQ ID NO:30，和HC-CDR3，其包含氨基酸序列SEQ ID NO:45，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:63，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:94，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性 再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:121所示的氨基酸序列或其变体，所述变体与SEQ ID NO:121所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:149所示的氨基酸序列或其变体，所述变体与SEQ ID NO:149所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:14，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:46，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:95，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:122所示的氨基酸序列或其变体，所述变体与 SEQ ID NO:122所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:150所示的氨基酸序列或其变体，所述变体与SEQ ID NO:150所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:15，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:47，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:64，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:96，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:123所示的氨基酸序列或其变体，所述变体与SEQ ID NO:123所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:151所示的氨基酸序列或其变体，所述变体与SEQ ID NO:151所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基 酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:16，HC-CDR2，其包含氨基酸序列SEQ ID NO:31，和HC-CDR3，其包含氨基酸序列SEQ ID NO:48，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:65，LC-CDR2，其包含氨基酸序列SEQ ID NO:76，和LC-CDR3，其包含氨基酸序列SEQ ID NO:97，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:124所示的氨基酸序列或其变体，所述变体与SEQ ID NO:124所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:152所示的氨基酸序列或其变体，所述变体与SEQ ID NO:152所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:17，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:49，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取 代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:66，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:98，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:125所示的氨基酸序列或其变体，所述变体与SEQ ID NO:125所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:153所示的氨基酸序列或其变体，所述变体与SEQ ID NO:153所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
例如，在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体(例如，全长抗FasL抗体)的药物组合物，重链可变结构域(VH)，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:17，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:50，或者所述VH的变体，其HC-CDRs中包含至多约5个氨基酸的取代；以及轻链可变结构域(VL)，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:60，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:91，或者所述VL的变体，其LC-CDRs中包含至多约5个氨基酸的取代。在一些实施例中，所述抗FasL抗体是全长抗体。在一些实施例中，所述全长抗FasL抗体是IgG1或IgG4抗体。在一些实施例中，所述疾病或病症选自例如，天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性 再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。在一些实施例中，所述癌症为FasL阳性癌症疾病。在一些实施例中，所述个体是人类。
在一些实施例中，提供一种用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)的个体的方法，包括向所述个体施用有效量的包含抗FasL抗体的组合物，其中所述抗体包含：VH，所述VH包含SEQ ID NO:126所示的氨基酸序列或其变体，所述变体与SEQ ID NO:126所示的氨基酸序列具有至少约80％序列同一性；以及VL，所述VL包含SEQ ID NO:154所示的氨基酸序列或其变体，所述变体与SEQ ID NO:154所示的氨基酸序列具有至少约80％序列同一性。
在一些实施例中，本文所述抗FasL抗体是包含IgG1或IgG4恒定区的全长抗FasL抗体。在一些实施例中，所述IgG1是人IgG1。在一些实施例中，所述IgG4是人IgG4。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:155组成。在一些实施例中，重链恒定区包含或由氨基酸序列SEQ ID NO:156组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:157组成。在一些实施例中，轻链恒定区包含或由氨基酸序列SEQ ID NO:158组成。
在一些实施例中，所述个体是哺乳动物(例如人、非人灵长类、大鼠、小鼠、牛、马、猪、绵羊、山羊、狗、猫等)。在一些实施例中，所述个体是人类。在一些实施例中，所述个体是临床患者、临床试验志愿者、实验动物等。在一些实施例中，所述个体年龄小于60岁(包括例如小于50、40、30、25、20、15或10岁)。在一些实施例中，所述个体年龄大于60岁(包括例如大于70、80、90或100岁)。在一些实施例中，所述个体是被诊断为或在遗传角度上易患本文所描述的一种或多种疾病或病症(例如炎性疾病、自体免疫性疾病或癌症)。在一些实施例中，所述个体具有一种或多种与本文所述的一种或多种疾病或病症相关的风险因子。
在一些实施例中，本申请提供一种向个体中在其表面表达FasL的细胞递送抗FasL抗体(例如本文所述的任一种抗FasL抗体，例如分离的抗FasL抗体)的方法，所述方法包括向该个体施用包含抗FasL抗体的组合物。
炎性疾病、自体免疫性疾病或癌症或其它任何表现出FasL异常表达的疾病的许多诊断方法和这些疾病的临床描述在本领域是已知的。这类方法包括，但不限于，例如免疫组化、PCR以及荧光原位杂交(FISH)。
在一些实施例中，本申请所述抗FasL抗体(例如全长抗FasL抗体)和/或组合物与第二、第三或第四药剂(包括例如免疫抑制剂、抗炎药、抗肿瘤剂、生长抑制剂、细胞毒剂、化学治疗试剂或血管抑制剂)联合使用来治疗与FasL-Fas信号通路相关的疾病。
抗FasL抗体的给药剂量和方法
施用于个体(例如人)的抗FasL抗体(例如分离的抗FasL抗体)组合物的剂量可能因特定组合物、给药方式和治疗疾病类型的不同而不同。在一些实施例中，组合物(例如，包含抗FasL抗 体的组合物)的量可在炎性疾病、自体免疫性疾病或癌症治疗中有效产生客观响应(例如，部分响应或完全响应)。在一些实施例中，抗FasL抗体组合物的量足以在个体中产生完全响应。在一些实施例中，抗FasL抗体组合物的量足以在个体中产生部分响应。在一些实施例中，抗FasL抗体组合物的给药剂量(例如当单独施用时)足以在使用抗FasL抗体组合物治疗的个体群体中产生高于20％、25％、30％、35％、40％、45％、50％、55％、60％、64％、65％、70％、75％、80％、85％或90％的总响应率。
在一些实施例中，组合物(例如包含分离的抗FasL抗体的组合物)的量足以延长个体的无进展生存期。在一些实施例中，组合物的量足以延长个体的总体生存期。在一些实施例中，在使用抗FasL抗体组合物治疗的个体群体中，组合物的量(例如当单独施用时)足以产生高于50％、60％、70％或77％的临床益处。
在一些实施例中，组合物(例如包含分离的抗FasL抗体的组合物)的量，单独使用或与第二，第三、和/或第四药剂联合使用时，是指在治疗前或与未接受治疗的其他受试者的相应活性相比，足以控制症状和减少病情加重的风险的量。可以采用标准方法来测量该疗效的大小，例如纯化酶的体外检测、基于细胞的检测、动物模型或人体试验。
在一些实施例中，当将组合物施用于个体时，组合物中抗FasL抗体(例如全长的抗FasL抗体)的量低于引起毒性效应(即，一种高于临床可接受毒性水平的效应)的水平，或者处于潜在副作用可以控制或耐受的水平。
在一些实施例中，遵循相同的给药方案，组合物的量接近的组合物的最大耐受剂量(MTD)。在一些实施例中，组合物的量高于MTD的80％、90％、95％或98％。
在一些实施例中，组合物中抗FasL抗体(例如全长的抗FasL抗体)的含量在0.001μg到1000μg的范围之内。
在如上所述任一个实施例中，组合物中的抗FasL抗体(例如全长的抗FasL抗体)的有效量，按照体重时计算，为0.1μg/kg到100mg/kg的范围之内。
抗FasL抗体组合物可通过多种途径施用于个体(如人类)，包括，例如静脉注射、动脉内给药、腹腔注射、肺内给药、口服给药、吸入给药、血管内给药、肌肉注射、气管内给药、皮下注射、眼内给药、鞘内给药、粘膜给药或经皮给药。在一些实施例中，使用组合物的缓释制剂。在一些实施例中，组合物通过静脉给药。在一些实施例中，组合物通过动脉给药。在一些实施例中，组合物通过腹膜内给药。在一些实施例中，组合物通过肝内给药。在一些实施例中，组合物通过肝动脉输注给药。在一些实施例中，组合物施用于远离第一病灶的部位。
制品及试剂盒
在本申请的一些实施例中，提供一种制品，所述制品包含一种物质，所述物质能够用于治疗与FasL-Fas信号通路相关的疾病(例如，炎性疾病、自体免疫性疾病或癌症)，或者用于递送抗FasL抗体(例如一种全长抗FasL抗体)到表面表达FasL的细胞。所述制品可以包括一种容器以 及在容器上或随该容器附带的标签或包装说明书。合适的容器包括，例如瓶子、小瓶、注射器等。容器可以由多种材料制成，例如玻璃或塑料。通常，该容器内装有能够有效治疗本文所述疾病或病症的组合物，并且具有一个无菌端口(例如该容器可以是一个静脉输液袋或是一个具有皮下注射针头可刺穿盖子的小瓶)。组合物中的至少一种活性物质即为本申请所述的抗FasL抗体。标签或包装说明书标示了该组合物可以用于治疗的特定病症。标签或包装说明书进一步包含给患者施用抗FasL抗体组合物的说明书。包括联合治疗的制品和试剂盒均在本文的考虑范围之内。
包装说明书是指通常包含在治疗产品的商业包装内的说明书，其包含关于与这些治疗产品使用有关的适应症、用法、剂量、施用、禁忌症和/或警告信息。在一些实施例中，包装说明书标明该组合物可以用于治疗与FasL-Fas信号通路相关的疾病(例如炎性疾病、自体免疫性疾病或癌症)。在一些实施例中，包装说明书标明该组合物可以用于治疗以下的疾病，包括天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。
此外，所述制品还可以包括第二容器，其包含药学上可接受的缓冲液，例如抑菌性注射用水(BWFI)、磷酸盐缓冲液、格林氏溶液或葡萄糖溶液。还可以包括从商业和用户角度而言所需的其他材料，包括其他缓冲液、稀释液、过滤器、针头和注射器。
同时还涉及可用于各种目的的试剂盒，例如用于治疗与FasL-Fas信号通路相关的疾病(例如炎性疾病、自体免疫性疾病或癌症)，或者用于递送抗FasL抗体(例如全长抗FasL抗体)到表面表达FasL的细胞中，任选与制品组合。本申请的试剂盒包括一个或多个容器，其包含抗FasL抗体组合物(或单剂量形式和/或制品)，并且在一些实施例中，进一步包含另一种药剂(例如本文所述的药剂)和/或与本文所述任一方法相一致的使用说明书。该试剂盒可进一步包括选择适合治疗个体的描述。本申请中试剂盒中所附带的使用说明书通常是标签或包装说明书上的书面说明(例如包含在试剂盒内的纸页)，机器可读的说明(例如，磁性或光学储存光盘上的说明)也是可以接受的。
例如，在一些实施例中，试剂盒包括一种包含抗FasL抗体(例如全长的抗FasL抗体)的组合物。在一些实施例中，试剂盒包括：a)包含本文所述的任一种抗FasL抗体的组合物，和b)至少一种有效量的其它药剂，其能够增强抗FasL抗体的效果(如治疗效果、检测效果)。在一些实施例中，试剂盒包括：a)包含本文所述的任一种抗FasL抗体的组合物，和b)向个体施用抗FasL抗体组合物用于治疗与FasL-Fas信号通路相关的疾病(例如炎性疾病、自体免疫性疾病或癌症)的使用说明书。在一些实施例中，试剂盒包括：a)包含本文所述的任一种抗FasL抗体的组合物，和b)至少一种有效量的其它药剂，其能够增强抗FasL抗体的效果(如治疗效果、检测效果)和c)向个体施用抗FasL抗体组合物和其它物质用于治疗与FasL-Fas信号通路相关的疾病(例如炎性疾病、自 体免疫性疾病或癌症)的使用说明书。所述抗FasL抗体和其他物质可以存在于独立的容器或同一个容器中。例如，该试剂盒可以包括一种特定组合物或两种或更多种组合物，其中一种组合物包括抗FasL抗体，另一种组合物包括另一种药剂。
在一些实施例中，试剂盒包含一种(或一组)编码抗FasL抗体(例如全长的抗FasL抗体)的核酸。在一些实施例中，试剂盒包含：a)一种(或一组)编码抗FasL抗体(例如全长的抗FasL抗体)的核酸，和b)一种表达核酸(或一组核酸)的宿主细胞。在一些实施例中，试剂盒包含：a)一种(或一组)编码抗FasL抗体(例如全长的抗FasL抗体)的核酸，和b)使用说明书，适用于：i)在宿主细胞中表达抗FasL抗体，ii)制备包含抗FasL抗体的组合物，和iii)向个体施用包含抗FasL抗体的组合物来治疗与FasL-Fas信号通路相关的疾病(例如炎性疾病、自体免疫性疾病或癌症)。在一些实施例中，试剂盒包括：a)一种(或一组)编码抗FasL抗体(例如全长的抗FasL抗体)的核酸，b)一种表达核酸(或一组核酸)的宿主细胞，和c)使用说明书，适用于：i)在宿主细胞中表达抗FasL抗体，ii)制备包含抗FasL抗体的组合物，和iii)向个体施用包含抗FasL抗体的组合物来治疗与FasL-Fas信号通路相关的疾病(例如炎性疾病、自体免疫性疾病或癌症)。
本申请所述的试剂盒以合适的形式进行包装。合适的包装包括，但不限于，小瓶、瓶子、广口瓶、软包装(例如密封的聚酯薄膜或塑料袋)等。试剂盒可以任选地提供其它的组分，例如缓冲液和说明信息。因此，本申请还提供制品，其包括小瓶、瓶子、广口瓶、软包装(例如密封的聚酯薄膜或塑料袋)等。
关于抗FasL抗体组合物的使用说明书，通常包括一些信息，诸如，剂量，给药周期和给药途径等。容器可以是单位剂量的，大包装的(如，多剂量包装)或亚单位剂量的。例如，提供一种包含足够剂量的如本文所述的抗FasL抗体(例如全长的抗FasL抗体)的试剂盒以对个体进行长期有效的治疗，例如一周、8天、9天、10天、11天、12天、13天、2周、3周、4周、6周、8周、3个月、4个月、5个月、7个月、8个月、9个月或更长时间。试剂盒还可包含多单位剂量的抗FasL抗体、药物组合物和使用说明书，并且以足够在药房中储存和使用的量进行包装，例如，医院药房和复方药房。
本领域的技术人员将认识到在本申请的范围和宗旨内可能的若干实施例。现在将通过参考以下非限制性实施例来更详细地描述本申请。以下实施例进一步阐明本申请，但不应解释为以任何方式进行限制其范围。
具体实施方式
实施例1：制备抗原
制备重组FasL/Fas蛋白
通过亚克隆分别将编码人FasL(human FasL，hFasL；GenBank ID号：356)胞外区的cDNA(北京义翘神州科技股份有限公司合成)构建到真核表达载体中。在编码上述蛋白的cDNA的末 端添加His标签和/或人Fc标签和/或其它的本领域技术人员常用标签，构建含有人、猴FasL胞外区编码序列的质粒。将上述质粒转染293F细胞进行表达以产生含有FasL胞外区的融合蛋白，例如His-hFasL、hFc-hFasL，其中，“His”代表His标签,“hFc”代表人Fc片段。
同上述方法，构建含有人Fas(human Fas，hFas；GenBank ID号：355)胞外区编码序列的载体，并转染293F细胞，以表达产生含有人Fas胞外区的融合蛋白，例如His-hFas，其中，“His”代表His标签。
根据制造商的操作说明，采用镍(Ni)柱-HisCap Smart 6FF 5ml预装柱(常州天地人和生物科技有限公司，SA036C15)进行固定化金属亲和层析(IMAC)纯化具有His标签的重组蛋白。具体操作如下：首先采用缓冲液A1(50mM Na3PO4、0.15M NaCl、pH 7.2)平衡镍柱，流速150cm/h，将含有融合蛋白的溶液(如细胞培养液上清)的pH调整至7.2，室温上样，流速150cm/h。随后，采用6倍柱体积的A1缓冲液再次平衡该柱，流速150cm/h。最后采用10倍柱体积的50mM PB溶液(包含0.15M NaCl和0.2M咪唑，pH 7.2)进行洗脱，收集洗脱液。采用超滤管将上述洗脱液进行超滤换液至PBS中，并浓缩到一定浓度。
采用蛋白A柱-MabCap At 4FF 5ml预装柱(常州天地人和生物科技有限公司，SA023C15)纯化具有Fc片段的融合蛋白。具体操作如下：首先采用6倍柱体积的PBS缓冲液(包含50mM PBS和0.15M NaCl，pH7.2)平衡蛋白A柱，流速为5ml/min。将培养液上清的pH调整至7.2，室温上样，流速为5ml/min。随后，采用6-10倍柱体积的PBS缓冲液再次平衡该柱，流速为5ml/min。至完全平衡后，加入洗脱液(包含0.1M Gly和150mM NaCl，pH3.2)进行洗脱，收集洗脱液。采用超滤管将上述洗脱液进行超滤换液至PBS中，并浓缩到一定浓度。
实施例2：筛选抗FasL的单链抗体(scFv)
构建scFv抗体噬菌体展示文库：
使用人FasL胞外区作为抗原，与等体积(v/v)佐剂一起免疫小鼠。取免疫后的小鼠血清，ELISA检测免疫后小鼠血清中总IgG滴度。几轮免疫后，使用小鼠脾脏建立噬菌体展示库。简言之，取免疫后的小鼠脾脏，提取RNA，经逆转录获得cDNA，采用VH和VK特异性引物扩增VH和VK片段，经过胶回收纯化后，连接VH和VK，构建scFv，并将其克隆到噬菌体展示质粒中，随后，将该质粒电转至大肠杆菌TG1中，利用噬菌体感染大肠杆菌TG1获得scFv抗体噬菌体展示文库。
筛选抗FasL单链抗体(scFv)：
从噬菌体展示库中分离并获得特异性结合hFasL的scFv。简言之，取2x1011PFU的噬菌体scFv文库加入到包被His-hFasL抗原的ELISA板中，37℃孵育2小时。采用PBST溶液洗涤8-15遍(随着筛选轮数增加，洗涤次数增加)，结合hFasL抗原的噬菌体被包被在ELISA板上的FasL抗原捕捉，而未结合的噬菌体被洗掉。用0.1M Glycine-HCl溶液(pH2.2)洗脱特异性结合hFasL抗原的噬菌体。将上述噬菌体感染指数生长期的TG1细胞，加入氨苄青霉素培养1小时后，加入 辅助噬菌体，28℃、220rpm摇床培养过夜。次日收集培养液，离心后获得上清，进入下一轮筛选。经多轮淘选后获得阳性scFv抗体文库。
ELISA方法检测抗FasL单链抗体：
将淘选后富集的噬菌体进行ELISA筛选。简言之，将His-hFasL抗原溶解在PBS溶液中，按照0.1μg/孔包被96孔板，4℃过夜。用PBST溶液洗涤1次后，每孔中加入90μL含有4％脱脂奶粉的PBS。随后向对应的孔中加入10μL phage-scFv培养液上清，37℃孵育1-2小时。用PBST溶液洗涤8次后，加入1∶4000稀释的抗M13-HRP抗体(Sino Biological，11973-MM05T-H)，100μL/孔。37℃孵育1h。PBST洗板6次后，加TMB显色液，100μL/孔，室温避光孵育10min。用2M H2SO4终止显色反应，用酶标仪读取450nm处的吸光度值。在筛选过程结束后，获得一系列阳性scFv抗体并对其进行测序。
实施例3：制备和表征全长的抗FasL的嵌合抗体
3.1制备全长的抗FasL嵌合抗体
将获得的阳性scFv抗体重构成具有人IgG1或IgG4重链恒定区和人kappa(κ)轻链恒定区的嵌合抗体。从噬菌体展示载体中扩增出VL和VH，分别构建入真核表达载体pTTa1-L(包含人κ恒定区)和pTT5-H1(包含人IgG1重链恒定区)或pTTa1-H4(包含人IgG4重链恒定区)中。将表达轻链的质粒和表达重链的质粒共转染293F细胞，37℃、5％CO2、120rpm培养6天，用Protein A亲和层析柱纯化培养液。抗体纯化方法与实施例1中使用蛋白A柱纯化的方法相同。超滤浓缩后测定抗体浓度并进行进一步的生化和生物活性分析。
3.2抗FasL抗体的结合能力测定
抗FasL抗体的亲和力
将构建的全长抗FasL嵌合抗体(重构成人IgG4形式)与人FasL进行结合试验，以反应抗FasL抗体与人FasL抗原的结合活性。简言之，将人hFc-hFasL抗原溶解在PBS溶液中，按照0.1μg/孔包被96孔板，4℃过夜。用5％牛奶37℃封闭1小时，再用PBST溶液洗涤6次。首先将每个抗体样品稀释至66.67nM，随后以1：4的比例进行梯度稀释。将梯度稀释后的样品分别加入96孔板中，每孔100μL，37℃孵育1小时。随后用PBST溶液洗涤6次。向各孔中加入100μL抗人kappa-HRP(SouthernBiotech，E1920-MJ11B，1:4000稀释)，37℃孵育1小时。用PBST溶液洗涤6次。每孔加入100μL TMB，37℃孵育10-20分钟，用2M H2SO4终止反应。利用酶标仪读取450nm处的吸光值。通过GraphPad Prism生成结合曲线，并计算出各抗FasL抗体的EC50值。
结果如表5所示，筛选出的抗FasL嵌合抗体FL-M04、FL-M06、FL-M07、FL-M09、FL-M13、FL-M27、FL-M37、FL-M39～FL-M46、FL-M51、FL-M52、FL-M55、FL-M58、FL-M60～FL-M62、FL-M65、FL-M68、FL-M69、FL-M71、FL-M76、FL-M77与人FasL抗原均有良好的结合 能力。上述抗FasL抗体与人FasL的结合能力明显优于FasL拮抗剂APG101(Fas融合蛋白，Apogenix)；也优于对照抗体MAB126-100(商业化抗FasL抗体，RD)或与之相当。
表5：抗FasL嵌合抗体与人FasL的结合能力
抗FasL抗体中和配体与受体的结合：
该实验用于鉴定抗FasL嵌合抗体(重构成人IgG4形式)中和配体FasL与其受体Fas结合的能力。简言之，将实施例1制备的的His-hFas按照0.1μg/孔包被96孔板，4℃过夜。用PBST溶液洗涤后，每孔加入100μL 2％牛奶。37℃封闭1小时，之后用PBST溶液洗涤。将各抗FasL抗体样品稀释至12.0μg/ml，随后以1：4的比例进行梯度稀释。将实施例1制备的hFc-hFasL抗原(1.25ug/mL)与梯度稀释的各抗FasL抗体混合后，37℃预混30min。将上述抗原-抗体预混物加入96孔板中，100μL/孔，37℃孵育1h。向各孔中加入100μL抗人IgG1Fc-AP抗体(SouthernBiotech，9054-04，1:3000)，37℃孵育1小时。用PBST溶液洗涤6次后，每孔加入100μL pNPP溶液，37℃孵育10-20分钟。读取405nm处的吸光度值，通过GraphPad Prism软件生成中和曲线。
结果表明，以FL-M04、FL-M06、FL-M07、FL-M09、FL-M13、FL-M27为例，抗FasL嵌合抗体中和FasL与Fas结合的能力与对照抗体MAB126-100相当(结果未展示)。
3.3抗FasL抗体的活性测定
抗FasL抗体抑制FasL抗原诱导的Jurkat细胞凋亡：
在加入放线菌素D抑制细胞分裂的情况下，外源FasL可激活细胞凋亡的信号转导通路并介导细胞凋亡，而细胞中ATP的量直接与培养物中的细胞数量成正比。基于以上原理，可利用细胞中ATP的量反映细胞凋亡水平，进而确定抗FasL嵌合抗体(重构成人IgG4形式)抑制FasL抗原诱导的Jurkat细胞凋亡的活性。
将处于对数生长期的Jurkat细胞(购自北京协和医学院细胞库，1101HUM-PUMC000075)接种于96孔板中，5×104个细胞/孔。将每个抗体样品稀释至6.667nM，随后以1：3的比例进行梯度稀释。将50μL放线菌素D(瀚晖制药有限公司，国药准字H20023504)、25μL hFc-FasL重组融合蛋白和25μL梯度稀释的抗FasL抗体加入含有Jurkat细胞的96孔板中，使放线菌素D、hFc-FasL重组融合蛋白的终浓度分别为32ng/mL和5ng/mL。在37℃，5％CO2条件下培养24小时。利用发光法细胞活力检测试剂盒(Promega,G7572)检测存在的ATP量，而存在的ATP量与产生的发光信号成正比，即向96孔细胞培养板中加入试剂，每孔50μL，混合后室温孵育10min。用酶标仪读取荧光值。通过GraphPad Prism软件生成曲线，并计算出各抗FasL抗体的IC50值。
结果如表6所示，抗FasL嵌合抗体FL-M04、FL-M06、FL-M07、FL-M09、FL-M13、FL-M27、FL-M37、FL-M39～FL-M46、FL-M51、FL-M52、FL-M55、FL-M58、FL-M60～FL-M62、FL-M65、FL-M68、FL-M69、FL-M71、FL-M76、FL-M77对FasL抗原诱导的Jurkat细胞凋亡均有明显的抑制作用。上述抗FasL抗体抑制FasL抗原诱导的Jurkat细胞凋亡的能力明显优于对照APG101，且与对照抗体119-4A(抗FasL抗体，Apogenix)相当。
表6：抗FasL嵌合抗体抑制FasL抗原诱导的Jurkat细胞凋亡的能力

抗FasL抗体抑制FasL抗原诱导的HepG2细胞凋亡：
实验原理同上，利用细胞中ATP的量反映细胞凋亡水平，进而确定抗FasL嵌合抗体(重构成人IgG4形式)抑制FasL抗原诱导的HepG2细胞凋亡的活性。
将处于对数生长期的HepG2细胞(购自北京协和医学院细胞库，1101HUM-PUMC000035)接种于96孔板中，2×104个细胞/孔。将每个抗体样品稀释至6.667nM，随后以1：3的比例进行梯度稀释。将50μL放线菌素D、25μL hFc-FasL重组融合蛋白和25μL梯度稀释的抗FasL抗体加入含有HepG2细胞的96孔板中，使放线菌素D、hFc-FasL重组融合蛋白的终浓度分别为1μg/mL和5ng/mL。在37℃，5％CO2条件下培养48小时。利用发光法细胞活力检测试剂盒(Promega,G7572)检测存在的ATP量，而存在的ATP量与产生的发光信号成正比。即向96孔细胞培养板中加入试剂，每孔50μL，混合后室温孵育10min。用酶标仪读取荧光值。通过GraphPad Prism软件生成曲线，并计算出各抗FasL抗体的IC50值。
结果如表7所示，抗FasL嵌合抗体FL-M04、FL-M06、FL-M07、FL-M09、FL-M13、FL-M27、FL-M37、FL-M39～FL-M46、FL-M51、FL-M52、FL-M55、FL-M58、FL-M60～FL-M62、FL-M65、FL-M68、FL-M69、FL-M71、FL-M76、FL-M77对FasL抗原诱导的HepG2细胞凋亡均有明显的抑制作用。上述抗FasL抗体抑制FasL抗原诱导的HepG2细胞凋亡的能力明显优于对照APG101；且上述抗FasL抗体中，除FL-M27、FL-M46、FL-M52、FL-M65与对照抗体MAB126-100基本相当外，其余抗体明显优于对照抗体MAB126-100。
表7：抗FasL嵌合抗体抑制FasL抗原诱导的HepG2细胞凋亡的能力

抗FasL抗体抑制FasL抗原诱导的NF-κB信号通路激活：
在加入放线菌素D抑制细胞分裂的情况下，外源FasL除了可激活细胞凋亡的信号通路外，还可激活NF-κB信号通路。采用Caspase抑制剂阻断细胞凋亡通路后，外源FasL仅能诱导NF-κB信号通路激活。HepG2-Dual(InvivoGen，hepg2d-nfis)为NF-κB-SEAP和IRF-Lucia双报告基因细胞系，其中外源FasL诱导NF-κB途径激活后，启动分泌型胚胎碱性磷酸酶(SEAP)的表达，其可通过QUANTI-BlueTM底物转化率来测定。基于以上实验原理，通过HepG2-Dual中SEAP的活性来确定抗FasL嵌合抗体(重构成人IgG4形式)抑制FasL抗原诱导的NF-κB信号通路激活的活性。
将处于对数生长期的HepG2-Dual细胞接种于96孔板中，1×105个细胞/孔。将每个抗体样品稀释至625nM，随后进行梯度稀释。将hFc-FasL(终浓度为700ng/ml)、放线菌素D、Caspase抑制剂Z-VAD-FMK(碧云天，C1202-5mg)和梯度稀释的抗FasL抗体加入含有HepG2-Dual细胞的96孔板中，37℃，5％CO2培养24小时。取40μL细胞培养基上清与160μL预热的QUANTI-BlueTM(Invivogen)溶液混合，孵育90分钟，读取650nm处的吸光值。经GraphPad Prism软件生成曲线，并计算出各抗FasL抗体的EC50值。
结果如表8所示，抗FasL嵌合抗体FL-M06、FL-M39～FL-M46、FL-M51、FL-M52、FL-M55、FL-M58、FL-M60～FL-M62、FL-M65、FL-M68、FL-M69对FasL抗原诱导的NF-κB信号通路激活均有明显的抑制作用。上述抗FasL抗体中，除FL-M55与对照APG101基本相当外，其余抗体明显优于对照APG101。
表8：抗FasL嵌合抗体抑制FasL抗原诱导的NF-κB信号通路激活的能力

Claims (22)

  1. 一种分离的特异性识别FasL的抗体，其中所述抗FasL抗体包含：
    (i)VH，所述VH包含如氨基酸序列SEQ ID NO:99所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，所述VL包含如氨基酸序列SEQ ID NO:127所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (ii)VH，其包含如氨基酸序列SEQ ID NO:100所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:128所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (iii)VH，其包含如氨基酸序列SEQ ID NO:101所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:129所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (iv)VH，其包含如氨基酸序列SEQ ID NO:102所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:130所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (v)VH，其包含如氨基酸序列SEQ ID NO:103所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:131所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (vi)VH，其包含如氨基酸序列SEQ ID NO:104所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:132所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (vii)VH，其包含如氨基酸序列SEQ ID NO:105所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:133所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (viii)VH，其包含如氨基酸序列SEQ ID NO:106所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:134所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (ix)VH，其包含如氨基酸序列SEQ ID NO:107所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:135所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (x)VH，其包含如氨基酸序列SEQ ID NO:108所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:136所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xi)VH，其包含如氨基酸序列SEQ ID NO:109所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:137所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xii)VH，其包含如氨基酸序列SEQ ID NO:110所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:138所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xiii)VH，其包含如氨基酸序列SEQ ID NO:111所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:139所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xiv)VH，其包含如氨基酸序列SEQ ID NO:112所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:140所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xv)VH，其包含如氨基酸序列SEQ ID NO:113所示的VH包含的HC-CDR1、HC- CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:141所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xvi)VH，其包含如氨基酸序列SEQ ID NO:114所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:142所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xvii)VH，其包含如氨基酸序列SEQ ID NO:115所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:143所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xviii)VH，其包含如氨基酸序列SEQ ID NO:116所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:144所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xix)VH，其包含如氨基酸序列SEQ ID NO:117所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:145所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xx)VH，其包含如氨基酸序列SEQ ID NO:118所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:146所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xxi)VH，其包含如氨基酸序列SEQ ID NO:119所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:147所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xxii)VH，其包含如氨基酸序列SEQ ID NO:120所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:148所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xxiii)VH，其包含如氨基酸序列SEQ ID NO:121所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:149所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xxiv)VH，其包含如氨基酸序列SEQ ID NO:122所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:150所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xxv)VH，其包含如氨基酸序列SEQ ID NO:123所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:151所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xxvi)VH，其包含如氨基酸序列SEQ ID NO:124所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:152所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；
    (xxvii)VH，其包含如氨基酸序列SEQ ID NO:125所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:153所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3；或
    (xxviii)VH，其包含如氨基酸序列SEQ ID NO:126所示的VH包含的HC-CDR1、HC-CDR2和HC-CDR3；
    以及VL，其包含如氨基酸序列SEQ ID NO:154所示的VL包含的LC-CDR1、LC-CDR2和LC-CDR3。
  2. 一种分离的特异性识别FasL的抗体，其中所述抗体包含：
    (i)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:1，HC-CDR2，其包含氨基酸序列SEQ ID NO:18，和HC-CDR3，其包含氨基酸序列SEQ ID NO: 32；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:67，和LC-CDR3，其包含氨基酸序列SEQ ID NO:77；
    (ii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:2，HC-CDR2，其包含氨基酸序列SEQ ID NO:19，和HC-CDR3，其包含氨基酸序列SEQ ID NO:32；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:78；
    (iii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:1，HC-CDR2，其包含氨基酸序列SEQ ID NO:18，和HC-CDR3，其包含氨基酸序列SEQ ID NO:32；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:67，和LC-CDR3，其包含氨基酸序列SEQ ID NO:79；
    (iv)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:3，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:33；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:52，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:80；
    (v)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:3，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:34；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:52，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:81；
    (vi)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:4，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:35；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:53，LC-CDR2，其包含氨基酸序列SEQ ID NO:69，和LC-CDR3，其包含氨基酸序列SEQ ID NO:82；
    (vii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:5，HC-CDR2，其 包含氨基酸序列SEQ ID NO:21，和HC-CDR3，其包含氨基酸序列SEQ ID NO:36；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:54，LC-CDR2，其包含氨基酸序列SEQ ID NO:70，和LC-CDR3，其包含氨基酸序列SEQ ID NO:83；
    (viii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:6，HC-CDR2，其包含氨基酸序列SEQ ID NO:22，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:84；
    (ix)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:23，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85；
    (x)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85；
    (xi)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:8，HC-CDR2，其包含氨基酸序列SEQ ID NO:25，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85；
    (xii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:72，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85；
    (xiii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85；
    (xiv)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:8，HC-CDR2，其包含氨基酸序列SEQ ID NO:25，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:56，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:85；
    (xv)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:7，HC-CDR2，其包含氨基酸序列SEQ ID NO:24，和HC-CDR3，其包含氨基酸序列SEQ ID NO:38；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:86；
    (xvi)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:9，HC-CDR2，其包含氨基酸序列SEQ ID NO:26，和HC-CDR3，其包含氨基酸序列SEQ ID NO:39；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:57，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:87；
    (xvii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:2，HC-CDR2，其包含氨基酸序列SEQ ID NO:27，和HC-CDR3，其包含氨基酸序列SEQ ID NO:40；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:58，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:88；
    (xviii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:10，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:41；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:59，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨 基酸序列SEQ ID NO:89；
    (xix)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:6，HC-CDR2，其包含氨基酸序列SEQ ID NO:22，和HC-CDR3，其包含氨基酸序列SEQ ID NO:37；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:55，LC-CDR2，其包含氨基酸序列SEQ ID NO:71，和LC-CDR3，其包含氨基酸序列SEQ ID NO:90；
    (xx)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:11，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:42；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:60，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:91；
    (xxi)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:12，HC-CDR2，其包含氨基酸序列SEQ ID NO:29，和HC-CDR3，其包含氨基酸序列SEQ ID NO:43；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:61，LC-CDR2，其包含氨基酸序列SEQ ID NO:75，和LC-CDR3，其包含氨基酸序列SEQ ID NO:92；
    (xxii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:12，HC-CDR2，其包含氨基酸序列SEQ ID NO:29，和HC-CDR3，其包含氨基酸序列SEQ ID NO:44；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:62，LC-CDR2，其包含氨基酸序列SEQ ID NO:75，和LC-CDR3，其包含氨基酸序列SEQ ID NO:93；
    (xxiii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:13，HC-CDR2，其包含氨基酸序列SEQ ID NO:30，和HC-CDR3，其包含氨基酸序列SEQ ID NO:45；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:63，LC-CDR2，其包含氨基酸序列SEQ ID NO:73，和LC-CDR3，其包含氨基酸序列SEQ ID NO:94；
    (xxiv)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:14，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:46；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID  NO:51，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:95；
    (xxv)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:15，HC-CDR2，其包含氨基酸序列SEQ ID NO:20，和HC-CDR3，其包含氨基酸序列SEQ ID NO:47；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:64，LC-CDR2，其包含氨基酸序列SEQ ID NO:68，和LC-CDR3，其包含氨基酸序列SEQ ID NO:96；
    (xxvi)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:16，HC-CDR2，其包含氨基酸序列SEQ ID NO:31，和HC-CDR3，其包含氨基酸序列SEQ ID NO:48；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:65，LC-CDR2，其包含氨基酸序列SEQ ID NO:76，和LC-CDR3，其包含氨基酸序列SEQ ID NO:97；
    (xxvii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:17，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:49；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:66，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:98；或
    (xxviii)VH，所述VH包含：HC-CDR1，其包含氨基酸序列SEQ ID NO:17，HC-CDR2，其包含氨基酸序列SEQ ID NO:28，和HC-CDR3，其包含氨基酸序列SEQ ID NO:50；以及VL，所述VL包含：LC-CDR1，其包含氨基酸序列SEQ ID NO:60，LC-CDR2，其包含氨基酸序列SEQ ID NO:74，和LC-CDR3，其包含氨基酸序列SEQ ID NO:91。
  3. 根据权利要求1或2中所述的分离的特异性识别FasL的抗体，其包含：
    (i)VH，其包含SEQ ID NO:99所示的氨基酸序列或其变体，所述变体与SEQ ID NO:99所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:127所示的氨基酸序列或其变体，所述变体与SEQ ID NO:127所示的氨基酸序列具有至少约80％序列同一性；
    (ii)VH，其包含SEQ ID NO:100所示的氨基酸序列或其变体，所述变体与SEQ ID NO:100所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ  ID NO:128所示的氨基酸序列或其变体，所述变体与SEQ ID NO:128所示的氨基酸序列具有至少约80％序列同一性；
    (iii)VH，其包含SEQ ID NO:101所示的氨基酸序列或其变体，所述变体与SEQ ID NO:101所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:129所示的氨基酸序列或其变体，所述变体与SEQ ID NO:129所示的氨基酸序列具有至少约80％序列同一性；
    (iv)VH，其包含SEQ ID NO:102所示的氨基酸序列或其变体，所述变体与SEQ ID NO:102所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:130所示的氨基酸序列或其变体，所述变体与SEQ ID NO:130所示的氨基酸序列具有至少约80％序列同一性；
    (v)VH，其包含SEQ ID NO:103所示的氨基酸序列或其变体，所述变体与SEQ ID NO:103所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:131所示的氨基酸序列或其变体，所述变体与SEQ ID NO:131所示的氨基酸序列具有至少约80％序列同一性；
    (vi)VH，其包含SEQ ID NO:104所示的氨基酸序列或其变体，所述变体与SEQ ID NO:104所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:132所示的氨基酸序列或其变体，所述变体与SEQ ID NO:132所示的氨基酸序列具有至少约80％序列同一性；
    (vii)VH，其包含SEQ ID NO:105所示的氨基酸序列或其变体，所述变体与SEQ ID NO:105所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:133所示的氨基酸序列或其变体，所述变体与SEQ ID NO:133所示的氨基酸序列具有至少约80％序列同一性；
    (viii)VH，其包含SEQ ID NO:106所示的氨基酸序列或其变体，所述变体与SEQ ID NO:106所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:134所示的氨基酸序列或其变体，所述变体与SEQ ID NO:134所示的氨基酸序列具有至少约80％序列同一性；
    (ix)VH，其包含SEQ ID NO:107所示的氨基酸序列或其变体，所述变体与SEQ ID NO:107所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:135所示的氨基酸序列或其变体，所述变体与SEQ ID NO:135所示的氨 基酸序列具有至少约80％序列同一性；
    (x)VH，其包含SEQ ID NO:108所示的氨基酸序列或其变体，所述变体与SEQ ID NO:108所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:136所示的氨基酸序列或其变体，所述变体与SEQ ID NO:136所示的氨基酸序列具有至少约80％序列同一性；
    (xi)VH，其包含SEQ ID NO:109所示的氨基酸序列或其变体，所述变体与SEQ ID NO:109所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:137所示的氨基酸序列或其变体，所述变体与SEQ ID NO:137所示的氨基酸序列具有至少约80％序列同一性；
    (xii)VH，其包含SEQ ID NO:110所示的氨基酸序列或其变体，所述变体与SEQ ID NO:110所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:138所示的氨基酸序列或其变体，所述变体与SEQ ID NO:138所示的氨基酸序列具有至少约80％序列同一性；
    (xiii)VH，其包含SEQ ID NO:111所示的氨基酸序列或其变体，所述变体与SEQ ID NO:111所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:139所示的氨基酸序列或其变体，所述变体与SEQ ID NO:139所示的氨基酸序列具有至少约80％序列同一性；
    (xiv)VH，其包含SEQ ID NO:112所示的氨基酸序列或其变体，所述变体与SEQ ID NO:112所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:140所示的氨基酸序列或其变体，所述变体与SEQ ID NO:140所示的氨基酸序列具有至少约80％序列同一性；
    (xv)VH，其包含SEQ ID NO:113所示的氨基酸序列或其变体，所述变体与SEQ ID NO:113所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:141所示的氨基酸序列或其变体，所述变体与SEQ ID NO:141所示的氨基酸序列具有至少约80％序列同一性；
    (xvi)VH，其包含SEQ ID NO:114所示的氨基酸序列或其变体，所述变体与SEQ ID NO:114所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:142所示的氨基酸序列或其变体，所述变体与SEQ ID NO:142所示的氨基酸序列具有至少约80％序列同一性；
    (xvii)VH，其包含SEQ ID NO:115所示的氨基酸序列或其变体，所述变体与SEQ ID NO:115所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:143所示的氨基酸序列或其变体，所述变体与SEQ ID NO:143所示的氨基酸序列具有至少约80％序列同一性；
    (xviii)VH，其包含SEQ ID NO:116所示的氨基酸序列或其变体，所述变体与SEQ ID NO:116所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:144所示的氨基酸序列或其变体，所述变体与SEQ ID NO:144所示的氨基酸序列具有至少约80％序列同一性；
    (xix)VH，其包含SEQ ID NO:117所示的氨基酸序列或其变体，所述变体与SEQ ID NO:117所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:145所示的氨基酸序列或其变体，所述变体与SEQ ID NO:145所示的氨基酸序列具有至少约80％序列同一性；
    (xx)VH，其包含SEQ ID NO:118所示的氨基酸序列或其变体，所述变体与SEQ ID NO:118所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:146所示的氨基酸序列或其变体，所述变体与SEQ ID NO:146所示的氨基酸序列具有至少约80％序列同一性；
    (xxi)VH，其包含SEQ ID NO:119所示的氨基酸序列或其变体，所述变体与SEQ ID NO:119所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:147所示的氨基酸序列或其变体，所述变体与SEQ ID NO:147所示的氨基酸序列具有至少约80％序列同一性；
    (xxii)VH，其包含SEQ ID NO:120所示的氨基酸序列或其变体，所述变体与SEQ ID NO:120所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:148所示的氨基酸序列或其变体，所述变体与SEQ ID NO:148所示的氨基酸序列具有至少约80％序列同一性；
    (xxiii)VH，其包含SEQ ID NO:121所示的氨基酸序列或其变体，所述变体与SEQ ID NO:121所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:149所示的氨基酸序列或其变体，所述变体与SEQ ID NO:149所示的氨基酸序列具有至少约80％序列同一性；
    (xxiv)VH，其包含SEQ ID NO:122所示的氨基酸序列或其变体，所述变体与SEQ  ID NO:122所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:150所示的氨基酸序列或其变体，所述变体与SEQ ID NO:150所示的氨基酸序列具有至少约80％序列同一性；
    (xxv)VH，其包含SEQ ID NO:123所示的氨基酸序列或其变体，所述变体与SEQ ID NO:123所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:151所示的氨基酸序列或其变体，所述变体与SEQ ID NO:151所示的氨基酸序列具有至少约80％序列同一性；
    (xxvi)VH，其包含SEQ ID NO:124所示的氨基酸序列或其变体，所述变体与SEQ ID NO:124所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:152所示的氨基酸序列或其变体，所述变体与SEQ ID NO:152所示的氨基酸序列具有至少约80％序列同一性；
    (xxvii)VH，其包含SEQ ID NO:125所示的氨基酸序列或其变体，所述变体与SEQ ID NO:125所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:153所示的氨基酸序列或其变体，所述变体与SEQ ID NO:153所示的氨基酸序列具有至少约80％序列同一性；或
    (xxviii)VH，其包含SEQ ID NO:126所示的氨基酸序列或其变体，所述变体与SEQ ID NO:126所示的氨基酸序列具有至少约80％序列同一性；以及VL，其包含SEQ ID NO:154所示的氨基酸序列或其变体，所述变体与SEQ ID NO:154所示的氨基酸序列具有至少约80％序列同一性。
  4. 根据权利要求1-3中任一项的分离的特异性识别FasL的抗体，其中所述抗体包含Fc片段。
  5. 根据权利要求4中的分离的特异性识别FasL的抗体，其中所述抗体是全长的IgG抗体。
  6. 根据权利要求5中的分离的特异性识别FasL的抗体，其中所述抗体是全长的IgG1、IgG2、IgG3或IgG4抗体。
  7. 根据权利要求1-6中任一项的分离的特异性识别FasL的抗体，其中所述抗体是嵌合的、人源化的或全人的抗体。
  8. 根据权利要求1-3中任一项的分离的特异性识别FasL的抗体是抗原结合片段，其中所述抗原结合片段选自Fab、Fab’、F(ab)’2、Fab’-SH、单链抗体(scFv)、Fv片段、dAb、 Fd、纳米抗体(nanobody)、双链抗体(diabody)和线性抗体。
  9. 一种核酸分子，其编码权利要求1-8中任一项所述的特异性识别FasL的抗体。
  10. 一种包含权利要求9中所述的核酸分子的载体。
  11. 一种分离的宿主细胞，其包含权利要求1-8中任一项所述的特异性识别FasL的抗体、权利要求9中所述的核酸分子或权利要求10中所述的载体。
  12. 一种制备特异性识别FasL的抗体的方法，其包含：
    a)在能有效表达特异性识别FasL的抗体的条件下培养权利要求11中所述的宿主细胞；和
    b)从宿主细胞中获得所表达的特异性识别FasL的抗体。
  13. 一种药物组合物，其包含权利要求1-8中任一项所述的特异性识别FasL的抗体、权利要求9中所述的核酸分子、权利要求10中所述的载体、权利要求11中所述的分离的宿主细胞或由权利要求12中所述方法制备得到的抗体，以及药学上可接受的载体。
  14. 根据权利要求13中的药物组合物，其中所述药物组合物进一步包括其他药剂，所述药剂选自免疫抑制剂、抗炎药、抗肿瘤剂、生长抑制剂、细胞毒剂、化学治疗试剂或血管抑制剂。
  15. 权利要求1-8中任一项所述的抗体、权利要求9中所述的核酸分子、权利要求10中所述的载体、权利要求11中所述的分离的宿主细胞、由权利要求12中所述方法制备得到的抗体、或权利要求13-14中任一项所述的药物组合物在制备治疗、预防和/或改善疾病或病症的药物中的用途。
  16. 一种治疗疾病或病症的方法，所述方法包括向所需个体施用有效剂量的如权利要求1-8中任一项所述的抗体、权利要求9中所述的核酸分子、权利要求10中所述的载体、权利要求11中所述的分离的宿主细胞、由权利要求12中所述方法制备得到的抗体、或权利要求13-14中任一项所述的药物组合物。
  17. 根据权利要求15中的用途或权利要求16中的治疗方法，其中所述疾病或病症为与FasL-Fas信号通路有关的炎性疾病、癌症或自体免疫性疾病。
  18. 根据权利要求17中的用途或治疗方法，其中所述疾病或病症选自天疱疮、移植排斥、移植物抗宿主疾病、全身炎症反应综合征、败血症、多器官功能障碍综合征、急性肺损伤、急性呼吸窘迫综合征、外伤、多发性硬化、特发性肺纤维变性、骨关节炎、炎症性肠病、Crohn’s病、溃疡性结肠炎、心肌梗塞、心肌病、缺血性再灌注损伤、糖尿病、脑损 伤、脊髓损伤、急性病毒性乙肝、急性病毒性丙肝、慢性丙肝、慢性乙肝、酒精性肝炎、非酒精性脂肪性肝炎、肝硬化、药物性肝损伤/肝衰竭、自免性肝炎、慢性肾病、急性肾病、糖尿病性肾病、癌症。
  19. 根据权利要求18中的用途或治疗方法，其中所述癌症为FasL阳性癌症。
  20. 根据权利要求15、17-19中任一项的用途，其中所述药物与另一种药剂组合施用。
  21. 根据权利要求16-19中任一项的治疗方法，该方法进一步包括向所需个体施用另一种药剂。
  22. 根据权利要求20中的用途或权利要求21中的治疗方法，其中所述另一种药剂选自免疫抑制剂、抗炎药、抗肿瘤剂、生长抑制剂、细胞毒剂、化学治疗试剂或血管抑制剂。
PCT/CN2023/072295 2022-01-21 2023-01-16 特异性识别FasL的抗体及其应用 WO2023138522A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202380009454.2A CN116829594A (zh) 2022-01-21 2023-01-16 特异性识别FasL的抗体及其应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210069822 2022-01-21
CN202210069822.X 2022-01-21

Publications (1)

Publication Number Publication Date
WO2023138522A1 true WO2023138522A1 (zh) 2023-07-27

Family

ID=87347839

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/072295 WO2023138522A1 (zh) 2022-01-21 2023-01-16 特异性识别FasL的抗体及其应用

Country Status (3)

Country Link
CN (1) CN116829594A (zh)
TW (1) TW202334235A (zh)
WO (1) WO2023138522A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024083021A1 (zh) * 2022-10-20 2024-04-25 北京三诺佳邑生物技术有限责任公司 特异性结合TRAIL或FasL的抗体组合以及双特异性抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106140A1 (en) * 2002-03-21 2005-05-19 Eli Lilly And Company Antagonistic anti-hfas ligand human antibodies and fragments thereof
CN108290950A (zh) * 2015-09-23 2018-07-17 阿珀吉科吉尼科斯股份公司 抗cd95l抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106140A1 (en) * 2002-03-21 2005-05-19 Eli Lilly And Company Antagonistic anti-hfas ligand human antibodies and fragments thereof
CN108290950A (zh) * 2015-09-23 2018-07-17 阿珀吉科吉尼科斯股份公司 抗cd95l抗体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024083021A1 (zh) * 2022-10-20 2024-04-25 北京三诺佳邑生物技术有限责任公司 特异性结合TRAIL或FasL的抗体组合以及双特异性抗体

Also Published As

Publication number Publication date
CN116829594A (zh) 2023-09-29
TW202334235A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
CN114555639B (zh) 特异性识别白细胞介素-4受体α的抗体及其用途
JP2023011887A (ja) 顆粒球－マクロファージコロニー刺激因子受容体αを特異的に認識する抗体及びその使用
WO2023138521A1 (zh) 特异性识别FasL的抗体及其应用
WO2023138522A1 (zh) 特异性识别FasL的抗体及其应用
WO2021259160A1 (en) Antibodies specifically recognizing c5a and uses thereof
WO2023030501A1 (zh) 特异性识别FcRn的抗体及其应用
WO2023186054A1 (zh) 特异性识别c5a的抗体及其应用
WO2024067344A1 (zh) 特异性识别light的抗体及其应用
WO2023284714A1 (zh) 特异性识别cd40的抗体及其应用
WO2023066171A1 (zh) 特异性结合乙型肝炎病毒表面抗原pre-S1的抗体及其应用
WO2023274007A1 (zh) 特异性识别cd40的抗体及其应用
WO2023217068A1 (zh) 特异性识别gdf15的抗体及其应用
WO2023016538A1 (en) Antibodies specifically recognizing fcrn and uses thereof
WO2024056010A1 (zh) 特异性识别nkg2a的抗体及其应用
WO2024083021A1 (zh) 特异性结合TRAIL或FasL的抗体组合以及双特异性抗体
CN117917436A (zh) 特异性识别trail的抗体及其应用
CN117917437A (zh) 特异性识别trail的抗体及其应用
TW202317633A (zh) 特異性識別ｔｎｆｒ２的抗體及其用途
CN118103397A (zh) 特异性识别tnfr2的抗体及其用途
TW202334232A (zh) 特異性識別C5aR1之抗體及其應用
WO2024020407A1 (en) Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 202380009454.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23742837

Country of ref document: EP

Kind code of ref document: A1